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Abstract 
First-line cancer treatments, such as surgical removal of tumours, are necessary but highly 
invasive and can only be of therapeutic benefit if the cancer has not yet spread to other 
organs. Chemotherapy and radiotherapy can help to slow the spread of cancer, but the 
systemic exposure leads to cumulative and cytotoxic effects, which leave the patient 
immune-compromised and susceptible to organ failure. This highlights the need to develop 
targeted therapies capable of delivering such drugs directly to the cancer cells, to 
overcome drug resistance and limit the cytotoxic effects associated with 
chemotherapeutics.  
Monoclonal antibodies (mAbs) provide a means to target conjugated drugs or radio-labels 
while also having therapeutic benefits in their own right. Cancer cells are often 
characterised by the overexpression of particular cell surface biomarkers, and these 
biomarkers make ideal targets for delivery of drugs via specific mAbs. The epidermal 
growth factor receptor (EGFR) is a validated cell surface antigen that has been extensively 
evaluated in the literature. EGFR is associated with a number of different cancers 
including breast and colon, and anti-EGFR mAbs are approved for therapeutic use (e.g. 
panitumumab and cetuximab). Drug-conjugated anti-EGFR mAbs are also under pre-
clinical and clinical evaluation. However significant challenges remain, as some cancers 
are refractive to mAb therapy due to pre-existing and acquired resistance to a given 
treatment, both mAb and drug related. The drug dosage carried by conjugated antibodies 
is limited to the number of molecules that can be attached to the antibody without 
compromising the antibody’s binding affinity. 
Another novel approach lies in the development of nanoparticles capable of carrying a 
high therapeutic payload, including cytotoxins, DNA, siRNA or other therapeutic agents. 
Inclusion of a targeting system on such drug delivery vehicles provides a means to deliver 
concentrated doses directly to sites of interest while simultaneously protecting the payload 
from the environment and vice versa. The EnGeneIC drug delivery vehicle 
(EDVTMnanocell) is a novel 400 nm anucleate bacterial nanoparticle, which can be loaded 
with high concentrations of various drugs and utilises bispecific antibodies (BsAbs) as a 
targeting moiety. These BsAbs bind both the EDVTMnanocell and the cancer cell 
biomarker. Initial clinical testing of the BsAb-EDVTMnanocell system has been shown to 
exhibit promising outcomes in vitro and in initial clinical trials. In preliminary studies, 
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EDVTMnanocells were targeted to EGFR-expressing cells utilising a BsAb produced by 
linking two separate mAbs via Protein A/G. However, problems were identified relating to 
product uniformity, with a propensity for forming cross-linked aggregates impacting the 
ability to produce these BsAb preparations economically. 
In this project we have created engineered BsAbs to facilitate the targeting of 
EDVTMnanocells directly to a cancer cell surface antigen, EGFR, allowing improved 
product quality and consistency. We have engineered a number of BsAb formats for 
production in the CHO-S expression system, and investigated their ability to bind to the 
EDVTMnanocell and subsequently facilitate targeting. We have related changes in BsAb 
structure to final BsAb product yield, stability and ability to bind recombinant and native 
targets in vitro and in vivo following purification by chromatography techniques. While all 
formats were capable of EDVTMnanocell targeting, differences in product yield and stability 
were observed. 
Development of processes to produce high levels of BsAbs have proved to be more 
complicated than standard production techniques required for mAb development owing to 
the lower expression levels of BsAbs and their inherent downstream instability. Slight 
modifications of the BsAb amino acid sequence resulted in two similar constructs showing 
a 6-fold difference in product yield. However, the same changes in sequence resulted in 
improved downstream and long-term stability of the product, strengthening the need to 
develop optimal systems for BsAb production. Surface Plasmon Resonance analyses 
showed that these engineered BsAbs retain high binding affinities for EGFR comparable to 
the parent mAb. Furthermore, BsAbs are able to bind EGFR-overexpressing MDA-MB-468 
breast cancer cells both independently and while bound to EDVTMnanocells. Selection of 
an engineered BsAb that has shown optimal value in the ability to consistently produce a 
uniform, predictable amount of BsAb has enabled further in vivo product characterisation. 
Tumour regression data produced with our research partners EnGeneIC has shown that in 
Balb/C athymic nude mouse xenograft models, doxorubicin-loaded EDVTMnanocells with 
bound BsAbs have a positive effect on tumour regression. The optimised format selected 
by EnGeneIC has now enabled the commencement of scale-up BsAb production for use in 
a Phase IIa clinical trial. 
The modular design of the BsAb optimised during this work allows the substitution of the 
EGFR targeting domain for other specificities. As such, this design is now being 
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investigated by other members of our laboratory for the targeting of EDVTMnanocells to 
other cancer cell biomarkers such as mesothelin and c-kit. This allows the EDVTMnanocell 
to be tailored to particular cancer types, leading to a personalised medicine approach for 
the patient. 
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1. Introduction
1.1. Cancer therapeutics 
Current cancer therapies have shown variable potency levels due to their lack of tumour-
specificity.  Early, and some current methods in treating cancer have been said to be 
reminiscent of military tactics – finding and destroying the target entity and its immediate 
environment with subsequent off-target injury or destruction (bystander effect) being an 
unfortunate but unavoidable consequence. Surgical procedures sometimes even involved 
near-complete removal of entire organs to ensure removal of a cancer.1 Even in today’s 
high-tech society chemotherapeutic drug administration leads to the destruction of rapidly 
dividing cells principally though interfering with DNA synthesis or replication, and so, not 
only cancer cells but some normal cells are affected, causing side-effects such as hair-loss 
and nausea. Furthermore, cancer treatments such as surgical removal of tumours are 
highly invasive and have limited therapeutic benefit if the cancer has spread to other 
organs.2, 3
Although the common belief is that prevention is better than cure,4 the nature of and 
expanse of cancers that exist is as yet not fully understood. As such, early detection has 
been identified as a major contributing factor in a clinician’s ability to manage and prevent 
detrimental disease onset in a patient. In aid of early detection numerous tools for 
improved diagnostics have been developed over the years such as various imaging 
technologies (MRI and CT scans), endoscopic techniques, and in the case of non-
melanoma skin cancer - optical coherence tomography.5-7 However barring a complete 
understanding of the biological scope and manifestation of all cancers (Cancer Genome 
Atlas), the full potential of diagnostic tools has not been fully realised and probably won’t 
be for some time. 
With confirmed disease diagnosis there is the obvious necessity to take action in the 
eradication of the cancerous manifestation. The first avenue for preventing the spread of a 
cancer tends to be surgery, in which case a benign tumour is excised from the surrounding 
tissue with minimal damage to the local environment. However rates of long-term patient 
survival following surgery, whether due to surgical complications or unpredicted spread of 
the disease, have not been overwhelmingly successful.8 If surgery isn’t expected to be the 
optimal treatment option it may be combined with radiotherapy or chemotherapy. 
1 
Depending on the circumstances the latter options may also be used as stand-alone 
alternative treatments.  
Radio- and chemotherapies have been used with varying levels of success. Radiotherapy 
involves the use of x-rays, gamma rays or other charged particles that are able to disrupt 
the DNA sequence relating to the cancer and so shrink the tumour. A patient can either be 
subjected to radiation by a machine called a linear accelerator delivering an external 
beam, or through systemic means whereby radioactive isotopes travel through the blood 
stream to attack cancer cells. Treatment of this nature also affects normal cell populations 
therefore clinicians need to plan a course of treatment carefully to maintain a patient’s 
overall well-being. Further to the original mentality that treating cancer equated to military 
strategies – one of the original drugs used as a chemotherapeutic agent was mustard 
gas.9 The reason for this was that physicians realised that the gas resulted in patients 
having very low white blood cell counts following gas exposure. They therefore inferred 
that if cancer patients were treated with the same it should result in a decrease in the 
rapidly increasing cancerous cells. 
Today chemotherapy covers a wide range of anti-neoplastic and cytotoxic drug treatment 
regimens, including antimetabolites, alkylating agents, anthracyclines, DNA 
methyltransferase inhibitors, platinum compounds and spindle poisons to name a few 
categories.9, 10 However, as these treatments aren’t selective towards particular tumour 
cells themselves, they are associated with many side-effects that can be more detrimental 
to the patient’s health.3 Furthermore, patients can also develop resistance to particular 
drug treatments rendering the drugs completely therapeutically ineffective. The ability of 
cancer cells to evade the immune system and acquire resistance to current treatments 
strengthens the need to develop targeted therapies capable of overcoming drug resistance 
and eliminating the emergence of multiple drug resistant tumour cells, associated with 
chemotherapeutics.1  
2 
1.2. Cell surface markers 
Breast, lung and prostate cancer are the most common cancers diagnosed in both 
developing and developed countries and account for the majority of cancer-related deaths. 
These prevalent cancer indications are followed by colorectal, stomach, liver, lung and 
cervical cancers.2 An obvious progression from the traditional global, “whole-person” cell 
treatment by radiotherapy and chemotherapeutic agents is to provide a means to 
specifically target a therapeutic agent directly to a cell or tumour of interest.3 By analysing 
markers specifically associated with or overexpressed on tumour cells compared with 
healthy cell populations, a tumour cell 'signature' can be defined, and these markers can 
become targets for therapeutics, while sparing the surrounding healthy cells from the 
cytotoxic effects of the treatment. Targeted therapeutics can therefore be used to 
specifically treat pancreatic, breast, prostate, colorectal, or any other cancer with a 
therapeutically beneficial identified cell surface marker. 
Many cell surface markers are currently under investigation as therapeutic targets, not only 
in cancer but also in inflammatory diseases and other indications.11-14 Amongst these are 
common validated targets such as the epidermal growth factor receptor (EGFR), CD20 
and Human epidermal growth factor 2 and 3 (Her2 and Her3).15-18 The table below 
provides a list of some of the common targets currently under investigation (Table 1.1). 
Table 1.1: Therapeutic cell surface targets 
Surface marker Cancer type Targeting treatment example 
Aminopeptidase Neovascular endothelial cells (Tumour angiogenesis) 
Various peptides carrying therapeutic 
payloads.19, 20
Folate receptor Various cancers including ovarian cancer Folate conjugates21-23
EGFR Various cancers including breast and colorectal cancer 
Various monoclonal antibodies (mAbs) 
such as Panitumumab and bispecific 
affibodies24, 25 
Her 2 Various cancers including ovarian and breast cancer Various mAbs such as Trastuzumab, ankyrin repeat proteins and Fynomabs26-29 
CD19, 20, 22, 25, 
and 33 Blood cancers such as Leukemia and lymphomas 
Various mAbs including Veltuzumab 
(CD20) and other engineered formats12, 14 
Carcinoembryonic 
antigen (CEA) 
Carcinoembryonic antigen. Colorectal, small-cell 
lung, ovarian cancer and adenocarcinomas Bispecific antibodies
30 
CD133 Head and neck squamous cell carcinomas Various mAbs and fusion proteins31
A number of factors need to be considered when deciding on a disease-specific marker as 
a target for therapeutics.  These factors include whether the target antigen is a secreted or 
cell membrane antigen, and whether it has a high surface density limited to a cancer cell, 
for example or whether it is also present at high levels on healthy cell populations. If the 
latter is true then the therapeutic benefit of the target most likely won’t be an improvement 
on current systemic drug administration regimens. There also needs to be a low 
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heterogeneity in antigen expression amongst cell populations of a certain type – otherwise 
the treatment will fail due to natural resistance at the target epitope. The target moiety 
should not be one that is naturally down-regulated or released from the cell surface; this 
would result in a decreased efficacy as the therapeutic molecules would simply be cleared 
from circulation. 
The researcher needs to determine whether or not the marker is internalised and whether 
either situation poses a problem to the proposed therapeutic system. As an example, if 
therapeutic benefit is achieved by the agent being delivered to the cell surface to block a 
particular site or to recruit immune cells then it may not be necessary for the marker to be 
internalised. If however the therapeutic mode of action (MOA) involves cessation of 
internal cellular pathways following uptake or internalisation of the therapeutic molecule, 
as is the case with siRNA delivery, then ligand internalisation is a major contributing factor 
to the system’s success.  
The majority of cancers consist of solid tumours; making factors like penetration 
capabilities and diffusion into cells through tumour vasculature important during the 
product design phase.32, 33 Binding affinities are another important factor for consideration. 
If for example a receptor has a very high affinity for its natural ligand, then any therapies 
that target this receptor would have to out-compete and therefore have a stronger binding 
affinity for the receptor. However, if a therapeutic agent’s binding affinity is too strong then 
the products will only bind to the outermost regions of the tumour environment and not be 
able to penetrate deep enough into the tumour – limiting the reach of the treatment.34 
Table 1.2 adapted from Tabrizi, 2012, summarises some of the most important 
considerations to be taken into account with regards to target selection for optimal affinity 
requirements. Understanding these characteristics would enable developers to critically 
predict the required balance between product binding affinity and dosage requirements to 
optimise therapeutic benefit without overspending on the cost of development and 
production.35 
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Table 1.2: Antigen properties for consideration in targeting moiety affinity design. Adapted from excerpts 
published in Tabrizi, 2012; Springer.35 
Antigen type Properties Explanation 
Secreted or 
soluble 
antigens 
Antigen levels 
In serum and comparison between diseased and normal individuals. Is the antigen 
readily available and produced in the body at high or low amounts? Low 
concentration antigen may require high affinity binders. 
Antigen serum 
clearance 
If a secreted target is cleared from a patient’s system rapidly, a targeting agent 
may be cleared from the system within a short time-frame as well depending on 
antigen/therapeutic complex size – providing little if any therapeutic benefit. A 
product could however be designed to bind a product such as PEG, BSA or 
natural immune system components which would increase product retention times. 
Antigen 
receptor(s) 
Affinity for natural ligands – targeting therapeutic would need a higher binding 
affinity for the receptor than the natural ligand (antigen) to compete and provide a 
benefit. Receptor density/cell – low concentration antigens may benefit from a 
therapeutic with a very high binding affinity.  
Serum antigen 
binding proteins 
Do other targeting moieties or antibodies exist naturally that could compete with 
the developed therapeutic? 
Other products 
in development 
Comparisons of available products on the market and in clinical trial with regards 
to affinity and biodistribution can inform developers as to what improvements are 
required to perform competitively in the biopharmaceutical market. 
Cell 
membrane 
antigens 
Expression 
pattern 
Location and cell density – Does the blood brain barrier, a solid tumour 
environment or other area which is difficult to reach need to be penetrated? A solid 
tumour environment may benefit from lower binding affinities to ensure that the 
therapeutic can disengage and travel deeper into the tumour micro-environment. 
The surface antigen density will affect the avidity of the binding interaction and the 
possibility of receptor cross-linking could have a positive or negative effect on the 
proposed therapeutic outcome. Avoid or limit product interaction with healthy 
tissues. If a target is highly prevalent in normal tissues as well as diseased targets, 
adverse off-target effects may occur.  
Receptor 
mediated 
internalisation 
If the receptor is internalised it may impact antibody clearance rates and ability to 
provide a therapeutic benefit if the product is then degraded inside the cell. Unless 
internalisation would provide a benefit a product may need to be designed that 
would limit or retard the occurrence of internalisation events. 
Shed 
extracellular 
domain or 
receptors 
Could lead to high clearance rates or unavailability of the receptor for a therapeutic 
to provide a benefit at the cell surface – therapeutic may need to target a structural 
component of the membrane protein, rather than external ligand-binding sites. 
Ligand affinity 
Competition between natural ligands for receptor would require that the 
therapeutic have a higher affinity. 
Other products 
in development 
Comparisons of products on the market and in clinical trial with regards to affinity 
and biodistribution can inform developers as to what improvements they would 
have to include in order to perform well in the biopharmaceutical market. 
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1.2.1. Epidermal Growth Factor Receptor 
Levels of EGFR expression have been associated with poor prognosis of disease 
progression in cancer patients. Mutations in EGFR, overexpression thereof and autocrine 
stimulation can lead to EGFR activation and altered activity of various intracellular 
compounds, which can lead to cancer. Overexpression of EGFR has been associated with 
tumours in colorectal, gastric, breast, glioblastoma and lung cancers to name a few.16, 36-38 
The widespread occurrence of EGFR-related tumours has made it one of the most 
commonly utilised validated cell surface markers in the development of targeting agents. 
EGFR is part of the family of receptor tyrosine kinases (RTKs) which when overexpressed 
confers a cancerous phenotype to cells, providing longevity to solid tumours.36, 39 There 
are four receptors in this family, EGFR, ErbB2, ErbB3 and ErbB4. EGFR (also known as 
HER1 or ErbB1) is normally activated by up to seven known ligands including EGF, TGFα, 
amphiregulin and heparin binding EGF-like growth factor (HB-EGF). When the ligands 
bind to EGFR, receptor-mediated dimerisation occurs and activates related intracellular 
pathways.40 A review by Burgess and colleagues noted that EGFR cell surface domains 
bind targets with variable affinities. EGF is bound by 2 – 5% of receptors at binding 
affinities (KD) corresponding to lower than 0.1 nM while the majority of receptors (92 
– 95%) bind the ligand at a higher 6 – 12 nM. This variation could possibly be
explained by the presence of different conformational changes in cell surface receptors.37
ErbB2 (Her2/neu) does not have any ligands that could induce its dimerisation but it has 
been suggested by Burgess that the monomer exists in a constantly active state, behaving 
as a heterodimerisation motif for other EGF receptors that are already bound to their 
respective ligands.37, 41 Overexpression of ErbB2 dimers is associated with 
many aggressive tumours, particularly in breast cancer. The ErbB2 receptor has a 
permanently mutated ligand binding site resulting in the receptor being in a constant 
state where it is able to either form homo- or heterodimers with nearby EGF receptors. 
Research has not been able to show that this permanently “active” state is the reason 
why the receptor causes cancer.37 ErbB3 (Her3) and ErbB4 (Her4) also undergo ligand 
binding to induce dimerisation to proteins called neuregulins (NRGs). Ligand binding 
then allows these receptors to either form homodimers or interact with available ErbB2 
receptors to form heterodimers.42 
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Targeting EGFR for therapeutic purposes has been achieved through the use of tyrosine 
kinase inhibitors as well as monoclonal antibodies (mAbs) while many other potential 
treatments are also in the clinical pipeline.15, 16, 38, 43-54 Several inhibitors directed against 
intracellular EGFR tyrosine kinase activity have been developed as therapeutic agents.52 
Tyrosine kinase inhibitors (TKIs) are small molecule drugs, and are therefore capable of 
penetration into solid tumours and are more cost effective to produce. Small molecules 
can however be cleared from a patients’ body through the renal system rather rapidly. The 
most well-known therapeutic agents are Gefitinib (Iressa) and Erlotinib (Tarceva).36, 53, 54 
mAbs are another therapeutic treatment option which has provided benefits in not only 
treating EGFR-related cancers but many other carcinomas and disease indications as 
well. 
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1.3. Monoclonal antibodies 
1.3.1. Historical perspective 
The development of antibodies as therapeutic agents began in the late 1800s with serum 
therapy, and has evolved through the development of technologies such as hybridoma 
formation, PCR, restriction enzyme cloning, site-directed mutagenesis, recombinant 
protein production, phage display and transgenic mice (Figure 1.1).55 
Figure 1.1: Early discoveries enabling current therapeutic mAb and fusion protein development. Adapted from 
illustration in chapter 1 of Therapeutic mAbs: from bench to clinic, ed. Zhiqiang An. Copyright, Wiley.55 
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Serum therapy was the first treatment relating to the use of antibodies as a therapeutic in 
indications such as diphtheria and tetanus. The therapeutic basis of these treatments was 
the presence of antibodies against disease-target antigens in the serum of immunised 
non-human sources such as mice, rabbits and horses. Low product purity of serum 
treatments caused adverse side-effects in patients which led to various techniques being 
developed to standardise quality and remove impurities. The subsequent discovery of 
antibiotics and chemotherapeutics as successful alternative treatments with less 
associated side-effects led to the decline of serum therapy as a therapeutic option. The 
development of hybridoma technology allowed standardised production of defined mAbs in 
cell culture, after mouse immunisation, and led to the first therapeutic mAb (Muromonab or 
Orthoclone).56, 57
1.3.2. mAb types and structure 
The most-common drawback in the use of murine mAbs (derived from mouse hybridomas) 
as a human therapeutic is in the widespread occurrence of the HAMA (Human anti-mouse 
antibody) response whereby the patient’s body produces antibodies to attack the murine 
components of the mAb (principally the Fc-domain).58 Recombinant antibody technology 
has endowed researchers with the ability to move away from using pure murine 
antibodies, and to introduce increasingly greater human-derived sequences to minimise 
immunogenicity (Figure 1.2). 
Figure 1.2: Types of mAbs. As illustrated in Brekke and Sandlie. Copyright Nature Reviews Drug Discovery58 
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The basic structure of IgG (mAb) molecules remains constant whether they are murine, 
chimeric, humanised or human. An IgG structure consists of both constant and variable 
heavy and light chain domains. The heavy chain consists of one variable domain (VH) 
connected to the first constant heavy domain (CH1). A hinge domain connects CH1 to the 
Fc domain which consists of CH2 (responsible for complement activation and FcRn binding) 
and CH3 (facilitates IgG dimerisation). The light chain has two domains, namely variable 
light, Lambda or Kappa (VL or VΚ respectively) and constant light – in combination with VH 
and CH1 a Fab molecule is formed. The association of a VH and VL chain constitutes the 
formation of an scFv fragment which contains a mAb’s complementarity-determining 
regions (CDRs). Three CDRs, responsible for the molecules ability to specifically bind 
targets, are located within the VH and VL (VK) domains (Figure 1.3).59  
A. B. 
Figure 1.3: Basic mAb or IgG structure. Adapted from illustrations as published in Elgert, 1996; Copyright John Wiley 
& Sons, Inc. .59 A. The structure of an IgG molecule and B. the sequence of heavy and light chains including the location 
of the two sets of three CDRs.
Chimeric antibody production through cloning murine variable domains onto human 
antibody chains was an initial improvement as are humanised antibodies developed by 
grafting murine CDRs into human mAbs.60, 61 Phage, ribosome and yeast display 
technologies allowed the in vitro development of fully human mAbs from cloned repertoires 
of human naive variable region genes.62-66  However, these mAbs tend to have lower 
binding affinities due to the lack of in vivo affinity maturation, and therefore need to 
undergo in vitro affinity maturation to be more effective as therapeutics. Development of 
10 
transgenic humanised mice provided in vivo means of isolating fully human mAbs that 
already have high affinities for their targets.62, 67  
1.3.3. Biopharmaceutical product market 
The protein therapeutics (biologics) market encompasses a large variety of products 
including coagulation factors, growth hormones, human insulin and mAbs – to name but a 
few. Monoclonal antibodies are currently estimated to be the fastest growing component of 
the protein therapeutic market owing to their superior ability to target disease, and their 
diversity – both as a product in their own right and in the number of diseases that mAbs 
can target.58, 64, 68-71 Global sales revenue of mAb-based products (inclusive of Fc-fusions, 
antibody fragments, antibody-drug conjugates and single mAbs) was estimated to be 
around $75 billion in 2013 – accounting for 50% of total biopharmaceutical product sales.72 
The first mAb approved for clinical use was Orthoclone (OKT3 – prevention of transplant 
rejection) in 1986 and since then a vast number of mAb-based products have entered 
clinical evaluation and been subsequently approved.14, 69, 72, 74, 75 As summarised in Ecker, 
fifty-eight mAb-based products have been approved since 1986, eleven of which were 
approved and subsequently withdrawn from the market. All of the currently marketed full-
length mAb products have been expressed using mammalian cell culture techniques.72 
The bi-annual reports published by Reichert provides extensive summaries of “antibodies 
to watch” with regards to being close to market release, regulatory review stage and late 
phase 3 antibody-products that are likely to progress to market approval. Also provided in 
each article is a link to a table describing a number of mAb-based products approved since 
1986 (http://www.tandf.co.uk/journals/pdf/announcements/kmab-antibodies.pdf).75  
Monoclonal antibody-based treatments have been developed for both cancer and non-
cancer related indications encompassing asthma, anthrax, breast cancer and lymphoma, 
to name a few. A number of EGFR-targeting mAbs have been approved for clinical use 
and are currently in development.75-79 The three most notable anti-EGFR mAbs include 
two approved mAbs (Cetuximab and Panitumumab) and a third (Necitumumab) currently 
under priority review at the FDA (Table 1.3).53, 54, 75, 80 These three mAbs are distinguished 
according to species, isotype and various biological characteristics including binding 
affinity and IC50.   
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Table 1.3: mAbs targeting EGFR approved and in clinical development.75, 76, 81 
Monoclonal antibody ID Species Isotype Clinical indication Clinical phase 
Cetuximab (Erbitux) Chimeric IgG1 
CRC, NSCLC, head 
and neck 
Approved, 2009 
Panitumumab (Vectibix) Human IgG2 CRC Approved, 2006 
Necitumumab Human IgG1 NSCLC 
3, under review by 
FDA 
Nimotuzumab (Theracim, 
Theraloc) 
Humanised IgG1 Head and Neck 
1 and 2, approved 
in India and China 
Zalutumumab (HuMax-
EGFR) 
Human IgG1 Head and Neck 
1, 2 and 3; 
development halted 
Panitumumab was the first fully human mAb derived from transgenic Xenomouse 
technology approved for clinical use.24, 67, 82, 83 It is an IgG2 mAb which distinguishes it 
from the other IgG1 formats and therefore has a low affinity for Fc-receptors. Although this 
can be viewed as a limitation in that an immune response cannot be mounted at the target 
antigen, an immune response is not always required and can be a hindrance given some 
MOAs. Utilising an antibody isotype which naturally has a low affinity for Fc-receptors 
circumvents the need to engineer a mAb with reduced affinity which could risk product 
instability.84 Panitumumab has a higher binding affinity (increased on-rate and slower off-
rate) for EGFR than both Cetuximab and Necitumumab; nevertheless it has been 
suggested that the latter two mAbs retain a greater functional “anti-cancer” effect on 
EGFR.80 
As an extension of mAbs being used as therapeutic products in their own right, it is also 
possible to enhance their therapeutic capabilities by re-engineering the antibody or 
attaching various moieties to its structural framework. Attaching peptides, radiolabels, 
drugs or any number of other particles to the mAb, combines the ability of the mAb to 
impose disease regression and also the therapeutic action of the attached ligand.85-88 
However  the development of antibody-drug conjugates (ADCs) is hampered by factors 
including conjugation chemistry, attachment method,  choice of linker, location on the mAb 
and the number of drug particles per mAb; all affecting potential therapeutic benefit and 
product stability.89 ADC development is a rapidly growing field with two ADCs currently 
approved for clinical use, namely Adcetris (brentuximab vedotin) and Kadycla (ado-
trastuzumab emtansine); in addition a radioimmunotherapeutic conjugate – Zevalin 
(ibritumomab tiuxetan), and many other new molecular entities based on mAbs are 
entering the clinical pipeline.89-97 Mylotarg (gemtuzumab ozogamicin), an ADC, was 
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originally approved for clinical use in AML patients but was subsequently withdrawn in 
2010 following new safety concerns raised by the FDA.92  
 
Monoclonal antibody-based technology has become well established as a therapeutic 
alternative to standard treatment regimens, and the production has become routine and 
reproducible. Recombinant DNA technologies provide developers with the opportunity to 
endow their product with higher, very specific affinity, potency and variable effector 
functions as applicable to the proposed purpose.84 Most mAbs have a longer serum half-
life than standard drug-based treatments thereby improving bioavailability. However mAb 
production is renowned for being time-consuming and very expensive and the follow-on 
costs to patients are also high. The larger size of mAbs also means that they have a 
decreased ability to penetrate tissues and the BBB.68-70, 72, 98-102 In addition to these 
factors, some patients may not receive a benefit from a selected mAb-product due to 
natural or acquired resistance at a selected marker.77, 79, 90, 103 The development of next-
generation biological therapeutics such as bispecific antibodies (BsAbs) provides a means 
to improve on some of these deficiencies and further enhance the positive attributes 
associated with mAbs.29, 30, 104-106 
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1.4. Bispecific antibodies 
BsAbs are a next-generation protein product with applications spanning both diagnostic 
and therapeutic fields. The most important factor classifying a protein as a BsAb lies in its 
ability to bind more than one target for which it has previously engineered specificities, 
unlike traditional mAbs which are limited to monovalent target binding. 
1.4.1. Historical perspective 
The development of processes relating to hybridomas, improved cell culture and 
recombinant protein engineering technologies has been a major driving force in the 
presently expanding field of BsAb engineering.107-109 Although BsAbs have only recently 
started gaining popularity amongst big pharmaceutical companies the theory and concept 
behind their development has been around for more than fifty years.110, 111 Original efforts 
in BsAb production were plagued with problems relating to aggregation, low yield, inactivity 
and heterogeneity in BsAb preparations. Academic interest surrounding the original 
concepts in producing BsAbs were initially realised by Nisonoff and Rivers around 1961. 
Their BsAbs were produced through oxidative recombination of pepsin digested and 
reduced rabbit antibody preparations.110 However, problems such as chemical protein 
denaturation and high reagent wastage associated with BsAb formation through chemical 
means were major barriers to production. In the early eighties, Milstein and Cuello 
reported a means to produce BsAbs that did not require chemical methods but would 
negatively impact final product binding affinity and cause protein denaturation (Figure 1.4). 
Milstein and Cuello’s process involved the fusion of two myeloma cell lines which enabled 
expression of hybrid molecules due to the mixed availability of different VH and VL chains 
from both parental cell lines.   They noted that out of ten possible antibody combinations 
that could be produced, only one was the desired BsAb (Figure 1.5), but they found that 
only a total of four out of ten were actually produced in their study. Their theoretical BsAb 
yield was expected to be 17% - 50% of total IgG produced.112, 113 During purification they 
found that the optimal chromatographic trace showed 3 peaks where the two flanking 
peaks were of parental mAbs and the middle peak of BsAbs, however this central peak 
would be a combination of inactive and active BsAbs (Figure 1.5). F(ab’γ)2 bispecific 
heterodimers were produced using a thioether-linkage and evaluated for their performance 
by Glennie et al.114 Purified product was heterogenous but 50 – 70% was found to be the 
bispecific heterodimers; although they reported relatively good bispecific product yields 
this was hampered by less efficient levels of retrieving starting parental Fab’γ fragments. 
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The benefit in the system is the lack of a murine Fc-domain to illicit a HAMA (human anti-
mouse antibody) immune response in patients. 
Figure 1.4: BsAb production by chemical conjugation or somatic hybridisation. Adapted from illustration published 
in Bispecific antibodies, ed. Kontermann; Copyright, Springer 107, 115 
Figure 1.5: Hybridoma produced antibody combinations. Theoretical antibody recombinations that can be produced 
from hybridomas assuming random association of heavy and light chains as predicted by Suresh, Cuello and Milstein; 
Copyright, Academic Press, Inc.112, 113 
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Early efforts in BsAb clinical development also had a number of problems including 
patients exhibiting immune responses due to adverse reactions to Fc-components and 
HAMA being produced due to the presence of murine components in the constructs.107, 116 
The relatively recent advent of being able to produce fully human mAbs such as 
Panitumumab (Xenomouse technology)67 and recombinant methodologies such as the 
removal of Fc-domain function84, 87 have been successful endeavors in the future of BsAb 
development (Figure 1.6). 
Figure 1.6: Historical BsAb development timeline. Diagram illustrates the path towards the development of next-
generation BsAbs for clinical development adapted from an illustration in Bispecific antibodies, ed. Kontermann; 
Copyright, Springer.107 
1.4.2. Modes of Action 
By binding two targets, patients who are resistant to drugs that bind one extracellular 
target can be provided with a therapeutically significant outcome following the independent 
binding of the second BsAb arm to a separate target, circumventing the need for multiple 
doses of different drugs and thereby lowering costs (Figure 1.7.A).117, 118 High affinity 
binding of one extracellular target can promote high avidity binding of the second target 
due to proximity on the cancer cell surface – another advantage of BsAbs, but this 
modality is yet to achieve significant success.32, 119 BsAbs can also be used as dual 
inhibitors of soluble targets to suppress various pathways, as is the case in RG7221 (Ang-
2 x VEGF), ABT-122 (TNFα x IL-17) and 120 (IL-4 x IL-13).121, 122  
The most common use of BsAbs to date has been in redirecting an immune response to a 
target antigen (Figure 1.7.B). BsAbs can bind an extracellular target on T-cells (T-cell 
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engagers), to activate and direct them to a tumour cell where cytolysis can occur, for 
example, DART, BiTE and FynomAb technology.29, 118, 123-127 Low drug potency of 
chemotherapeutics associated with the lack of drug localisation at cancer targets can also 
be improved by BsAbs binding directly to a drug128 (Figure 1.7.C) or drug loaded particle 
(Figure 1.7.D) while the second arm binds a disease target.103, 118, 129  
Figure 1.7: Applications of BsAbs. Therapeutic modalities include: (A) crosslinking separate antigens on the cell 
surface; (B) T cell engagement by cross-linking CD3 on cytotoxic T cells to tumour cells; (C) targeting drugs or 
radiolabels to cell surface; (D) targeted delivery of drug-laden nanoparticles to tumour cells. Copyright 2015 The Authors. 
Published with license by Taylor & Francis Group, LLC. 
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1.4.3. Current development 
Three methods are generally used in BsAb production, namely hybridoma technology, 
chemical conjugation and the third option which can create an inordinate amount of 
construct variation – recombinant protein engineering. Expression of recombinant BsAb 
formats has been completed using both bacterial and mammalian expression systems. 
Purification requirements can become excessive in situations where heterogenous 
mixtures of monospecific, multi-specific, active and inactive formats are produced – driving 
up the time and cost factors associated with BsAb production. 
Each method has its associated disadvantages. Hybridomas can potentially produce ten 
different variants,107, 112, 113, 130 chemical conjugation can cause protein denaturation,110, 111,
131 and both methods have potentially low BsAb product yields. Recombinant antibody 
engineering may require excessive sequence fine-tuning at times – a particular designed 
format might not express well in one system (glycosylation requirements limit ability to 
produce in bacterial systems), or an scFv being in a particular orientation may incur 
instability to the format and need either stability engineering or to be moved to a different 
position in the construct sequence.87, 115, 125, 132-143  
Many different BsAbs have been studied thus far but for long only one had been approved 
for clinical use, namely Catumaxomab.144-146 The BsAb is produced from a rat/mouse 
hybridoma and is characterised as a Triomab due to it having binding affinity for CD3 on 
T cells and the EpCAM antigen in ovarian cancer while still maintaining Fc-mediated 
activity through recruitment of macrophages and NK cells. Recently a second BsAb 
(Blinatumomab; trade name Blincyto), a T-cell engaging tandem scFv, was also approved 
for clinical use in the treatment of acute lymphoblastic leukemia.75 Although there are only 
two clinically approved BsAbs, many are currently undergoing clinical evaluation (Table 
1.4) and the recent approval of Blinatumomab is a promising occurrence in the clinical 
progression of next-generation biological therapeutics.147 
A multitude of BsAb formats have been developed over the last two decades and been 
extensively reviewed (Figure 1.8).104-106, 115, 118, 125, 133, 135, 139, 140, 148-156 Format design is of 
particular interest in how it behaves in a particular application. As an example, using an 
IgG-like BsAb might not be preferable if the molecule’s large size would negatively impact 
tumour penetration whereas a small diabody or tandem scFv format in the same system 
would improve on this in a solid tumour environment.157  
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Figure 1.8: BsAb formats. A summarising image of some of the many BsAb formats that have been developed as 
described by Kontermann; Copyright, Taylor and Francis.118 
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Recently BsAbs have been described as grouped in three different categories (PEGS 
Europe conference, 2014): 
1. Symmetric, bivalent
2. Asymmetric, monovalent
3. Fragments
Symmetric, bivalent 
A large number of companies are investigating BsAb formats of this type (Table 1.5).104 
The most well-known formats are F-mab2, DVD-Ig, IgG-like and scFv-IgG fusion BsAbs. F-
star’s BsAb technology is an extension of their monovalent Fcab product which is 
produced by engineering the CH3 domain of an Fc to be able to bind a specific target 
antigen.158 Normal mAbs can then have their Fc-domains replaced by a particular Fcab 
and in so doing the mAb acquires affinity for a secondary target. F-star’s BsAb is still in the 
pre-clinical stages but they have initiated clinical trials for the monovalent Fcabs. 
Questions still remain as to how engineering the CH3-domain could affect Fc effector 
functions and also how or if binding affinity is affected by the presence of a second 
targeting moiety in the constructs. 
Table 1.5: Companies developing symmetric, bivalent BsAbs. Information from PEGS Europe conference, 2014. 
BsAb format Companies References 
Two-in-one antibody Genentech 159, 160 
Dual-targeting-IgGs GSK/Domantis 161 
F-mab2 F-star 158 
DVD-Ig Abbvie 162, 163 
IgG-like BsAb Eli Lilly 164, 165 
scFv-IgG fusions Biogen Idec, Numab, Roche, Zymogenetics/BMS 51, 136, 166-169 
Fynomabs Covagen 29, 127 
Zybodies Zyngenia 170, 171 
Fibronectin-antibody fusions MIT (D. Wittrup) 30 
IgG-like and scFv-IgG fusion BsAbs can mediate complement activation and bind other Fc 
cell-surface receptors, however they can be engineered to limit, in some cases, 
undesirable functions of the Fc region.84 For example if a particular therapeutic or 
diagnostic application would be negatively impacted by a mounted immune response 
which causes toxicity in the patient due to using a functional Fc-linker, a better option is to 
engineer the domain to be inactive. However in other cases such as when a BsAb is used 
to deliver drug payloads to targets it may be beneficial to maintain the ability of the Fc to 
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recruit immune system components to provide an added “attack” in the diseased region. 
Removing Fc-function requires very stringent engineering however and careful decisions 
need to be made on which functions to maintain or discard (Figure 1.9).104, 119 
Figure 1.9: Antibody structural engineering for modified pharmacological effects. Adapted from illustration by 
Beck; Copyright, Nature Reviews Immunology.119 
Important questions that need to be considered during Fc-engineering include the 
following: which Fc-domains are beneficial in the system – complement activation, protein 
A binding for purification, dimerisation motifs, half-life extension? Will modification of a 
sequence result in product aggregation or instability?87, 119, 172-176 The Fc interacts with 
various cell surface markers which increase the construct’s retention time. One of the 
markers it interacts with is FcRn which regulates IgG homeostasis; it is a protective carrier 
of IgG. Selecting the correct IgG isotype is also important because IgG3 doesn’t bind FcRn 
efficiently and so has a shorter serum half-life, and IgG2 and IgG4 are naturally non-
activating.141, 156 To improve BsAb activity in vivo Chames and Baty32 stated that affinity for 
some Fc-receptors has to be modified: 
• increase binding to activating receptors such as FcγRI, FcγRIIa and FcγRIIIa
• decrease binding to FcγRIIb inhibitory receptors
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NK cells express FcγRIIIa receptor which is important for tumour cell lysis, whereas the 
FcγRIIa receptor is beneficial for target cell apoptosis through recruitment of neutrophils, 
monocytes, macrophages and dendritic cells. Macrophage and dendritic cell activity can 
activate cytotoxic T cells through cross-priming when disease-related antigens are 
presented on the class 1 MHC complex.177 These cells also express inhibitory FcγRIIb 
however, which possesses high homology with the beneficial receptor FcγRIIa. A review 
by Presta provides a significant amount of information regarding Fc engineering.156 
Binding to FcRn increases half-life at pH 6 in the endosome but not at pH 7.4 in the blood. 
Antibodies that are not bound to FcRn are catabolised in the endosome. To improve FcRn 
binding the Fc should only be engineered for enhanced binding at pH 6.0, not 7.4 
otherwise there will only be a decreased half-life. Not all published mutations to enhance 
FcRn activity have the same effect on different mAb constructs. As examples, an anti-
hepatitis B mAb had enhanced effector function but an anti-TNFα mAb with the same 
mutation didn’t show any increase in FcRn activity.178, 179 All of these factors further 
complicate the process of enhanced Fc-engineering. 
IgG fusion proteins also require substantial amounts of stability engineering at times to 
prevent aggregation.180 Variable chain stability can be enhanced by incorporating cysteine 
residues for disulfide stabilisation at Kabat position 44 of the heavy chain and position 100 
of the variable light chain for intramolecular stabilisation.141, 181 Schanzer states that 
making (G4S)4-6 linker repeats stabilises scFvs.141 Expression levels reported by Schanzer 
show that having the scFv linked to the N-terminal region of the IgG results in 4-5 times 
lower expression levels in HEK cells whereas incorporating disulfide stabilisation into the 
constructs results in 1.5-1.9 times lower expression levels. There appear to be quite a few 
trade-offs when it comes to adding the disulfide stabilisation; Schanzer showed that when 
the scFv isn’t disulfide stabilised it has a higher biological benefit. In addition to this a 
number of other scFv stability engineering options have been described.136 Sometimes the 
inclusion of disulphide bridges can increase product yield while still preventing 
aggregation.182  
Another important factor to consider relates to the optimal linker type and length 
connecting additional scFvs or other binding proteins to an IgG’s Fc domain. Shorter 
linkers can make a construct more rigid and could potentially interfere with stability and 
binding function, depending on the included amino acid sequences. It was however 
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reported that varying linker lengths between 15 and 30 residues (3 – 6 G4S repeats) did 
not affect BsAb expression levels. However, they found that longer linker lengths reduced 
the tendency of these molecules to aggregate.141 ADCC activity varies amongst different 
scFv-IgG fusion proteins relating to where the additional targeting moiety is attached to the 
primary structure.182 
DVD-Ig or Dual Variable Domain-Ig technology involves fusion of additional variable 
domains to the N-terminal end of an antibody.119, 162, 163 The bispecificity of this format is 
expressed on a single polypeptide, thereby avoiding the problem of other design formats 
that may undergo hetero- or homodimer miss-pairing of different heavy and light chain 
components. BsAb development involves the utilisation of two different mAbs and 
connecting the variable domains. This creates a single molecule for expression which 
improves single product homogeneity, yield, efficient purification and scalability. However it 
is noted that the linker design between the two variable domain targeting moieties can 
significantly influence the ability of a designed construct to bind its target antigen.162 A 
notable benefit of this BsAb format is that it is very stable and so does not aggregate. 
Asymmetric, monovalent 
One of the most common problems associated with asymmetric bispecifics is that co-
expression of four chains (2 Heavy and 2 light) within a single cell can result in the 
formation of ten potential products.112, 113 Numerous methods have been employed to 
address this problem. Firstly there is the use of a common light chain to increase 
theoretical proportions of final product; however this process still produces a heterogenous 
mixture which makes purification more time consuming.  
Another option is through forced heterodimerisation by means of Fc-engineering. Knob-in-
hole (KIH) mutations, developed by Paul Carter’s group at Genentech, can be inserted into 
the two CH3 domains of the individual mAb monomers to be dimerised. 63, 150, 154, 155, 183 
The design concept is that an amino acid residue on one chain is substituted for an amino 
acid with a larger side chain while a second CH3 interface has a hole inserted by 
substituting large amino acid residues with ones that possess small side chains. A 
common light chain and different heavy chains were included to cater for the possibility of 
heavy chain/light chain miss-pairing. KIH technology has been used to produce a number 
of different formats including Crossmab (Figure 1.10) – involving forced heterodimerisation 
of heavy and light chains; orthogonal Fab interfaces and truncated monovalent heavy 
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chains, namely MetMabs.150, 165, 184 Crossmab production can result in a heterogenous 
mixture of products including light chain dimers, knob-knob and hole-hole variants, 
however stable cell lines can secrete up to 90% of the BsAb product in the supernatant. 
Final purification involves a four step process to remove all contaminants. 
Figure 1.10: Crossmab development through Fab domain exchange and KIH technology. Adapted from illustration 
in Schaefer et al.150 
Moore et al mention a number of different mutation sets that they used to produce knob-in-
hole variants.138 According to them their best mutation set (Knob - Y349T:T394F and Hole 
- S364H:F405A) produces more heterodimers compared with the Atwell et al paper (89%
versus 85% heterodimers).63, 138 Moore et al predicted, but didn’t test, that having the
variable fragments on the C-terminal end would promote increased heterodimer formation.
They also included a mutation of G236R:L328R that prevents binding of the Fc to FcγR’s
and the complement. The linkers they used to connect the variable fragments to CH3
included hinge components as well as variable lengths of G4S repeats.
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Their results suggested that having the C-terminal variable fragments attached to CH3 
doesn’t prevent the required heterodimerisation from occurring. They also observed larger 
aggregates but attributed them to the biophysical properties of the C-terminal scFv 
because they did not observe the large aggregates when they used other variable 
domains at this position. The linker used to link the variable fragments to CH3 was: 
• For connecting the anti-CD16 fragments: SSD KTH TSP PSP (G4S)3 GGGG
• For connecting the anti-CD3 fragments: SSD KTH TSP PSP SG
Large aggregates were visible for the CD3 version but not the CD16 version with the 
longer linker – implying that linker length influences BsAb product stability but this is also 
dependent on the nature of the linked variable fragments. Another set of mutations used in 
BsAb design by Merchant et al 154 included the same KIH set as in Atwell et al 63 (Knob - 
T366W and Hole - T366’S:L368’A:Y407’V) as well as disulfide engineering to stabilise 
heterodimers using a  S354C:Y349’C mutation.137 
Electrostatic steering heterodimerisation also produces 89% heterodimers.135 Amgen 
produced heterodimeric Fc domains by incorporating mutations in the Fc that promote 
electrostatic interactions.185 This summary on the symposium refers to W. Yan as being 
the speaker on this topic. Performing a K392’D:K409’D mutation on one CH3 domain and 
a D356’K:D399’K mutation on the second CH3 arm results in forced heterodimerisation 
and is therefore useful in bispecific production. Some homodimers do form but at very low 
levels. This format can otherwise be known as charge pairs. Jin and Zhu 137 mention that 
by combining the KIH technology and electrostatic steering effects135 a higher degree of 
heterodimers could be produced during expression. However, multiple mutations could 
affect immunogenicity. 
In vitro assembly can also be used to resolve light chain/heavy chain miss-pairing. In this 
instance “half-antibodies” are expressed and purified separately and reassembled under 
redox conditions to produce the final BsAb.152, 186 Overall the method is very efficient in 
BsAb production and homodimer contaminants only equate to about 5% of total produced 
product. An efficient purification system is essential to streamline the BsAb production 
process. Catumaxomab production is completed using Rat/mouse quadroma cell lines and 
the heavy/light chain pairing happens on a preferential intra-species basis which limits the 
amount of mispairing during production. Affinity chromatography can be used to purify 
BsAbs based on specific motifs present in the preferred format present in the supernatant. 
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Alternative fragment BsAb formats 
Out of a total of 23 BsAbs currently undergoing clinical trials, 15 are fragment-based 
formats (PEGS, Europe conference, 2014). Tissue penetration is important in therapeutic 
molecules, especially in solid tumours.157 Molecular size affects penetration; therefore 
having the Fc might make the molecule too big to penetrate tissues efficiently.132 Small 
products do tend to have shorter serum half-lives however but this can easily be mitigated 
by binding to human serum albumin (HSA) or PEG.187, 188 PEGylation can lead to 
decreased immunogenicity but also partial inactivation and decreased affinity of the 
antibody. HSA interacts with FcRn and does not decrease binding affinity. Muller et al 
showed that HSA’s presence increases serum half life/circulation time.189  
Variable lengths of G4S linkers are utilised in many different BsAb platforms. Shorter 
lengths promote a certain amount of rigidity and are therefore ideal in preventing certain 
components of a construct from interacting. Longer linker lengths at 12-15 nucleotides are 
more flexible and are therefore useful when you’re trying to build a scFv where you want 
the VH and VL chains to associate with one another and form a functional scFv. If longer 
linkers were used to join two separate scFvs the risk would be that mismatched folding 
would occur resulting in inactive scFvs being formed in the BsAb construct.187 
Symmetric bivalent fragment constructs include scFv-Fc fusions such as those produced 
by Emergent Biosolutions (Trubion), the ADAPTIR platform (previously known as the 
Scorpion/SMIP platform) and also Affimed’s Tandem Diabodies (TandAbs). TandAbs are 
homodimeric tetravalent molecules that lack an Fc but still maintain a longer, 12 – 24 hour 
serum half-life.190 They are designed as two complementary monomeric polypeptide 
chains that can dimerise without covalent linkages. Self-association of monomers is 
prevented by limiting the linker length connecting variable chain components on the single 
polypeptide (Figure 1.11). Co-expression of the two polypeptides enables variable 
domains to pair up through intermolecular pairing to produce functional, tetravalent 
TandAb BsAbs.  
Emergent Biosolutions’ ADAPTIRTM platform comprises a monospecific 105 kDa molecule 
(formerly known as a SMIP) with a structure similar to a traditional mAb (150 kDa) but 
lacking a CH1 domain.191, 192 An extension of the monospecific ADAPTIRTM platform 
provides a means to produce a BsAb193 (160 kDa) by adding additional binding moieties 
(scFv, extracellular domains or ligands) to the C-terminal domain (formerly known as 
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SCORPION) (Figure 1.12). Whereas the main mode of action under investigation for 
TandAbs is to redirect an immune response, ADAPTIR multi-specifics are used to either 
crosslink two cell surface targets or bind and neutralise two soluble target antigens. 
Linkers connecting N- and C-terminal ADAPTIR binding domains to the Fc are not 
substantially described 191, 194 however they are said to change binding moiety spatial 
orientation compared with mAbs (60-80 A° versus 95-140 A° respectively) which endows 
the molecule with modified signal responses according to the Emergent Biosolutions 
website (http://www.emergentbiosolutions.com/node/76).  
Figure 1.11: TandAb BsAb formation. Adapted from illustration in McAleese and Esser.190 
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Figure 1.12: Format variations of ADAPTIR multi-specifics. Adapted from illustration on 
http://www.emergentbiosolutions.com/node/76 
 
Numerous monovalent bispecific scaffolds are also under development some of which are 
summarised in Table 1.6. Nanobodies or single-domain antibodies (sdAbs) are derived 
from variable domains (VHH) of camelid heavy chain antibodies (HcAb) which naturally lack 
light chains.195, 196 These VHH are generally 11-12 kDa in size and would therefore have a 
low serum half-life when administered in isolation. As such one option is to produce then 
as tandem sdAbs that bind HSA for increased serum half-life in addition to the therapeutic 
target. Although nanobodies lack Fc-mediated effector functions, not all therapeutic 
applications benefit from the domain’s presence.84, 104 It has been shown that tandem 
sdAbs are highly stable and are produced at good yields.197 Furthermore four nanobodies 
have entered clinical trials so far (Table 1.4; Ablynx).  
 
Table 1.6: Summary of monovalent, bispecific scaffolds in development. 
BsAb platform Company Reference 
Nanobodies (camelid) Ablynx 196, 198 
scFv-albumin fusions Merrimack 139, 189, 199 
scFv fusions Macrogenics, Micromet/Amgen 123, 142, 200, 201 
Adnectins Adnexus/BMS 202 
Affibodies Affibody 25, 203 
Darpins Molecular Partners 204-206 
Anticalins Pieris 207 
 
The most commonly utilised monovalent formats are scFv fusions or tandem scFvs. Two 
well characterized formats of this type are the Bispecific T-cell Engager (BiTETM; 
Micromet/Amgen) and Dual Affinity Retargeting (DART) molecules (Macrogenics). 126, 199-
201, 208-210 Typically tandem scFv-based formats are recombinant products that consist of 
two scFvs connected by flexible peptide linkers such as Glycine-Serine repeat motifs.147 
DARTs consist of two separate chains, designed to include proprietary disulphide 
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stabilisation linkages, which are co-transfected in either mammalian or bacterial cells. 
Blinatumomab is an example of a BiTE which has gone through clinical trials and for which 
a BLA has subsequently been filed (Table 1.4).124, 211  
BiTEs are highly potent with an EC50 in the picomolar range but DARTs have been 
described as being even more potent.200 The enhanced stability of the DART molecule 
decreases product aggregation levels and consequently improves cell killing due to an 
increased amount of time being spent in contact with target cells. Nonetheless, numerous 
BiTEs and one DART is currently in clinical trials and many more DARTs in the preclinical 
pipeline (http://www.macrogenics.com/products.html) (Table 1.4). The small size of these 
BsAbs may increase solid tumour penetration levels but their size also means they have a 
very short in vivo half-life and, in the case of Blinatumomab, have to be administered by 
continuous infusion over a 28 day period.212  
There are also other non-antibody protein scaffolds under development that are able to 
bind targets.  These include DARPins (Designed ankyrin repeat proteins), lipocalins, 
fynomers and affibodies, to name a few.213  As an example, DARPin technology utilises a 
synthetic scaffold of 13-17 kDa without any cysteines derived from ubiquitous receptor 
proteins. Repeat sequences consist of a β-turn and two flanking α-helices arranged so that 
a binding surface is created that provides access to randomisable loops that can be 
modified to provide novel target binding surfaces. The size of the DARPin can easily be 
modified by varying the number of repeat motifs present to enable binding of different 
targets. DARPins have the potential of being very effective therapeutic products. They 
have high thermodynamic stability, are soluble up to 100 mg/ml and exhibit high 
thermodynamic stability and binding affinity.27, 204-206, 214, 215 Boder and Jiang noted that the 
smaller a designed scaffold is the lower its immunogenicity is expected to be. It is 
therefore likely that DARPins may not induce significant immune responses in patients but 
the impact of the synthetic sequences is yet to be ascertained.216 One DARPin is currently 
in clinical trials and others are also currently in the preclinical pipeline. 
1.4.4. Future prospects and hurdles to development 
Two of the biggest problems that need to be addressed in BsAb development are product 
stability and the means to upscale manufacturing without significant cost outlays. 
Furthermore, when designing a BsAb many factors need to be considered to select the 
optimal characteristics for a proposed therapeutic system. A large bulky format will limit a 
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product’s ability to penetrate deep into the tumour vasculature, and if administered in 
isolation a very small product such as a DARPin, nanobody or tandem scFv will be cleared 
from the patient’s system very quickly. In the latter mentioned situation the BsAbs would 
either have to be modified to have their half-lives extended by binding a larger partner 
molecule (HSA, PEG, nanoparticles or other drugs) or the benefit of repeat dosages needs 
to outweigh the high associated costs and time spent administering the drugs.  
 
Careful consideration needs to be given to how multiple binding domains will affect each 
other in a single BsAb construct. Different targeting pairs, including the order of the 
moieties, can influence each other on many different levels including stability, binding 
affinity and mode of action – either as an enhancement or more commonly a decrease in 
BsAb design fecundity. The combination of binding moieties included in a system is also 
important when considering targeting two cell surface receptors on a single cell surface – if 
an incorrect pair is chosen the BsAb might over-stimulate a pathway that is meant to be 
suppressed. Notable prospects in the use of BsAbs as therapeutics are not limited to them 
being used as singular therapeutic agents. Besides being used as complementary 
therapies to chemotherapeutic treatments or in redirecting an immune response, they can 
also be used as facilitators of drug delivery by binding specific drugs or even drug-laden 
nanoparticles. 
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1.5. Nanoparticles 
Nanoparticles (NPs) are substantially larger than other next generation therapeutics with 
diameters ranging from 1 – 1000 nm with the majority being smaller than 400 nm. The 
applications of these novel technologies have the potential to provide benefit across a 
number of fields relating to molecular imaging, diagnostics and targeted gene and drug 
delivery-based therapeutics.217, 218 A major benefit of NPs over the use of standard 
chemotherapeutic treatment regimens lies in the ability of NPs to be loaded with high drug 
doses thereby limiting systemic drug exposure and protecting the patient from associated 
toxicity.219, 220 Furthermore, NP payloads are not limited to standard drugs and the 
therapeutic catalog can be expanded to include DNA, siRNA and other peptides. The 
ability to carry such payloads not only provides a means to combat resistance to various 
standard treatments (siRNA knock-out of chemotherapeutic resistance traits) but 
simultaneously protects the small molecules from the environment which would otherwise 
result in their degradation and inability to provide a therapeutic benefit.103, 221 To 
understand the main mechanism by which NPs reach a target or tumour cell some 
knowledge of the physiological characteristics of the tumour microenvironment is 
required.222, 223
1.5.1. Passive and active targeting 
The major factors relevant to NP targeting in the human tumour environment were 
extensively described by Bertrand et al., 2014.224 Improved understanding relating to 
tumour biology, including leaky vasculature and the enhanced permeability and retention 
effect (EPR effect), has accelerated the development of NPs for targeted delivery in both 
passive and active formats.220 As tumours grow their eventual size becomes restricted due 
to insufficient availability of oxygen. As a result, the tumour cells secrete growth factors 
which promote the formation of additional vascular structures. These structures are 
however “leaky” and capillary sizes range from 200 to 2000 nm, enabling oxygenated 
blood to easily extravasate into the tumour microenvironment; described as enhanced 
permeability. Enhanced retention is then promoted due to the absence of a functional 
lymphatic drainage system to drain interstitial fluid from the tissues to the lymphatic 
system. The process allows molecules smaller than 4 nm to escape but retains anything 
larger; a process which allows NPs, whether passively or actively targeted, to enter and 
remain in the tumour microenvironment (Figure 1.13).223-225  
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Figure 1.13: NP drug delivery through passive and active targeting. Adapted from illustration published in Peer, 
2007; Copyright, Nature Nanotechnology.226 Passive targeting (A) takes place by utilising the EPR effect associated with 
leaky vasculature in the tumour microenvironment whereas active targeting involves the same mechanism but provides 
an improvement due to specific cell-targeting and the potential for enhanced cellular uptake of payload-carrying NPs. 
Active targeting as illustrated in the inset can result in the NPs i) releasing the payload close to the target cell, ii) binding 
to the cell-surface and undergoing a slow, controlled payload release without particle internalisation, or iii) particle 
internalisation and subsequent endosomal degradation and payload release. 
Non-targeted (passive) NPs can be rapidly cleared from circulation by opsonisation where 
NPs are engulfed by macrophages or accumulation in the liver or spleen. However various 
means have been developed which circumvent this phenomenon such as coating passive 
NPs with polyethylene glycol (PEG). PEG-layers circumvent NP clearance by preventing 
protein absorption to NP surfaces (a trigger for opsonisation).225 An obvious factor 
affecting NP accumulation in a tumour environment is particle size. The optimal particle 
size is expected to be between 10 nm and 500 nm to avoid both renal clearance and 
phagocytic internalisation respectively.227 Smaller particles are able to better penetrate the 
tumour, particularly solid tumours with low permeability, but are then also more prone to 
being recycled back into the vascular system.  
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NP charge, whether positive or negative affects the efficacy of the particles in vivo. It is 
expected that charges ranging from -10 mV to +10 mV can aid in avoiding phagocytic 
internalisation and prevent NP-aggregation.227 Negative particles exhibit varied effects in 
tumour treatment but positive charged particles are thought to preferentially interact with 
tumour blood vessels which subsequently limits their ability to penetrate deeper into a 
tumour or back into circulation. A positively charged particle also associates with the 
extracellular matrix which further limits particle diffusion. Coating particles with substances 
such as salt and heparin can mask charges and improve therapeutic efficacy. Lastly, 
particle shape also impacts levels of tumour accumulation in that elongated products 
exhibit higher tumour accumulation levels. 
The EPR effect is well described in animal models but has not been evaluated as 
extensively in humans due mainly to the difference in analytical methods (tissue extraction 
in animals). Available data suggests that the EPR effect may vary between patients and 
different cancer types exhibit variable levels of the EPR effect. Therefore relying on this 
mechanism as the primary means of NP delivery will likely not always present in a 
therapeutic benefit. Without a means to direct payload carrying NPs to specific targets 
agents such as siRNA and protein-based treatments, which cannot overcome the tumour 
environment and cross cell membranes, are unlikely to provide a therapeutic benefit.223, 224 
The incorporation of targeting moieties into the NP structure, generally referred to as 
functionalisation, provides an advantage by further minimising off-target effects exuded by 
the NP-payloads (Figure 1.13).226 Providing NPs with a targeting function does not 
however overcome the problems associated with NP opsonisation and subsequent 
clearance although actively targeted NPs may improve the likelihood of a particle and its 
payload being internalised at a cell surface receptor. Selecting an optimal means to 
provide NPs with targeting functions, namely ligand type and conjugation methods, plays a 
major role in the efficacy of the overall proposed actively targeted NP system.224 NPs can 
be functionalised using a variety of different targeting ligands including antibodies, sugars 
and many other small molecules. The surface architecture of NPs influences the number 
of targeting moieties that can be bound on the NP surface. A resulting high surface density 
of targeting moieties incurs multivalency to the NP and thereby enhances the potential of 
the particles to exhibit high avidity binding at targets.224 
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An important consideration in active targeting is the strength of the bond between the NP 
and the targeting moiety. The method by which targeting moieties are bound to NP 
surfaces plays an important role in the production process.224, 228 Various chemical 
conjugation methodologies have been employed, however the chemistry involved can 
sometimes be time-consuming, expensive and inconsistent which is a barrier to up-scaled 
production of targeted-NPs for clinical evaluation. Furthermore, the timing of conjugation 
needs to be considered. If it is likely that solvents used in NP-loading may render the 
targeting moiety non-functional or degraded then conjugation needs to happen after NPs 
have been pre-loaded with the drugs of choice and purified. Another important 
consideration, particularly with NP systems where non-covalent ligand attachment is 
utilised, is whether or not the ligand will change the NP’s immunogenic profile. As 
described in Bertrand et al. the physiochemical properties of both the NP and the targeting 
ligand influence the actively-targeted NPs functionality and ability to be internalised at 
target cell surfaces (Figure 1.14).224  
Figure 1.14: NP and targeting ligand properties affecting biodistribution and function. Adapted from illustration 
published in Bertrand et al.224 
The types of targeting ligands (various proteins, peptides, nucleic acids, small molecules 
and antibody-based fragments) used to actively target NPs have been extensively 
reviewed; herein we will focus on antibody-based products and their targets.223-225 The first 
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antibody (mAb)-targeted NPs were described in the early 1980s.229, 230 While being a very 
effective means to give a NP targeting capabilities, the large size of whole mAbs (150 kDa) 
means that they can significantly alter the size and hydrodynamic radius of a NP, altering 
the NPs ability to effectively penetrate tissues. Conjugating mAbs to NP surfaces can also 
be problematic as the mAbs are sensitive to various chemicals and may become 
denatured during the process. The presence of Fc-components attracts immune cells 
which can subsequently result in NP clearance before they are able to reach their targets. 
The action of the Fc-domain can be subdued by total exclusion of the Fc by only using Fab 
or scFv domains as targeting moieties. Utilising scFvs (25 kDa) provides an additional 
advantage in that their association with NPs doesn’t increase the hydrodynamic radius as 
much as whole mAbs.49, 223  
1.5.2. Types of nanoparticles 
Developing the optimal NP is influenced by a number of factors including the primary 
material composition of the NP, size and biodegradability.231 They have to be able to 
withstand the surrounding biological environment to control payload release while still 
being degradable at target locations, be taken up preferentially in areas where a biological 
benefit is required, possess good pharmacokinetic profiles, be non-immunogenic 
themselves and not aggregate.226 It may be difficult or impossible to develop NPs that 
have all of the optimal characteristics required in therapeutic applications. Various 
published reviews provide a comprehensive list of NPs that have undergone clinical 
evaluation.218, 226, 227 The two most commonly utilised classes of NPs in clinical 
development are liposomes and polymeric carriers.218, 223, 224, 226, 227, 231-233   
Liposomal nanoparticles 
Liposomes are formed through association of lipid molecules to form enclosed bilayers 
and can carry both hydrophilic and hydrophobic compounds.22, 223, 227, 234 An attractive 
feature of liposomes is their relative ease of production under non-toxic conditions and low 
immunogenicity in patients. However they tend to be unstable and easily cleared from the 
bloodstream while also lacking the ability to enable controlled release of payloads. 
Functionalising liposome surfaces by inclusion of targeting moieties or PEGylation (as in 
PEGylated Doxil/Caelyx, the first approved liposome-drug for cancer) improves product 
stability.218, 223, 225, 235 Three non-PEGylated liposomes (DaunoXome, Myocet and Onco 
TCS) have been approved for cancer treatment while a fourth, Depocyt, is undergoing 
clinical trials (Phase I-III) against leukemia and glioblastoma. An additional 3 PEGylated 
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liposomes (Thermodox, SPI-77 and NL CPT) are progressing through clinical evaluation to 
join the approved Doxil/Caelyx liposome formulation as potential cancer treatments.218 
Actively targeted liposomal particles are also under development; eight lipid-based 
particles have been functionalised to target cell surface receptors not limited to cancer-
related indications and are currently in various clinical phases of development.219, 224 
 
Polymeric nanoparticles 
Polymeric NPs are produced by association of many different types of monomers, 
branched or un-branched. Some polymeric forms are even capable of being responsive to 
environmental stimuli where a drug-payload can be released when a temperature, pH or 
other change happens in the particle’s immediate environment.218, 227, 231, 236 It can be 
difficult to efficiently load drugs into a polymeric NP’s core (albeit more efficient than 
liposomes), and polymers that self-associate can become too large for therapeutic 
applications.227 A definite advantage of polymeric NPs over liposomal formats is their 
ability to undergo controlled drug-release, improved drug-loading capabilities and superior 
stability.219 Although no polymeric NPs have been approved for clinical use yet, seven 
passive and three actively targeted polymer-NPs are currently undergoing clinical trials for 
various cancer indications.218, 225 Even though there are advantages in developing 
polymeric NPs instead of liposomal formats, there are many more lipid-based NPs in the 
clinical pipeline. However this is not necessarily due to liposomal NPs possessing superior 
properties but rather due to the fact that liposomes have been under investigation for a 
much longer period of time.220, 229, 230 Other NP formats such as quantum dots, gold 
nanocarriers and carbon nanotubes are also under investigation but have not progressed 
through to the clinical trial stage yet.225, 226, 237 
 
1.5.3. The EnGeneIC delivery vehicle 
The EnGeneIC delivery vehicle, otherwise known as the EDVTMnanocell, constitutes 
another class of NP-based drug delivery system. These particles are bacterially-derived, 
anucleate, 400nm particles devoid of the genes required for cell division, and can be 
loaded with very high doses of cytotoxic drugs and siRNA.103, 129, 238, 239 Although many 
may consider the EDV’s large 400 nm size to be a potential hindrance to therapy, this may 
not be the case. EDV size is thought to limit the BsAb-EDV system’s ability to penetrate 
normal tissues (such as skin and gastrointestinal cells) which only have fenestrations 
ranging between 50 and 100 nm compared with tumours (10 – 1000 nm).239 This attribute 
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would provide an advantage over other smaller NPs which are able to more readily 
penetrate normal tissues and illicit various side effects in patients. 
EDV production and loading 
EnGeneIC’s bacterial strain of choice for EDVTMnanocell production is Gram- Salmonella 
typhimurium which has undergone genetic manipulation to produce minCDE- 
chromosomal deletion mutants. The purification protocol includes various crossflow steps, 
a salt treatment and subsequent filtration and, ensures that the end product retains its 
characteristic LPS surface, is sterile and more than 90% pure. Loading nanocells depends 
on the drug concentration of the incubating solution, time, and occurs down a 
concentration gradient. Nanocells can be loaded easily with high concentrations of a 
variety of drugs (Doxorubicin (Dox), Cisplatin (Cis), Paclitaxel (Pac), Vinblastine (Vin), etc) 
having different charge, hydrophobicity and solubility despite the presence of a bilayer 
membrane. Drug efflux was shown to be notably absent over a 72 hour period when the 
EDVs were incubated in buffered saline gelatin.129 To load EDVs with siRNA, plasmids 
encoding the sequences for siRNAs are transformed into the S. typhimurium strain prior to 
nanocell purification. Each nanocell was shown to be preloaded with up to 50 copies of 
plasmids and 14 000 copies of siRNA.103, 239  
EDV targeting 
The EDVs are actively targeted to cancer cell surface targets through the use of BsAbs 
(designed to bind the nanocell’s natural surface lipopolysaccharide (LPS) and EGFR on 
cancer cells simultaneously) (Figure 1.15).129, 238, 240, 241 EnGeneIC’s original BsAb format 
was produced by mixing equimolar amounts of two full mAbs (anti-LPS and anti-EGFR) 
with a protein A/G molecule. To conjugate the BsAb to the EDV all that is required is a 
simple mixing step of both the purified BsAbs and EDVs followed by a brief incubation 
period shaking at room temperature and subsequent spin/wash cycles in phosphate 
buffered saline (PBS). Thus, using a BsAb to target NPs requires no complicated chemical 
conjugation steps, allowing for efficient and scalable production without compromising 
either the NP, drug or antibody integrity.  Furthermore, the NPs are loaded with drugs or 
other therapeutic compounds prior to them being functionalised with the desired targeting 
moiety. This method is beneficial in ensuring that the BsAb to be used for targeting is not 
negatively impacted by the harsh conditions associated with drug loading and nanocell 
production.129 
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Figure 1.15: Loading and functionalisation of EDVTMnanocells. As illustrated in MacDiarmid and Brahmbhatt.239 
In vitro and in vivo results 
The use of a protein A/G was described as the reason why complement-mediated toxicity 
through interactions with the Fc were not observed in the original system since the Fc is 
blocked for complement activation by protein A/G.129, 239 Active targeting of nanocells not 
only facilitates targeted drug delivery but provides a means for these NPs to be taken up 
into the cell (endocytosis) and degraded intracellularly for optimal payload release. 
Although the mechanism (e.g. macropinocytosis) by which the NPs enter the cell is not yet 
fully understood, EnGeneIC have demonstrated that nanocells targeted using their Protein 
A/G BsAb format do enter the cell and provide a therapeutic benefit. EnGeneIC’s initial 
data showed that single cells could carry as many as 40 – 50 nanocells enclosed in 5 – 6 
vacuoles. In comparison, non-targeted EDVs do not enter the cell which suggests a 
definite link to the active targeting being a requirement for particle internalisation. Over 
time internalised targeted EDV membrane integrity is lost and the payload released, as 
shown in MacDiarmid et. al.129, 241 
In vivo mouse xenograft models and studies of canine lymphomas have shown significant 
amounts of tumour regression even though drug and antibody concentrations were low. 
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EnGeneIC found that administering 150 µg of free Dox in mouse xenograft models does 
not illicit the same high tumour growth inhibition as treating with BsAb-EDVTMnanocells 
loaded with a mere 0.08 µg Dox. Similarly, treatments with Pac required 8000-fold lower 
amounts compared with standard systemic drug administration. In addition to this lower 
drug concentration, they also noted that there appeared to be a distinct absence of some 
of the toxic effects normally associated with chemotherapeutic drug treatments. Data has 
shown that in comparison to the clinically approved passive liposome, Doxil, nanocells 
targeting EGFR and loaded with Dox required 100-fold lower doses to achieve similar 
tumour regression in xenograft models.129, 238  
It is also possible to load EDVs with siRNA or DNA as a therapeutic means to knock out 
genes responsible for drug resistance in tumour cells which subsequently increases the 
therapeutic benefit of treating with chemotherapeutic agents which would otherwise have 
been ineffective.103, 221, 239 The importance of this attribute lies in that siRNA is normally 
poorly membrane permeable, easily degradable by serum nucleases, illicit off-target 
effects and intracellular delivery is a requirement for therapeutic efficacy. The nanocell 
provides a platform whereby siRNA can be used as a viable therapeutic option by 
overcoming all of these potential drawbacks.103, 239 Sequential treatments using firstly 
siRNA-loaded targeted nanocells followed by a drug a tumour was known to be resistant 
to, showed evidence of the reversal of the resistance phenotype. 
Furthermore, a study on trophoblast overgrowth associated with various gynaecological 
disorders, including ectopic pregnancies, confirmed the ability of EGFR-targeting BsAb-
EDVs to effectively treat trophoblast tissue with Dox. The actively targeted NP-system was 
much more effective than both a non-specific and non-targeted EDV format.241 Initial 
biodistribution studies showed a definite advantage in actively targeting the EDVs to 
cancer cells in that a much higher drug doses was localised at the site of interest. Although 
the results also indicated that EDVs were present in the lungs, spleen and liver, these 
were rapidly cleared and were only detected at very low levels after 24 hours.  
1.5.4. BsAbs as facilitators of therapeutic NP delivery 
The EDV is unique amongst other targeted NPs currently in clinical trials by its use of 
BsAb for targeting rather than chemically conjugated moieties. EnGeneIC’s original BsAb 
format was quite large, and consisted of two mAbs (150kDa each) plus the additional 
protein A/G molecule used to connect the individual mAbs. The method of BsAb 
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production could even result in products of up to six mAbs. Although their original work did 
not note any problems with penetration associated with the increased hydrodynamic radius 
of the nanocell, it is logical to expect that in a clinical setting where the EPR effect isn’t as 
well understood the larger product size may be a hindrance in therapeutic efficacy. Thus 
the development of a smaller NME to functionalise the nanocell surface could prove to be 
a much more potent endeavour.103, 129, 239, 240 
 
Schneider et al. described a means to utilise BsAbs to deliver siRNA to tumour cells. They 
found that although the siRNA was effectively delivered and internalised, the siRNA was 
unable to escape the endosome to provide a therapeutic benefit. To overcome this barrier 
to therapy they formulated the siRNA into polyconjugate (Dynamic polyconjugates or 
DPCs) or liposomal NPs targeted to cells with BsAbs.242, 243 They found that using the 
BsAbs as facilitators to deliver siRNA carrying DPCs of a endosomolytic nature to target 
cells, resulted in a highly specific and effective means to incur mRNA knockdown in 
targeted cells. However the process involved conjugating digoxigenin (BsAb scFv target 
on NP) to siRNA which is then formulated into the NP or polymer surface, in addition to the 
inclusion of the BsAbs that have to undergo proteolytic cleavage; all of which makes the 
production process less efficient. Next they evaluated the use of PEGylated lipid-based 
NPs. Here the PEG-surfaces were functionalised with a target for the C-terminal end of the 
BsAbs which also made the functionalisation process less efficient. They also noted that a 
decrease in mRNA knockdown was evident possibly due to the presence of PEGylated 
surfaces. Comparatively the means by which the EDVTMnanocell is functionalised is far 
simpler and as siRNA can be housed inside the nanocell system it is protected further from 
possible environmental degradation.103, 128, 242, 243  
 
Another actively targeted format, which utilises diabodies as the targeting moieties for 
polymerised lipid NPs (PLNs), required that cysteines be added to the Db. This enables 
the Db to be conjugated to the PLN using maleimide chemistry.244 A BsAb targeting 
methoxy PEGylated (mPEG) liposomal NPs and EGFR on cancer cells was produced by 
Kao et al.228 Although this BsAb binds the NP non-covalently by the same means as in the 
EDVTMnanocell, the use of liposomal NPs is in this instance the drawback in comparison 
with the nanocell system. As previously mentioned, EDVTMnanocells can be loaded with 
higher drug concentrations and exert a greater therapeutic benefit than other liposomal 
NPs (e.g. Doxil). However the system has many attractive features similar to that of 
EDVTMnanocells. A lack of chemical conjugation steps circumvents the risk of degradation 
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of drugs, NPs and targeting moieties. The modular nature of the BsAbs enables a means 
to effectively substitute one disease-targeting moiety for another and because the BsAbs 
can only attach in a specific orientation, the NP surface can be relatively homogenous 
given a uniform surface antigen distribution.103, 129, 228, 238, 239, 241, 245 Another major 
difference however is that the format described by Kao et al. is applicable across a wide 
variety of NPs as long as they possess mPEG on their surfaces, whereas the BsAb in the 
EDVTMnanocell system is designed specifically for the LPS on its surface.129, 228, 240 
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1.6. Conclusion and research aims 
1.6.1. The future of nanoparticles 
Factors important in NP design and development include characterisation of the degree of 
accumulation in tumour environments, drug loading capabilities, controlled versus rapid 
payload release (is the drug housed internally or on the NP surface) and immunogenic 
profiles. Couvreur noted that developing products that mimic natural products and are able 
to escape the endosome once inside a cell could be an ideal means to enable effective NP 
delivery to target surfaces.220 Given that the EDVTMnanocell is based on a naturally 
occurring entity and has been shown to efficiently release payloads intracellularly following 
endosomal escape, nanocells may well be a highly promising technological advance 
amongst developed NP systems.103, 129, 240, 241, 245  
NP development for clinical use is still in its infancy and a lot of work remains to be done to 
fully evaluate all aspects of NPs and how their physical characteristics (charge, surface 
material, ligand density, shape etc.) affect biological and therapeutic outcomes in patients. 
The benefit of active targeting also needs to be fully elucidated given that it is believed that 
the main method by which both passively and actively targeted NPs reach tumour cells is 
via the EPR effect. Nonetheless, the inclusion of targeting moieties in NP-delivery systems 
seems to enhance particle uptake and internal release of drug payloads, which is of 
particular benefit in the case of siRNA delivery where external degradation would have 
precluded any potential therapeutic benefit. However, the degree to which particle uptake 
and controlled payload release varies between different types of NPs still needs to be 
determined. The most important benefit of actively targeted NPs however is in that they 
provide a means to avoid non-specific activity of drug payloads on normal tissues; thereby 
increasing the therapeutic benefit at a targeted site where treatment is actually required.218,
219, 223, 224, 227, 228, 231, 238
The wide variety of targeting moieties available to functionalise NP surfaces endows 
different products with various physiological characteristics. Moreover the means by which 
these targeting moieties are conjugated to the NP surface is of significant consequence. 
The use of chemical treatments to conjugate ligands to NP surfaces can be costly, 
inconsistent and time-consuming; thus making the use of alternative options such as 
engineered BsAbs specific for a disease cell surface target and the NP itself very 
appealing. BsAbs provide a means to simply and efficiently “label” NPs with targeting 
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moieties in a homogenous orientation on its surface to present to target antigens, thereby 
completely avoiding the drawbacks of chemical techniques. 
1.6.2. Research aims and strategy 
The BsAb format utilised in the original EDVTMnanocell system was produced by 
conjugation of two mAbs (anti-EGFR and anti-LPS) to Protein A/G.  Protein A/G has six 
binding sites for mAbs, so can therefore bind multiple specificities.129 Although this design 
showed proof of principle in the use of BsAbs to direct EDVTMnanocells to their targets, 
manufacture of this design is cumbersome and inconsistent.  This is because there is no 
control of how many of each mAb binds the Protein A/G molecule, resulting in a 
heterogeneous product. A more homogeneous and scalable approach to producing BsAbs 
is to produce them recombinantly. Different recombinant formats need to be evaluated to 
determine how the design influences production and final product quality.129, 240 
The aim of this project is to develop novel, modular, BsAb formats that can be used in 
conjunction with the novel drug delivery vehicle technology developed by EnGeneIC Ltd; 
the EDVTMnanocells, to target specific cancer cell surface markers. To achieve this aim a 
number of objectives needed to be achieved, namely: 
1. Design a number of novel BsAb formats, with specificites towards a tumour cell
surface marker (EGFR) and a surface antigen on the EDVTMnanocells (LPS).
2. Construct and express the BsAb formats, and evaluate for product yield, stability
and in vitro binding affinities.
3. Perform bioassays on BsAbs to evaluate their suitability in targeting cancer cells
when bound to EDVTMnanocells.
By engineering modular BsAb formats we can develop a technology that will utilise mAbs 
and scFvs that are either novel or have already passed clinical trials to be inserted into the 
BsAb-EDVTMnanocell system with ease for simple target redirection, enhancing the 
potency of the targeting moieties via the linked cytotoxic payload.225, 246 The research 
described herein will inform researchers across multiple fields as to a means to efficiently 
evaluate and optimise targeting moieties of an actively targeted drug delivery system. This 
research improves on EnGeneIc's original protein A/G BsAb format by using recombinant 
technologies to produce a more scalable and cGMP compliant targeting moiety, which 
avoids the use of chemical conjugation and multistep NP functionalisation.  By 
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incorporating these new BsAb designs into the EDVTMnanocell, EnGeneIC have developed 
an active NP delivery system ahead of its counterparts. 
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2. Materials and methods
2.1. EnGeneIC delivery vehicle (EDVTMnanocell) production 
Protocols outlining the production process involved in EDVTMnanocells (EDVs) 
manufacturing are described in the supplementary material of MacDiarmid et al. (2007).129 
Initially a number of different EDV-producing bacterial strains were created and analysed 
to select the optimal version.129 Finally a Salmonella typhimurium minCDE¯ strain was 
selected for EDV production.103, 129 Currently the production of EDVs has been scaled up 
to be completed in a fermenter using conditions similar to that previously described in 
MacDiarmid et al. (2007).129 EDV purification is completed using a number of cross-flow 
filters instead of the centrifugation steps previously described to ensure product 
homogeneity and the complete removal of contaminating matter such as parental bacterial 
cells, endotoxin and other cellular debris.129 
The production process currently takes 3 days to complete and further technical details 
relating to the method are subject to confidentiality and cannot be revealed by EnGeneIC 
Pty Ltd (personal communication I. Sedliarou). 
2.2. Routine molecular biology techniques 
2.2.1. Vector design 
Vectors containing BsAb sequences were developed by either GeneArt (Life 
Tachnologies) or staff at the National Biologics Facility (NBF) based at the Australian 
Institute for Bioengineering and Nanotechnology (AIBN). For the purpose of transient 
mammalian expression BsAbs were cloned into pcDNA 3.1+ (Invitrogen).  
2.2.2. Bacterial transformation 
Restriction enzyme (New England Biolabs or Roche Life Science) digested vectors and 
fragments of interest were cleaned up (Qiagen QiaExII gel extraction kit) and subsequently 
underwent ligation (Roche Rapid DNA Ligation kit) to produce new plasmids containing 
recombinant protein DNA sequences for eventual mammalian expression. For bacterial 
transformation to take place ligation mix was added to either TOP10 or α-select gold 
efficiency (Bioline) competent cells that were thawed on ice. The mixture was left to 
incubate on ice for 15 minutes then underwent a heat shock treatment in a 42 °C 
waterbath for 30 seconds and placed back on ice for another 2 – 5 minutes. Sterile LB was 
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subsequently added to the mix and the samples placed at 37 °C, shaking at 220 rpm for 1 
hour after which the sample was spread out on agar plates containing either LB-Ampicillin 
or LB-Kanamycin depending on the required selective pressure for correct clone growth to 
take place. Plates were incubated at 37 °C overnight.  
2.2.3. Colony PCR 
To screen whether or not clones from bacterial transformation carried the fragment of 
interest colony PCRs were routinely performed. A mastermix was set up for the PCR that 
contained 0.5 µM (final concentration) of each primer (T7-Forward and BGH-Rev), sterile 
water and Promega 2× mastermix, from which 10µl was aliquoted out per colony to be 
screened. Selected colonies were picked using a sterile, short, 10 µl pipette tip and dipped 
in the PCR mix containing tube. The tip was then transferred to an appropriately labelled 
sterile 1.5 ml eppendorf tube and stored until a positive clone is selected to be cultured for 
DNA stock preparation. 
The PCR tubes were placed in the thermocycler and a pre-programmed colony PCR 
program loaded with the following conditions: 
94 °C 10 min 
25 cycles of: 
• 94 °C 1 min
• 50 °C 30 sec
• 72 °C 2 min
72 °C 10 min 
15 °C hold 
On completion of the run 1.5 µl of loading dye was added to each reaction and 5 µl of the 
samples run on a 1% agarose gel for 30 – 40 minutes. Positive clones were identified 
according to the expected insert size. 
2.2.4. E. coli culture for maintenance of DNA stocks 
For the purpose of maintaining DNA stocks prepared either as a miniprep for molecular 
biology processes (Qiagen QiaQuick Miniprep kit) or a maxiprep for transfection 
(Invitrogen HiPure Filter Maxiprep kit), E. coli cultures were grown using LB broth at either 
5 ml or 400 ml volumes respectively. LB broth was prepared by adding 25 g/L of premixed 
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LB powder to RO water after which the media was autoclaved at 121 °C for sterilisation 
purposes. Selective pressures were applied to ensure growth of the correct clones by the 
addition of either 100 µg/ml Ampicillin or 30 µg/ml Kanamycin, to the sterile LB broth. A 
single colony or starter culture prepared from a single colony was then added to the 
prepared growth media for minipreps or maxipreps, respectively. Cultures were incubated 
at 37 °C for 8 – 18 hours depending on the application, and 220 rpm. 
On completion of incubation period cultures were spun at 5 200 g at room temperature for 
20 minutes. The supernatant was then discarded and miniprep and maxipreps completed 
using manufacturers’ recommended reagents and conditions. DNA concentrations were 
determined using a nanodrop spectrophotometer and stored at -20 °C. 
2.2.5. DNA Sequencing set up 
Sequencing reactions were set up following plasmid DNA extraction from E. coli culture 
using a Qiagen QiaQuick Miniprep kit. DNA concentrations were determined using a 
nanodrop. Each reaction contained a single primer and therefore 2 reactions were set up 
per plasmid sample as follows: 
200 – 250 ng plasmid DNA 
10 pmol Primer (Forward or Reverse) 
Sterile water to make up a 12 µl total volume 
Prepared samples were submitted to the Australian Genome Research Facility (AGRF), 
Brisbane node, for sequencing on AB3730xl Sequencers following completion of a BigDye 
Terminator (BDT) v3.1 (Life Technologies) labelling reaction and subsequent sample 
cleanup using CleanSeq beads. Traces received from the AGRF were analysed for the 
presence of the DNA sequence of interest and absence of any mutations such as 
deletions, frame-shifts and point mutations. Positive confirmation of the plasmid quality led 
to maxipreps being completed to prepare high quality amounts of DNA template for the 
purpose of sterile transient transfection. 
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2.3. Sequence design 
 
2.3.1. EGFR-ecd 
The DNA sequence of the extracellular domain (amino acid residues 25-645) of wildtype 
human EGFR (Swiss-Prot P00533) was synthesised by Geneart, incorporating a 
mammalian leader sequence from IgK and a C-terminal His tag (Figure 2.1.a), with codon 
optimisation for expression in CHO cells.  Further constructs consisting of amino acids 
residues 25-525 followed by either human or mouse Fc tags were created (Figure 2.1.b-c), 
similar to that described by Adams, 2009.48 
 
2.3.2. EGFR-targeting and negative-control scFv 
The sequence information for the heavy and light chain variable regions for the 
commercial anti-EGFR mAb panitumumab (Vectibix) was obtained from US Patent 6 235 
883. The sequence for an unrelated control antibody (anti-RSV) palivizumab (Synagis) 
was obtained from the RCSB Protein Data Bank file, 2HWZ (Figure 2.2). 
 
2.3.3. EDV-targeting scFv 
The heavy and light chain variable region sequences of the anti-LPS mAb (Figure 2.2) 
were determined by isolating and sequencing cDNA isolated from the hybridoma 1H10, 
using established protocols.247 
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Figure 2.1: Recombinant EGFR sequences. The a) initial EGFR sequence included a C-Terminal His-tag and 116 
additional amino acids (green) not included in the b) human-Fc and c) mouse-Fc tagged recombinant EGFR sequences. 
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Figure 2.2: Variable chain sequences for BsAb design. The a) anti-EGFR (panitumumab) sequences were reverse 
engineered from the US patent while the b) negative control, anti-RSV (palivizumab), variable fragment details were 
sourced from a Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank File. The final variable 
sequences for c) the anti-LPS, EDVTMnanocell targeting, scFv designs were determined by sequencing cDNA from a 
1H10 hybridoma. 
2.3.4. BsAb sequences 
The DNA templates for all BsAb formats except the original IgG-like format were 
synthesised by Geneart with codon optimisation for CHO expression. Construct designs 
are shown in Figure 2.3, showing the location of the immunoglobulin leader sequence, 
glycine-serine linkers, Fc domains, stabilisation linkers and engineered cysteine residues. 
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The tandem scFv included 6xHis and c-myc tags for purification and detection, whilst the 
other constructs utilised the Fc domain for purification and detection. 
Tandem scFv 
The DNA template for BsAb Vectibix-G4S-1H10 was synthesised by GeneArt (Figure 
2.3.a) and was subsequently cloned into a mammalian expression vector (pcDNA 3.1+) to 
produce a tandem scFv format. This BsAb was designed to include a 5 amino acid glycine-
serine linker (G4S) between the Vectibix- and 1H10-scFv; the shorter linker reduces 
flexibility and therefore prevents miss-folding from occurring between different scFv 
components (Table 2.1). The sequence was flanked by a N-terminal His- and C-terminal 
myc-tag to aide in detection and downstream purification; creating a 55kDa construct. 
A second tandem scFv was designed to be used as a negative control that would be 
unable to bind EGFR receptors. Here we used the variable chains of a commercial anti-
RSV mAb, namely palivizumab (Synagis). Any binding to EGFR from this construct would 
suggest non-specific binding by the BsAb format or EDVTMnanocells depending on the 
context of the experiment. 
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Figure 2.3: BsAb sequence information. a) Engineered sequence sent to GeneArt to develop Vectibix-G4S-1H10 
tandem scFv BsAb. b) Fc-containing Vectibix-Fc-1H10 sequence developed by splicing overlap extension (SOE) PCR 
and restriction enzyme digestion. c) Sequence designs sent to GeneArt to develop Knob-in-Hole formats for co-
transfection. Both a) b) and c) show the locations of restriction enzyme sites used during cloning and to produce a 
modular structure which would enable scFvs to be exchanged for different ones easily when the need arises to target 
different markers. 
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Fc-containing BsAb through Splicing Overlap Extension (SOE) PCR 
The second BsAb (Fc-containing) format was designed to incorporate a longer linker 
between the scFvs (Figure 2.3.b) and give it the ability to function as a quadromer by 
binding two of both the EGFR (cancer cell) and LPS (EDV) antigens. We used an IgG1 Fc-
domain to link and separate the two scFvs spatially thereby developing the Vectibix-Fc-
1H10 homodimeric Fc-containing BsAb (Table 2.1), similar to the scFv-Fc-scFv BsAb 
dimer described in Jendreyko et al, 2003 among others.118, 151, 169, 193 Fc-domains (Hinge-
CH2-CH3) were amplified from in-house materials. To create the Fc-containing BsAb 
construct we firstly produced a plasmid that contained the sequence for the Fc-domain and 
1H10-scFv. The only scFv that needs to be interchangeable is the cancer cell-specific 
scFv; therefore no restriction enzyme sites were included between the Fc and 1H10-scFv 
because the anti-LPS component is considered to be a permanent component of all the 
construct designs for this project. The Fc sequence and 1H10 sequences were PCR 
amplified from their original vectors, using primers which incorporated complementary 
overhang sequences to allow subsequent SOE PCR (Table 2.2). After purifying the 
individual bands a number of splicing overlap extension (SOE) PCRs were performed to 
produce the required Fc-1H10 sequence.248 The cycling conditions were: 
98 °C 30 sec 
10 cycles of: 
• 98 °C 10 sec
• 50 °C 30 sec
• 72 °C  1 min
20 cycles of: 
• 98 °C 10 sec
• 68 °C 30 sec
• 72 °C 1 min
72 °C 10 min 
15 °C hold 
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Table 2.2: Splicing overlap extension. Primer sets as used in the development of the homodimeric Fc-containing BsAb 
format from IgG1 Fc and Panitumumab (Vectibix) tandem scFv sequence components. 
To complete this part of the experiment I then transformed the Fc-1H10 sequence into a 
mammalian expression vector following restriction enzyme (RE) digestion and performed a 
colony PCR of the resulting colony. Next the Vectibix (Panitumumab)-scFv component 
was PCR amplified from the tandem scFv construct using primers: Vect_Fc-link_Forward 
and Vect_Fc-link_Reverse (Table 2.2); and transformed into the new Fc-1H10 plasmid to 
produce Vectibix-Fc-1H10. No additional tags were added onto the construct as the 
presence of the Fc-domain would enable identification and purification through the Fc-
domain’s ability to bind protein A. 
Knob-in-hole (KIH) BsAbs 
The third designed format was developed to limit the number of EDVs that one BsAb can 
bind by only having a single 1H10-scFv present on the construct (Figure 2.4). 
Heterodimeric BsAb formats were based on the common Knob-in-hole constructs and 
partly on the TandAb BsAb designed by Affimed where variable linker lengths are used to 
Primer name Primer sequence (5’ – 3’) Tm (°C) Description 
Fc_Fc-link_ 
Forward 
TTA ATT GAG CTC ATA 
TAT TCC GGA GGA GGC 
GGA TCA ACC CAC ACC 
TGC CCT 
73 
Fc individual PCR primer including a 5’ 
overhang with Sac1 and BspE1 RE sites and a 
sequence for a SG4S linker. 
Fc_longoverlap_ 
Reverse 
CCA GCT GCA CCT CTG 
ATC CAC CAC CTC CTG 
ACT TGC CAG GAG ACA 
GG 
76 
Fc individual PCR antisense primer sequence 
for 3’ end of Fc region and overhang for SOE 
PCR to connect to 1H10-scFv. No RE sites. 
1H10_Fc-link_ 
Reverse 
GGC GCC TCT AGA TCA 
GAT GAT TTC CAG GCG 
66 
1H10-scFv individual PCR antisense primer 
sequence for 3’ end of 1H10 region and 
overhang to include a stop codon followed by a 
Xba1 RE site. 
1H10_longoverlap_ 
Forward 
CCT GTC TCC TGG CAA 
GTC AGG AGG TGG TGG 
ATC AGA GGT GCA GCT 
GG 
76 
To create a long overlap between the 3’ end of 
the Fc and 5’ end of the 1H10-scFv. No RE 
sites. 
Vect_Fc-link_ 
Forward 
AAT AAT GAG CTC CAG 
CTC CAG CTG CAG G 
63 
Vectibix (Panitumumab) scFv individual PCR 
primer including a 5’ overhang with a Sac1 RE 
site. 
Vect_Fc-link_ 
Reverse 
GGC CCG TCC GGA CTT 
GAT TTC CAC CTT GG 
67 
Vectibix (Panitumumab) scFv individual PCR 
antisense primer sequence for 3’ end of 
Vectibix region and overhang to include a 
BspE1 RE site. 
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determine chain association for functional BsAb formation (Table 2.1).138, 140, 155 Knob-in-
hole (KIH) engineering of the CH3 sequence facilitates heterodimeric association as 
described in Atwell et al. 1997.63 A “knob” was produced in one heavy chain by amino acid 
substitution for a longer side chain (T366’W) whereas a “hole” was produced in the second 
heavy chain by amino acid substitutions for shorter side chains (T366’S:L368’A:Y407’V); 
sequence positions as indicated by Kabat et al. 1991.63  As in Vectibix-Fc-1H10 (Fc-
containing); here the Fc constitutes the linker region that effectively separates the two 
scFvs – two DNA templates were required, one containing the 1H10 Vh region and “knob” 
mutation and one containing the 1H10 Vk region and “hole” mutation (Figure 2.3.c).  To 
ensure that the VH- and VL-chains associate with one another to form a functional 1H10-
scFv, linker length between the Fc CH3 domain and the 1H10-scFv component was 
designed to include only the longer linker as described below (Figure 2.4). 
Figure 2.4: Diagram representing sequence orders for the design of BsAb construct 3. a) Sequence of construct 
“light” chain. b) Sequence of construct “heavy” chain. 
Stability engineered formats 
Cysteine stabilisation substitutions were made at Kabat position VH44 and VL100 of the 
scFvs.141, 181 Fc-containing variants included either a short (G4S) linker or a longer linker 
(SSDKTHTSPPSPGGGGSGGGGSGGGGSGGGG) as described in Moore et al. 2011; 
connecting the CH3 domain to the 1H10-scFv (Table 2.1).138  
2.3.5. Commercial mAbs – positive and negative controls 
Whole mAbs for panitumumab (Vectibix) and palivizumab (Synagis) were created by 
reformatting the BsAb sequences using a previously described method.249 
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2.4. Mammalian cell culture 
2.4.1. Cell resuscitation and passaging 
Aseptic techniques were maintained in all cell culture related experiments and processes 
completed in Class II biosafety cabinets that were cleaned using 80% (V/V) ethanol and 
UV sterilised at the end of each day. Media prepared in the cabinets were heated to 37 °C 
in a water bath located external to the cabinet but still within an area dedicated to large-
scale quality protein production. 
Chinese Hamster Ovary cells,250 in this instance the suspension adapted CHO-S 
(Invitrogen), were stored in cryovials located in liquid nitrogen. Resuscitation involved 
transporting selected vials on dry ice and thawing the cells at 37 °C after which 1 ml of pre-
warmed media (CD-CHO + 8 mM Glutamax) was added directly to the cells. The cell 
suspension was transferred to a 125 ml shaker flask to make up a total volume of 20 – 30 
ml (Table 2.3) so that cells equated to a viable density of around 0.2 × 106 cells/ml in the 
prepared media. Flasks were maintained for 2 - 3 days shaking in a humidified incubator at 
37 °C with 5 % carbon dioxide and 220 rpm. For passaging cells were routinely seeded at 
0.2 – 0.4 × 106 cells/ml in 20 – 30 ml media, and densities were maintained to not exceed 
3.4 × 106 cells/ml. CHO-S cell counts were performed using a Cedex HiRes (Roche) which 
also provided values such as cell viability, size and aggregation rate.  
Table 2.3: Vessels for cell culture. 
Growth type Maximum cell number or culture volume Vessel Supplier 
Adherent 
8 x 106 cells,     
4-8 ml media 25 cm
2 T-flask 
Corning Inc (Corning, 
NY, USA). 
20 x 106 cells,   
10-40 ml media 75 cm
2 T-flask 
40 x 106 cells,            30-
60 ml media 150 cm
2 T-flask 
Suspension 
8-40 ml 125 ml shake flask Corning Inc. 
40-100 ml 250 ml shake flask 
100-180 ml 500 ml shake flask 
180-300 ml 1 L shake flask 
0.3-1 L 3 L shake flask 
2.4.2. Transient cell culture media and techniques 
Transient expression of all BsAbs was performed using PEI-mediated transfection of 
suspension adapted CHO cells using CD-CHO (Gibco, Life Technologies) chemically 
defined media supplemented with 8 mM Glutamax and 0.4% anti-clumping agent (ACA), 
as previously described (Table 2.3).251 Knob-in-hole chains were co-transfected at a 1:1 
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DNA ratio (1H10-Vh:1H10-Vk). Culture supernatants were harvested 7-10 days post-
transfection by centrifugation, then filtered and stored frozen at -80 °C until purification 
could be completed. 
2.5. Qualitative western blot for BsAb expression analysis 
300ml transient transfections were completed for all BsAb constructs, and cell pellet and 
supernatant samples taken at 2, 5, 7 and 9 days post-transfection. Transfections were all 
harvested at Day 9 and supernatants stored at -80 °C until purification could take place. 
Pellet samples were collected by spinning down 1ml of each sample at 9 000 g, removing 
supernatant, and washing 3 times with sterile PBS and storing at -20 °C. The removed 
supernatant was collected to ascertain whether or not BsAb had been secreted from the 
cells at the various time points. Pellet samples were resuspended in 50µl Dulbecco’s PBS. 
For western sample preparation 10µl of supernatant and pellet samples were added to 4 µl 
4× LDS Sample Buffer (Invitrogen) and 2 µl 10× Reducing Agent (Invitrogen). Supernatant 
samples were incubated at 95 °C for 5 minutes whereas pellet samples were incubated for 
15 minutes before loading onto a Novex 4-12 % Bis-Tris PAGE gel and run for 35 minutes 
at 200 V in 1× MES buffer (Invitrogen). 
Separated proteins were transferred to PVDF membrane using a BioRad Trans-Blot Turbo 
Transfer System and PVDF Transfer packs, with a 7min mixed molecular weight transfer 
protocol, as per the manufacturer guidelines. Following transfer, the membrane was rinsed 
with PBS-T and blocked in PBS-T + 2 % milk, then secondary antibody added for 30 
minutes. For the tandem scFv BsAb, a mouse anti-6xHis-HRP conjugated (BD 
Biosciences) secondary antibody was used, and an anti-human IgG (Fab)’2-HRP (Sigma-
Aldrich) was used for the Fc-containing and Knob-in-Hole variants. Both secondaries were 
at 1mg/ml and used at a 1:10 000 dilution in PBS-T. Membranes were then washed 3 
times in PBS-T at 5 minute intervals while shaking and 5mL ImmunStar WesternC solution 
added to each membrane for imaging using a BioRad ChemiDoc MP. 
2.6. Affinity chromatography 
2.6.1. IMAC and TFF 
His-tagged constructs (tandem-scFv and EGFRecd-His) were initially purified by IMAC 
chromatography. Mammalian cell culture media contains chelating agents that interfere 
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with this mode of purification therefore it was first buffer exchanged using tangential flow 
filtration (TFF). 
Optimised protocol for His-tagged tandem scFv purification 
Optimisation of the tandem-scFv purification protocol led to the use of two sequential 
IMAC chromatography steps. First step using a HisTrap Excel (GE Healthcare) column 
which tolerates nickel chelating agents present in mammalian cell culture media, followed 
by HisTrap FF (GE Healthcare) which further removes impurities.  Manufacturer-
recommended buffers were used for equilibration and loading – no Imidazole used for 
equilibration and a 20 mM Imidazole wash with the HisTrap column, 20 mM Imidazole for 
equilibration of HisTrap FF and 500mM Imidazole for all elution steps.  The eluted product 
was buffer exchanged into PBS using a HiPrep desalting column after each IMAC step. 
Tandem scFv BsAb monomer was isolated using a GE gel filtration column (HiPrep 26/60 
Sephacryl S-200 HR) and the monomer subsequently used for kinetic experiments and 
long-term stability studies. Products were stored at 4 °C unless specified otherwise. 
2.6.2. Protein A 
For constructs containing an Fc domain, purification was performed in one step using a 
MabSelect SuRE Protein A HP column (GE Healthcare). Buffers used include 1× PBS for 
loading and 0.1 M Glycine, pH 3.0 for elution. Following purification the BsAbs were 
desalted into Dulbecco’s PBS buffer for storage using the HiPrep desalting column. 
Products were stored at 4 °C unless specified otherwise. 
2.7. Protein quality 
Post-purification quality control was routinely completed. All samples were analysed by 
nanodrop, PAGE gels and SEC HPLC. 
2.7.1. Quantification 
A Nanodrop 1000 (ThermoFisher) was used to determine protein concentrations post-
purification by incorporating extinction coefficients (Table 2.4) and using 1 x Dulbecco’s 
PBS as a blank sample unless the protein was eluted into a different buffer. 
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Table 2.4: BsAb vector and protein data. The NBF designation of each vector ID refers to the reference in the National 
Biologics Facility (NBF) plasmid database. 
BsAb ID pcDNA 3.1 vector ID 
Co-
transfection 
Vector ID 
Insert 
size (bp) 
(incl. 
Leader) 
Insert AA 
length 
(without 
leader) 
Molecular 
Weight 
(kDa) 
Extinction 
coef. 
Theoretical 
pI 
Tandem 
scFv  NBF 713 - 1593 509 54.39 1.63 5.91 
Fc-
containing NBF 715 - 2179 723 77.96 1.54 6.31 
KIH 1 (Cys) 
NBF732 NBF733 1922 615 65.89 1.34 6.38 
NBF733 NBF732 1940 621 66.85 1.68 6.39 
KIH 2 
NBF734 NBF735 1940 621 66.81 1.69 6.53 
NBF735 NBF734 1922 615 65.75 1.33 6.38 
Fc-
containing 
(Cys) 
NBF736 - 2246 723 78.04 1.53 6.20 
Fc-
containing 
(Cys 
Longlink) 
NBF737 - 2321 748 80.04 1.49 6.24 
Fc-
containing 
(Longlink) 
NBF738 - 2321 748 79.95 1.49 6.34 
Non-
specific 
tandem 
scFv 
NBF748 - 1595 509 54.49 1.80 6.63 
- pcDNA 3.1 - 80 - - - - 
2.7.2. PAGE gels 
Pre-cast protein gels were used for all routine PAGE gels to determine sample purity and 
protein size. The gels used were NuPAGE Novex Bis-Tris 4-12 % gels (Invitrogen) with 
either 10 or 15 wells run in 1 x MES buffer (Invitrogen) alongside a SeeBlue2 pre-stained 
protein size marker. Samples were prepared according to manufacturers 
recommendations with the addition of 4 x LDS sample buffer, 10 x reducing agent and 
Milli-Q water and heated for 10 minutes at 70 °C. The gel runs were completed at 200 V 
and 400 mA for 45 – 50 minutes before being removed, washed in Milli-Q water and 
stained using SimplyBlue SafeStain (Invitrogen) for final imaging. 
2.7.3. Size exclusion chromatography (SEC) HPLC 
A mobile phase of 0.1 M sodium phosphate buffer, 0.2 M sodium chloride, pH 6.8 was 
prepared and filtered using a 0.22 µm filter. A gel filtration standard was included on each 
run of the HPLC to calculate molecular weights by their retention times. Samples were not 
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concentrated prior to performing SEC so as to avoid the potential of concentration based 
aggregation that might occur. The guard column and SEC-HPLC column were connected 
to the HPLC system, flushed and equilibrated in mobile phase. 100 µl sample injections 
were used in all cases with a flow rate of 0.8 ml/min. Columns were stored in 20 % ethanol 
pre- and post- run completion. 
2.8. Stability monitoring 
2.8.1. Storage buffer formulation 
Buffers composed of a variety of different components have been used in designing 
optimal formulation buffers. The incorporation of excipients into formulation buffers allows 
the added benefit of being able to optimise the composition even further by tailoring the 
buffer to exactly suit the inherent structure of a single antibody format.  
In the present study ten different buffer systems were investigated to determine the 
optimal means of stabilising an engineered Fc-containing BsAb through multiple 
freeze/thaw cycles. Purified Fc-containing BsAb, Vectibix-Fc-1H10 desalted into 
Dulbecco’s PBS was separated into aliquots of which some was left in PBS and others 
dialysed into either a Tris- or Histidine-based buffer. Various excipients were added to 
aliquots of the soluble BsAb (See results Table 3.2) and each one split in half and stored 
at either 4 °C or -20 °C. The concentrations of the Fc-containing BsAb in the different 
formulation buffers were measured at least once weekly over a 3 month period at both 4 
°C and -20 °C storage temperatures. Regular SEC HPLC runs were also performed to 
monitor product stability as were SDS-PAGE gels.  
2.8.2. Dialysis into formulation buffers 
The dialysis was completed in one of 2 stock solutions initially prepared as 5 x stock 
solutions: 
50 mM Tris-HCl + 150 mM NaCl pH 8.0 
50 mM Histidine pH 7.4 + 150 mM NaCl 
In preparation for dialysis, bottles of Milli-Q water was autoclaved as were the stock 
solutions, beakers and stirrers to ensure that all components were sterile. Buffers and 
water were stored at 4 °C. For dialysis 3 ml dialysis cassettes (Pierce/Thermo Scientific 
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Slide-A-Lyzer) were immersed in 1 x buffer solutions and 3 ml Fc-containing BsAb injected 
into the cassette’s entry-port. A float was placed over the cassette and the beaker covered 
with foil and transferred to magnetic stirring blocks located at 4 °C. Samples were left 
stirring for 2 hours before the first buffer change was done followed by another buffer 
change after 16 hours. A final buffer change was then done 7 hours later and left to stir 
overnight for 17 hours at which point each 3 ml sample was removed from the dialysis 
cassette using a syringe and needle and aliquoted out appropriately into eppendorf tubes 
to which excipients could then be added.  
Excipient stock solutions: 
2 M L-Arginine 
1 M Sucrose 
1:100 of Polysorbate-80 (Tween-80) 
Sample buffers were prepared as in Table 3.2 and in each case a blank buffer sample was 
also prepared. Each sample was halved and 1 tube stored at 4 °C and the other at -20 °C. 
2.8.3. DLS performed at CSL 
Analysis was completed by CSL, Melbourne, Australia. Molar mass and hydrodynamic 
radius (Rh) was determined using SEC-MALS. A Wyatt WTC-030-N5 4.6 column was 
used with buffer composed of 100 mM phosphate/200 mM Sodium chloride, pH 6.8. The 
column was equilibrated in the buffer and flow rate set to 0.2 ml/min with 100 µl sample 
injections. A DAWN Heleos MALS detector  was normalised using BSA and used in series 
with an Agilent 1200 series UV diode array detector and an Optilab T-rEx RI detector. 
Wyatt’s Astra VI software was used to calculate the weight-averaged molar mass and 
hydrodynamic radius. 
2.8.4. Analysis of tandem scFv by differential scanning calorimetry 
The tandem scFv BsAb was concentrated to 1mg/ml in PBS using membrane based 
centrifugal concentrators with nominal molecular weight cutoff (NMWCO) of 10Kda 
(Millipore).  500 µl of 1 mg/ml tandem scFv was vacuum degassed and loaded into the 
sample chamber of the VP differential scanning calorimeter (VP-DSC, Microcal).  The 
same volume of PBS was loaded into the reference chamber.  The sample and reference 
chambers were scanned once from 25 °C to 90 °C for 1 h to determine the melting profile 
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of the tandem scFv.  The data was analysed using Origin 7.0 software and graphed as 
time (min) (x axis) versus heat capacity (Cp) (y axis). 
2.9. Functional binding 
2.9.1. Surface plasmon resonance (SPR) 
To evaluate binding affinities of the EGFR-targeting Vectibix-scFv’s on all constructs, 
kinetic data was collected from High performance (Multi-cycle) Kinetic Assays (HPKA) 
performed on a Biacore T-200. A CM5 chip was coated with an anti-mouse IgG antibody 
on flow cells 1 and 2 as described in the Mouse Antibody Capture Kit guidelines (GE 
Healthcare). Recombinant EGFR-mFc was captured on flow cell 2 at 10 µg/ml for 8-15 
seconds and variable concentrations of BsAb (1, 3, 10, 30 and 60 nM) flowed over both 
flow cells 1 and 2. Recommended flow rates (30 µL/min) and regeneration conditions (10 
mM Glycine pH 1.7; 10 µL/min for 180 sec) were used. The dissociation phase was 1800 
seconds. Reference subtractions of flow cells 2-1 were incorporated in the analysis as 
were blank and buffer only sample runs. Kinetic analyses were performed using a 1:1 fit of 
binding curves using BiaEvaluation software (GE Healthcare). 
2.9.2. Biolayer interferometry kinetic characterisation of LPS binding 
The binding of mAbs and BsAbs to LPS molecules was tested utilising Biolayer 
Interferometry and the ForteBio Octet module. Aminopropylsilane (APS) biosensors 
(ForteBio) were briefly hydrated in PBS and coated with 1mg/ml LPS (Salmonella enterica, 
serotype typhimurium - Sigma L7261) diluted in PBS. A concentration range of the 1H10-
mAb (anti-LPS) or tandem-scFv BsAb was set up using 2 fold dilutions starting at 40 ug/ml 
and subsequently tested for binding to immobilised LPS. PBS was added to LPS coated 
sensors as a reference. 
2.9.3. Flow cytometry against MDA-MB-468 breast cancer cells 
All BsAb and mAb samples had been stored at 4 °C prior to commencement of the 
experiment. For the indirect flow cytometry (FACS) protocol cell viability was determined to 
be greater than 90% for each experiment completed. All components were added to a cell 
suspension of washed, 2 × 105 MDA-MB-468 cells in 100 μl of 10 % FBS/DPBS and kept at 
4 °C to prevent receptor-mediated endocytosis from occurring. No sodium azide was added 
to the cell suspensions. Primary BsAb and mAb stock dilutions to 10 μg/ml were made in 
ice cold 5 % BSA + Dulbecco's PBS buffer as were secondary antibody dilutions. Final  
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BsAb and mAb concentrations were at 1 μg/ml in the final cell suspension volume. After 
adding primary antibodies to the cells, samples were incubated for 30 minutes at 4 °C in the 
dark. Cells were washed 3 times by cycles of centrifugation at 400 g for 5 minutes, 
supernatant removal and cell resuspension in cold PBS until the final wash step at which 
point appropriate concentrations of secondary antibody was added to the cells resuspended 
in cold 5 % BSA + Dulbecco's PBS buffer. Samples were again incubated for 30 minutes at 
4 °C in the dark. FITC-conjugated anti-myc (AbD Serotec; Bio-Rad) was used as the 
secondary for detecting binding shifts when the Vectibix tandem scFv and nonspecific 
tandem scFv were incubated with MDA-MB-468 breast cancer cells; whereas APC-
conjugated F(ab)’2 fragment goat anti-human IgG (Jackson Immunoresearch) was used for 
detection of all mAb, Fc-containing and Knob-in-hole constructs. Three final wash cycles 
were completed following incubation and the cells resuspended in cold, 5 % BSA + 
Dulbecco's PBS buffer. Cells were stored in the dark, on ice and fluorescence shifts 
subsequently analysed on the Accuri C6 flow cytometer. Cells were gated using forward 
and side scatter, and the cell sample incubated with secondary antibody only was used to 
determine the cut-off fluorescence for non-specific binding. Events were limited to 100 μl or 
100 000 events. 
2.9.4. BsAb- EDVTMnanocell preparation 
1 x 1012 Non-targeted EDVTMnanocells were incubated with 1 mg of Invitrogen’s NH2-
reactive AlexaFluor488 (EnGeneIC internal protocol) and excess dye was removed by 4 
spin wash cycles in sterile PBS. The fluorescently labeled EDVTMnanocells were counted 
using a NanoSight at EnGeneIC Pty Ltd and found to be 5 × 1010 EDVs/ml. Doses 
were prepared as 2.5 × 1010 EDV (AF488) particles in 0.5 ml, which were then incubated 
with 6 µg of various BsAb constructs at room temperature for 30 min while shaking at 
300 rpm. Samples then underwent 3 PBS spin wash cycles at 9 000 g for 8 min each to 
remove any excess BsAb. BsAb-EDVTMnanocells were resuspended to concentrations as 
required for specific experiments. 
2.9.5. BsAb- EDVTMnanocells aggregation analysis using fluorescence microscopy 
Microscope slides were cleaned and labelled appropriately after which 5 – 10 µl of BsAb-
EDVTMnanocells were placed on the slides and sealed with clean cover slips. The 
AlexaFluor 488 (AF488) was used as an indication of EDVTMnanocell aggregation. 
Visualisation was completed on an Olympus IX81 confocal microscope. 
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2.9.6. Co-localisation of BsAbs alongside EGFR-ecd and EDVTMnanocells 
AF488-labelled, non-targeted and targeted EDVTMnanocells were prepared as previously 
mentioned and observations made regarding clumping of the BsAb-EDVTMnanocells 
during each resuspension. BsAb-EDVTMnanocells were resuspended to an approximate 
concentration of 4 × 1010 EDVs/ml in 500 µl. Counts and aggregation analysis were 
again performed using established techniques on the nanosight. EGFR-His (1 mg) 
labelling was completed using a DyLight650 amine-reactive labelling kit (Thermo 
Scientific) as per the manufacturer's instructions after having been concentrated to 1.6 
mg/ml using a 10 kDa spin column.  
To set up samples for co-localisation imaging, 2 µg EGFR-His (DyLight650) was added to 
5 × 109 particles of each of the conjugated BsAb-EDVTMnanocells. The resulting 
suspension was then incubated at RT for 30 min on a shaker at 300 rpm to allow sufficient 
time for recombinant EGFR binding to occur. Samples underwent 3 spin wash cycles as 
before to remove excess unbound labelled EGFR-His and checked for evidence of 
clumping resulting from BsAb-nanocell interaction with recombinant EGFR. EGFR-BsAb-
nanocell suspensions were resuspended to a concentration of 0.4 × 1010 EDVs/ml. For 
analysis on an Olympus IX81 confocal microscope using Xcellence RT software, slides 
were prepared by pipetting 10 µl sample onto a clean slide which is then spread out by 
addition of a cover slip. 
2.9.7. Flow cytometry of BsAb-EDVTMnanocells in vitro binding to MDA-
MB-468 cells 
EnGeneIC staff maintained MDA-MB-468 cells as part of their routine internal processes in 
their laboratories. 1 × 105 MDA-MB-468 cells grown on coverslips in 400 µl RPMI + 5% 
FBS + 1% PC-SM were treated with 1 × 109 pre-targeted and AF488-labeled 
EDVTMnanocells and returned to 37 °C for 3 h. This was repeated for the non-targeted 
EDVTMnanocell and each of the five BsAb-EDVTMnanocells – non-specific and ABX-EGF 
tandem-scFv, KIH 1 (Cys), Fc-containing (Cys) and Fc-containing (CysLonglink); with only 
the cells only control remaining untreated. On completion of the 3 h incubation period, 
coverslips were washed 3 times with sterile DPBS and cells scraped for flow analyses on a 
Beckman FC500 flow cytometer. Flow rate was set to high and cells were again gated 
using forward and side scatter. The “cells only” sample was used to determine the cut-off 
fluorescence for non-specific binding. Events were detected over a 250 sec period. Final 
analyses were completed using CXP and VenturiOne software.  
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2.9.8. Confocal microscopy of in vitro binding of BsAb-EDVTMnanocells to MDA-
MB-468 cells
Everything except for confocal microscopy, which was performed using ANFF-Q facilities, 
was completed at EnGeneIC’s premises. MDA-MB-468 cells were incubated on coverslips 
in the presence or absence of targeted [non-specific and ABX-EGF tandem scFv, KIH 1 
(Cys), Fc-containing (Cys) and Fc-containing (CysLonglink)] and non-targeted 
EDVTMnanocells – 7 slides total. EDVTMnanocells (labeled with AF488) were added to 
each of 6 samples at a ratio of 10 000 EDVs per cell and the seventh was left as a “cells 
only” control. Plates were returned to 37 °C for 3 hours which was followed by 3 washes in 
sterile DPBS.  
Fixative volume of 500 µl, or enough to cover each coverslip, of 4% PFA was added to 
each of the 7 samples and left for 10 minutes for cells to become fixed. This was again 
followed by 3 DPBS washes. After the final wash 500 µl DPBS was added to each well to 
cover the coverslips completely. An anti-EGFR mAb, 528 mAb, was labeled with AF647 to 
be used as a cell membrane stain; 4 µg of which was added directly to each sample. Wells 
were mixed gently and left for 10 min to allow cells to stain sufficiently. All coverslips were 
again washed 3 times with DPBS followed by a final wash in Milli-Q water. 
Coverslips were removed from the water and placed on tissue paper cell-side-up to allow 
complete drying to occur, at which point they were mounted on clean slides using Fluka 
Eukitt (Sigma-Aldrich) quick-hardening mounting medium. Dry slides were stored at 4 °C 
until confocal microscopy could be completed. Microscopy was completed on a LSM Zeiss 
710 confocal using a plan-apochromat 63x/1.40 Oil DIC M27 objective and ZEN 2008 
software for image formatting. 
2.9.9. Effect of ABX-EGF tandem scFv-EDVTMnanocell on tumour regression 
in vivo 
The experiment was performed in compliance with the NHMRC Australian guidelines for 
the care and use of laboratory animals and with the approval of the EnGeneIC Animal 
Ethics Committee. Five to six week old female Balb/C athymic nude mice were obtained 
from the Laboratory Animal Services at the University of Adelaide, South Australia. The 
animals were housed at the EnGeneIC Animal Facility under specific pathogen free 
conditions.  
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MDA-MB-468 cells were obtained from ATCC and grown in RPMI with 10% fetal calf 
serum and penicillin/streptomycin. Each mouse was injected subcutaneously on the left 
flank with 1 x 107 cells in 100 µl of media together with 100 µl of growth factor reduced 
matrigel (BD Biosciences). Tumour volume was determined by measuring length (l) and 
width (w) and calculating volume (V = l x w2 x 0.5). Once the tumours reached 80 – 100 
mm3 the mice were randomized into treatment groups which included 7 mice per group. 
The treatment groups were as follows: 
• Group 1 – Saline
• Group 2 –  Tandem scFv EDV (ABX-EGF or Panitumumab tandem scFv BsAb targeted
EDVTMnanocell not loaded with Doxorubicin)
• Group 3 – EDV Dox (Non-targeted EDVTMnanocell loaded with Doxorubicin)
• Group 4 – Protein A/G EDV Dox (Protein A/G linked BsAb targeted EDVTMnanocell
loaded with Doxorubicin)103, 129
• Group 5 – Tandem scFv EDV Dox (ABX-EGF or Panitumumab tandem scFv BsAb
targeted EDVTMnanocell loaded with Doxorubicin)
The amount of Doxorubicin was measured by HPLC for all loaded EDVTMnanocells and 
determined to be 1 ± 0.1 µg per 1 × 109 EDVTMnanocells (one iv dose); method completed 
as previously described.103, 129 All treatments were injected intravenously via the tail vein 
and administered three times a week for three weeks. Tumours were measured using a 
caliper three times a week.  The mice were weighed twice a week for three weeks. 
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3. Bispecific antibody design, production and function
3.1. Chapter summary 
The design of BsAbs impacts expression levels in CHO cells, product stability and antigen 
binding.  The utility of our engineered BsAbs was to target a novel nanocell (EnGeneIC 
Delivery Vehicle, EDV or EDVTMnanocell) to the EGFR. EDVTMnanocells are coated with 
LPS, and BsAb designs incorporated the binding site of an anti-LPS antibody (1H10) with 
the anti-EGFR commercial antibody panitumumab (ABX-EGF or Vectibix).  We engineered 
various BsAb formats including monovalent and bivalent binding arms and linking scFv 
fragments via either glycine-serine (G4S) or Fc-linkers.  Aggregation of BsAbs was a 
common occurrence with more complex designs.  A tandem G4S-linked scFv format was 
the most stable, but had lower expression yields than complete mAbs.  The Fc-containing 
BsAbs showed increased expression levels compared to a tandem scFv, but a greater 
propensity for aggregation.  Engineering additional disulphide bridges into the scFvs of the 
Fc-containing BsAbs decreased aggregation, but also expression levels.  Various buffer 
formulations were evaluated with regards to their ability to maintain BsAb stability during 
short and long term storage at both 4 °C and -20 °C with multiple freeze/thaw cycles. 
Results suggested that the addition of arginine to PBS was the simplest means to stabilise 
the tandem scFv at -20 °C however the formulation merely slowed the aggregation rate in 
the case of the Fc-containing BsAb format. Binding analyses utilising ELISA, surface 
plasmon resonance, flow cytometry and fluorescence microscopy for antigen co-
localisation, showed that binding to LPS and to either soluble recombinant EGFR or MDA-
MB-468 cells expressing EGFR, was conserved for all construct designs. 
3.2. Introduction 
Therapeutic mAbs approved for clinical use such as Avastin (anti-VEGF), Humira (anti-
TNF α), Herceptin (anti-Her2), Erbitux and Vectibix (anti-EGFR) make up a significant 
portion of the global pharmaceutical market.246, 252 Of the total mAb sales in 2010, half are 
attributed to cancer related therapies.17 In 2012 half of the antibody based oncology 
products under clinical evaluation were complete IgG mAbs. The remaining candidates 
included drug conjugated or radio-labeled mAbs, protein- and glyco-engineered mAbs, 
fragment or domain antibodies.195, 253, 254 Also under evaluation are BsAbs12, which are 
subject to increasing interest in recent years owing to their ability to target multiple 
antigens.118, 124, 188, 255
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BsAbs are able to crosslink antigenic determinants and so have value beyond that of 
single antigen specific mAbs (Figure 1.7).32, 117, 118, 125, 246, 256  An emerging application of 
BsAbs is active targeting of drug-loaded NPs (NP) to tumour sites by cross-linking the NP 
to tumour cells, leading to endocytosis, fusion with lysosomes and drug release 
intracellularly.103, 118, 129, 246 However, the most prominent therapeutic utility for BsAbs in 
cancer therapeutics is the cross-linking of cell surface antigens or receptors, so that 
immune cells can be tethered to cancer cells through a BsAb.118, 123-126  
Catumaxomab (Removab) was approved for therapeutic use in Europe in 2009 and 
remains the only approved therapeutic BsAb, although the number of BsAb formats 
entering clinical trials is increasing steadily.12, 256  Catumaxomab is a T-cell engager, with 
specificity for both CD3 on cytotoxic T cells and the EpCAM antigen on ovarian cancer 
cells, for the treatment of malignant ascites.144-146 However BsAbs are not natural 
immunoglobulins, and unlike the well-understood cellular processes of natural 
immunoglobulin expression, assembly in the endoplasmic reticulum and secretion in B 
cells,101, 257 the stability and expression levels of BsAbs are less understood and 
influenced by design. 
Recombinant BsAbs are constructed by combining binding modules such as scFvs or 
single domain antibodies (sdAbs) – such as shark and camelid antibodies;115, 196, 205, 258 
into a single polypeptide utilising linkers such as the flexible Glycine-Serine (G4S) motif 124,
126, 188 or Fc (Hinge-CH2-CH3 domains) to tether the binding modules.  On their own, scFv 
components are unstable but by including a linker between them, and if required additional 
cysteines, stability can be improved.199 Design of recombinant BsAbs is only limited by 
imagination, and a variety of novel designs have been reported (Figure 1.8).32, 118 Formats 
used thus far range from non-IgG like varieties containing chemical or protein linkers or 
various Fc-motifs, through to recombinant Fc-containing, Dock-and-lock and knob-in-hole 
(KIH) BsAbs.115 Some of the more well-known formats include Triomabs, Dual Affinity 
Retargeting (DART) molecules, Bispecific T-cell Engagers (BiTEs), and the F-star mAb2 TM 
BsAbs.124, 143, 144, 158, 200
Product design may endow the BsAb with specific properties, such as enhanced serum 
half-life through PEG- or BSA-conjugation, complement activation capability through 
interaction with the Fc domain and increased tissue penetration.156, 193 Single domain 
antibodies (sdAbs) can bind targets without the need to be connected to heavy and light 
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chains; for example shark and camelid nanobodies. sdAbs are capable of binding targets 
(extra- and intracellular) with affinities comparable to full mAbs and their small size allows 
penetration into sites that cannot be reached by standard mAbs. They have high refolding 
capabilities, are very stable and product yield ranges from 0.5 to 5 mg/L depending on the 
bispecific design specifications and the type of domain used; but functional BsAbs are not 
always produced.195 
Chemical conjugation can be used to produce BsAbs, however antibody inactivation, low 
associated yield and product heterogeneity has limited the progress of these formats to the 
clinic – yields of 10 to 40% dimeric BsAb from hetero-bifunctional reagents and 65 to 75% 
from homo-bifunctional reagents. In comparison the use of Thiomab technology to produce 
bis-Fabs, using a bis-maleimide cross-linker, is highly reproducible with high conjugation 
rates and homogeneity however the biological effect is sometimes altered relative to the 
parental mAb.131 Bispecific diabody production relies on heterodimeric association of two 
chains; however as expression is achieved within a single cell inactive homodimers are 
also produced.187, 199 Incorporating cysteines for stability in the Fv fragments has been 
shown to improve the proportion of functional heterodimers produced during expression.259 
Nonetheless unnatural recombinant BsAb formats remain harder to express in suitable 
homogenous quantities and as a result a lot of work remains to be done to determine what 
the most beneficial BsAbs are for potential clinical and diagnostic use. 
In this study we designed several BsAbs based on three basic format designs for the 
purpose of delivering the EnGeneIC delivery vehicle (EDVTMnanocell) to the EGFR and to 
replace the currently used protein A/G linked mAbs.15, 16, 18 The EDVTMnanocell (a 400 nm 
particle of bacterial origin capable of carrying a drug payload) was originally targeted using 
a BsAb moiety produced by incubating two different mAbs with protein A/G (Pierce, 
USA).129 Although functional BsAbs capable of delivering the EDVTMnanocell were 
prepared, it was noted that multimer formation and the inability to control the ratio of mAbs 
bound to the protein A/G (which has 6 potential Fc-binding sites) rendered the targeting 
entity unsuitable for commercial manufacture and downstream clinical trials.129, 231 
Recombinant BsAbs offer an advantage of producing one antibody with dual target binding 
capability. 
The EDVTMnanocell is coated with LPS129, and thus BsAb designs incorporated scFvs 
derived from an anti-LPS antibody (1H10) with the anti-EGFR commercial antibody 
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panitumumab (Vectibix or ABX-EGF).24, 67, 83 ABX-EGF was developed via transgenic 
humanised mouse technology by Abgenix Inc.24, 67, 83, and is approved for clinical use in 
the treatment of colorectal cancer. ABX-EGF has picomolar affinity for EGFR and its 
properties, including affinity, specificity and immunogenicity; have been extensively 
evaluated and is an ideal model antibody to incorporate into the design and testing of 
bispecific formats.129 Three BsAb formats were evaluated for EDVTMnanocell targeting; a 
G4S-linked tandem scFv format, homodimeric Fc-containing BsAbs and Knob-in-Hole 
(KIH) engineered formats to promote forced heterodimerisation of the EDV-targeting 
variable fragments. Additionally, modifications of the latter two formats were investigated, 
incorporating additional disulfide bridges in the scFv domains and longer linkers between 
the Fc-CH3 and anti-LPS scFv interface (Table 2.1).  We have evaluated these different 
formats with regard to expression yields, stability post-purification, their ability to bind 
respective targets and their effect on EDVTMnanocell clumping. The purpose of which is to 
determine which is the optimal BsAb for use in the proposed delivery system of drug-
loaded EDVTMnanocells to target cancer cells. 
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3.3. Results 
3.3.1. Production, yield and stability 
All format sequences except for the Fc-containing BsAb were produced by GeneArt. The 
Fc-domain and 1H10-scFv sequences were PCR amplified from their original vectors and 
subsequently purified (Figure 3.1.b) The Fc-containing BsAb was produced through SOE 
PCR techniques as previously described. The largest band in Figure 3.1.c (~1500 bp) is of 
the successfully produced Fc-1H10 sequence, the remaining bands of ~800 bp in size are 
the original DNA templates added into the PCR mix. Colony PCR confirmed the presence 
of the required sequence (Figure 3.1.d). The gel image shows the presence of two bands 
following colony PCR, one which is the positive band (~2500 bp) and the other a result of 
non-specific binding of the primer. The positive result was also confirmed by sequencing 
the insert at the Australian Genome Research Facility (AGRF). 
Figure 3.1: Gel electrophoresis images of the development of the Fc-1H10 sequence. a) Hyperladder size standard 
run using 5 ul per well. b) Gel following PCR to produce the Fc-sequence using primers: Fc_Fc-link_Forward and 
Fc_longoverlap_Reverse; and producing 1H10 scFv from the tandem scFv using primers: 1H10_longoverlap_Forward 
and 1H10_Fc-link_Reverse. c) SOE PCR results to create Fc-1H10 product. d) Gel showing a positive colony PCR 
containing the Fc-1H10 insert (Table 2.2). 
Soluble proteins such as mAbs and BsAbs are notoriously unstable in solution which 
represents one of the major barriers in therapeutic product development. Herein BsAbs 
were produced in CHO-S transient cell culture and purified from culture supernatant by 
either IMAC or Protein A affinity chromatography techniques.  
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BsAb yield and expression 
We observed that BsAb yields are much lower when compared with standard mAbs (Table 
3.1).Tandem scFv BsAb expression routinely yielded 4 - 5 mg/L transient cell culture 
supernatant, whereas Fc-containing and Knob-in-Hole formats lacking scFv disulphide 
engineering yielded 9 - 14 mg/L. Engineering disulphide bridges into Fc-containing and 
Knob-in-Hole variant scFvs dramatically decreased BsAb yield 6 - 9 fold compared to that 
of non-stabilised formats.141 
Table 3.1: Product yield. A comparison of all 7 BsAbs developed in the present study relating to the total amount in 
milligrams retrieved following purification of either IMAC purification using HisTrap Excel and HisTrap FF for tandem-
scFv purification and MabSelect Sure Protein A for all constructs with an Fc followed by desalting into Dulbecco’s PBS 
for storage at 4 °C. The results show that all bispecific formats tested express at a much lower level than the whole mAb. 
Additionally, the tandem scFv produces at a much lower level than the Fc-containing format and non-stabilised KIH 
format and that when disulphide engineering is included there is a significant decrease in overall product yield. *Yield 
expressed as mg BsAb produced from a theoretical 1 L transient culture volume. Actual culture volume was 300 ml.
BsAb ID Yield* (mg/L) 
IgG1 mAb 52.6 
Tandem scFv 4.23 
Fc-containing 11.93 
Fc-containing (Longlink) 9.57 
Fc-containing (Cys) 1.88 
Fc-containing (Cys Longlink) 1.09 
KIH 1 (Cys) 1.65 
KIH 2 14.07 
BsAb Secretion 
Although the secretory pathway for native mAb expression is well documented 101, 257 
engineering antibodies through manipulating or deleting the Fc region will inevitably result 
in altered BsAb flux through the secretory pathway compared to native mAbs, and perhaps 
to retention in the endoplasmic reticulum.242, 260 To investigate whether the various formats 
were being efficiently secreted or retained within the cell, culture supernatant and cell 
lysate samples were taken over a 9 day period post-transient transfection and analysed by 
a qualitative Western blot (Figure 3.2). Cell numbers weren’t standardised in this 
experiment therefore each successive time point is of increasing cell numbers; however 
each similar time point is comparable between formats because cell number and viability 
were similar on day of sampling for each transient transfection (results not shown). An 
increase of secreted BsAb was observed over time and there did not appear to be any 
significant retention of BsAb in the cell pellet during the same period; confirming that each 
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BsAb is being secreted and retention is an unlikely explanation for the decreased 
production yield recorded in some samples. It may however be due to individual 
transfection conditions requiring optimisation. 
Figure 3.2: Qualitative western blot of BsAb transient expression in CHO-S over time. (A) Secreted BsAb and (B) 
CHO cell lysate samples were taken at 2, 5, 7 and 9 days post-transfection.  BsAbs were expressed in 300ml cultures. 
Typically, trend shows increase in secreted BsAb (A) and a decrease in intracellular BsAb (B) with increasing cell 
numbers over time.  (1) tandem scFv, (2) Fc-containing, (3) Fc-containing (Longlink), (4) Fc-containing (Cys), (5) Fc-
containing (CysLonglink), (6) KIH 1 (Cys) and (7) KIH 2. Smearing in (B) is an indication of higher cell numbers with each 
subsequent time point.  
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Tandem scFv and Fc-containing BsAb stability 
Reduced SDS-PAGE analyses for purified tandem scFv and Fc-containing BsAb samples 
showed the expected monomeric sizes: 55 kDa for tandem scFv and around 80 kDa for 
Fc-containing BsAbs. Non-reduced PAGE gels showed the tandem scFv maintained its 
monomeric size of 55 kDa, whilst the Fc-containing BsAbs formed an expected dimer 
(Figure 3.3). The Fc-containing format forms a dimer via the hinge region of the Fc-
domain. A benefit of dimerisation is the increased avidity associated with multiple binding 
sites being present for the same target. 
Figure 3.3: SDS-PAGE gels of purified BsAbs under reducing and non-reducing conditions. Size standard is 
Seeblue plus 2 in MES running buffer. a) PAGE gel of purified tandem scFv BsAb (Vectibix-G4S-1H10) showing that the 
format exists as a monomer of 55 kDa under both reducing and non-reducing conditions. b) PAGE gel of purified Fc-
containing (Vectibix-Fc-1H10) showing the presence of the monomeric form of the BsAb at ~78 kDa under reducing 
conditions, and a multimer of ~160 kDa and greater under non-reducing conditions. It is also likely that Vectibix-Fc-1H10 
(NBF715) is undergoing Asparagine N-linked glycosylation which also accounts for the increased molecular weight.
Further analysis of the purified product sizes were performed by size exclusion 
chromatography (SEC) which confirmed the monomeric confirmation of the tandem scFv 
and the presence of Fc-containing BsAb multimers. However, after storing the Fc-
containing BsAb in PBS for a period of time it became apparent that aggregation occurs in 
solution to form large multimer aggregates at 4 °C and it is unstable at -20 °C (Figure 3.4). 
A potential drawback associated with multimer formation is that the EDVTMnanocells 
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subsequently aggregate through multiple interactions of the 1H10-scFv and therefore 
become non-viable as therapeutic agents. 
 
 
Figure 3.4: Size exclusion chromatography results of purified BsAb products stored in PBS buffer. a) SEC of 
Vectibix-G4S-1H10 showing that more than 90% of the product exists as the 55 kDa monomer of the BsAb. b) SEC of 
Vectibix-Fc-1H10 stored at -20 °C in PBS performed within one week of purification showing the presence of ~160 kDa 
BsAb dimers as the major product but also ~700 kDa products indicating the possibility of aggregation. c) SEC of 
Vectibix-Fc-1H10 stored at 4 °C in PBS performed approximately 1 month post-purification indicating that the major 
product present is a ~700 kDa octamer (tetramer of dimers) and that although the dimer still exists, it is a minor 
component of the BsAb solution. 
 
At 4 °C the BsAb concentration stays constant over time when stored in PBS however at -
20 °C the BsAb appears to reduce in concentration without any visible signs of 
aggregation to account for the loss of soluble product. Possible causes for the observed 
product loss could be that the anti-LPS portion of the BsAb might be binding to the plastic 
tubes or degradation resulting from pH shifts relating to the sample being stored in PBS,261 
but this is yet to be confirmed. The instability prompted the need to perform a formulation 
study (Table 3.2) to determine whether an alternative buffer would improve stability and 
decrease aggregation levels during storage.262 Various buffer formulations were tested to 
improve the storage stability of the BsAbs. Homodimeric Fc-containing BsAb formats, 
without additional stability engineering, formed large aggregates post-purification when 
stored at 4 °C, and exhibited similar product loss as the tandem scFv when stored in 
DPBS at -20 °C, possibly explained by pH changes in the buffer.261 From initial buffer 
formulation evaluations for the Fc-containing BsAb, we determined that the most effective 
method to stabilise and maintain the BsAb concentration levels was to add 100 mM L-
Arginine (Buffer 10) directly to the sample in PBS after purification (Table 3.2). 
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Formulations tested thus far have not shown significantly improved stability of Fc-
containing and KIH variants, and there is evidence of concentration-dependent 
aggregation above 0.1 mg/ml (results not shown). Size exclusion chromatography (SEC) 
HPLC analyses over a 1 month period indicated that tandem scFv stability, when stored at 
a concentration of 0.12 mg/ml, is affected by buffer formulation. Product storage in a 
formulation of PBS/trehalose resulted in slightly increased aggregation levels when stored 
at -20 °C compared with 4 °C. However, stability was maintained at both 4 °C and -20 °C 
in a HEPES/Trehalose buffer formulation (Figure 3.5.A). Dynamic light scattering (DLS) 
data confirmed the tandem scFv to be a monomer of 55 kDa in size, with a hydrodynamic 
radius of 2.5 nm (results not shown). Thermostability determined by differential scanning 
calorimetry (DSC) indicated that the tandem scFv has a melting temperature (Tm) of 57 °C 
(Figure 3.5.B).  
Figure 3.5: Tandem scFv stability data. A) Tandem scFv samples were stored in various buffers at different 
temperatures to evaluate stability during storage over a 3 month period. The representative trace is indicative of stable 
product stored in Hepes/trehalose buffer for 3 months. B) Thermostability of tandem scFv BsAb in PBS was determined 
by differential scanning calorimetry and indicates unfolding and subsequent aggregation of the tandem scFv BsAb at 57 
°C. Copyright 2015 The Authors. Published with license by Taylor & Francis Group, LLC. 
78 
Table 3.2: Formulation study to evaluate the stability of Fc-containing BsAb Vectibix-Fc-1H10 at different 
storage temperatures over a 3 month period. Aliquot volumes were halved and stored at either 4 °C or -20 °C over a 3 
month period during which time various observations were made regarding buffer ability to promote product stability. 
Buffer ID Buffer Composition Results 
PBS only 1 x Dulbecco’s PBS 
Control samples: When stored at -20 °C no visible aggregation occurs but the BsAb 
“disappears” from solution evidenced by loss of A280 (possible degradation). 
Storing the Fc-containing BsAb at 4 °C prevents apparent degradation from 
occurring but there is evidence of aggregation present following HPLC and PAGE 
gel analysis.  
1 
50 mM Tris-HCl+150 mM NaCl 
pH 8.0 + 100 mM Arginine  
BsAb concentration level maintained over the first 1.5 months at which point it 
started decreasing at both 4 and -20 °C. Aggregation also visible on gel at both 
temperatures.  
2 
50 mM Tris-HCl+150 mM NaCl 
pH 8.0 + 0.25 mg/ml 
Polysorbate 80  
Could not get accurate A280 readings at -20 °C. The concentrations appeared to 
increase according to the Nanodrop values - attributed to polysorbate interference. 
Storage at 4 °C showed maintenance of concentration levels but aggregation also 
evident in gel image.  
3 
50 mM Tris-HCl+150 mM NaCl 
pH 8.0  
Storage at 4 °C showed maintenance of concentration levels but aggregation 
evident in gel image. BsAb concentration level maintained over the first 1.5 months 
at which point it started tapering off at -20 °C.  
4 
50 mM Histidine + 150 mM 
NaCl pH 7.4 + 100 mM Arginine 
Concentration level maintained at both 4 and -20 °C. Aggregation visible on gel at 
both temperatures.  
5 
50 mM Histidine + 150 mM 
NaCl pH 7.4 + 0.25 mg/ml 
Polysorbate 80  
Could not get accurate readings at -20 °C. The concentrations appeared to 
increase according to the nanodrop values - attributed to polysorbate interference. 
Storage at 4 °C showed maintenance of concentration levels but aggregation also 
evident in gel image.  
6 
50 mM Histidine + 150 mM 
NaCl pH 7.4 + 0.25 mg/ml 
Polysorbate 80 + 100 mM 
Arginine  
Concentration level maintained at both 4 and -20 °C. Aggregation visible on gel at 
both temperatures. However the use of polysorbate in the buffer was deemed to be 
unsatisfactory for use with the EnGeneIC delivery vehicle.  
7 
50 mM Histidine + 150 mM 
NaCl pH 7.4  
Storage at 4 °C showed maintenance of concentration levels but aggregation 
evident in gel image. BsAb concentration level maintained over the first 1.5 months 
at which point it started decreasing at -20 °C.  
8 PBS + 100 mM Sucrose 
Aggregation present but appears to be less than for other buffers when compared 
on gel image. Storage at 4 °C showed maintenance of concentration levels but 
apparent degradation occurred soon after excipient addition and storage at -20 °C. 
9 
PBS + 100 mM L-Arginine 
(pH10.65)  
Concentration level maintained at both 4 and -20 °C. Aggregation visible on gel at 
both temperatures. 
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Buffers composed of a variety of different components have been used in designing 
optimal formulation buffers. The incorporation of excipients into formulation buffers allows 
the added benefit of being able to optimise the composition even further by tailoring the 
buffer to exactly suit the inherent structure of a single antibody format. In the present study 
ten different buffer systems were investigated to determine the optimal means of 
stabilising an engineered Fc-containing BsAb. A number of the buffers enabled longer 
storage times while maintaining the structural integrity and binding affinities of the BsAb 
irrespective of the occurrence of multiple freeze/thaw events (results not shown). Addition 
of 100 mM L-Arginine appeared to be the simplest means of preventing the loss of BsAb 
when stored at -20 °C. Although adding 100 mM L-Arginine to PBS stabilises the BsAb at -
20 °C, it does not prevent the observed aggregation; it merely slowed the aggregation rate 
(Figure 3.6).263  
Figure 3.6: Size exclusion chromatography comparing Vectibix-Fc-1H10 (NBF 715) stability. a) NBF 715 stored at 
4 °C in PBS only for 1.5 months. b) NBF 715 stored at 4 °C in PBS + 100 mM L-Arginine for 1.5 months. c) NBF 715 
stored at 4 °C in PBS + 100 mM L-Arginine for 3 months. d) NBF 715 stored at -20 °C in PBS only for 1.5 months. e) 
NBF 715 stored at -20 °C in PBS + 100 mM L-Arginine for 1.5 months. f) NBF 715 stored at -20 °C in PBS + 100 mM L-
Arginine for 3 months. 
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The concentrations of Fc-containing BsAbs in the different formulation buffers (Table 3.2) 
were measured at least once weekly over a 3 month period at both 4 °C and -20 °C 
storage temperatures (Figure 3.7). From these results we determined that the easiest 
method to stabilise the BsAb concentration levels was to add 100 mM L-Arginine (Buffer 9) 
directly to the sample in PBS after purification.  
Figure 3.7: Concentration monitoring of Fc-containing BsAbs in different formulations. Graph shows effects of 
storage temperature on BsAb stability with respect to aggregation; BsAb samples stored at either 4 °C or -20 °C in 
different formulation buffers. 
SDS-PAGE analysis was performed on samples stored in formulation buffers at 4 °C and -
20 °C at 1 and 3 months post-dialysis and excipient addition. The gel image below gives 
an indication of apparent concentration levels of Fc-containing BsAb when stored for 3 
months in the different formulation buffers listed in Table 3.2 at either 4 °C or -20 °C. Some 
aggregation appears to be present in all samples however the apparent degradation which 
occurred to BsAb stored in PBS at -20 °C (Figure 3.8: Gel a and b; lane 3) does not seem 
to have occurred for any of the formulation samples except when sucrose was added to 
the PBS as an excipient (Buffer 8; -20 °C). Interestingly however, the larger aggregation 
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products (>200 kDa) are visible in all lanes except the samples stored in PBS only and 
PBS + 100mM Sucrose (Buffer 8) at -20 °C which were unstable. As aggregation wasn’t 
eliminated through formulation optimisation a number of stability engineering options for 
the Fc-containing and KIH BsAb variants were investigated (Table 2.1).63, 138, 141, 155  
Figure 3.8: SDS-PAGE gels of Fc-containing BsAb after 3 months storage at either 4 °C or -20 °C in different 
formulation buffers. Lane number indications exclude the lane containing the size marker. Numbers 1 through 9 on the 
image indicate the buffer identification number from Table 3.2.  Lanes i are of purified Fc-containing BsAb stored in an 
eppendorf tube in PBS at 4 °C; Lanes ii is of purified BsAb stored in a glass HPLC vial in PBS at 4 °C; Lanes iii is of 
purified BsAb stored in an eppendorf tube in PBS at -20 °C - in both gel images a) and b). Lane 1 is again of purified Fc-
containing BsAb stored in an eppendorf tube in PBS at 4 °C as a control. a) Reduced SDS-PAGE gel of samples stored 
at 4 °C with regular freeze/thaw cycles over a 3 month period and b) non-reduced SDS-PAGE of the same. c) Reduced 
SDS-PAGE gel of Fc-containing BsAb formulation samples stored at -20 °C with regular freeze/thaw cycles over a 3 
month period; and d) non-reduced SDS-PAGE of the same. 
BsAb stability engineering 
A number of stability engineering strategies including modification of the Fc-containing 
format and inclusion of Knob-in-hole (KIH) BsAb variants were investigated (Table 2.1).63,
138, 141, 155 Reduced gels of the Fc-containing BsAb, KIH BsAb and variants thereof, 
showed the expected monomeric sizes (KIH BsAbs at 70 kDa) (Figure 3.9) but there was 
size variation on non-reduced gels. Non-disulphide stabilised Fc-containing and KIH 
BsAbs are larger than their stabilised counterparts (possibly a result of larger associated 
hydrodynamic radii of the unfolded proteins) suggesting a link between disulphide 
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engineering and folding of the molecule. KIH 1 (Cys) appeared as a 140 kDa band 
whereas the non-disulphide engineered format showed a band at around 180 kDa. 
Similarly for the homodimeric Fc-containing formats with the non-cysteine stabilised 
variants having an apparent molecular weight 40kDa larger than expected (Figure 3.9). 
 
 
Figure 3.9: SDS-PAGE gels of purified stability engineered BsAbs under reducing and non-reducing conditions. 
Size standard is Seeblue plus 2 in MES running buffer. Lane number indications exclude the lane containing the size 
marker. Reduced gel a) shows BsAb monomers as expected in lanes 1 – Fc-containing, 2 – KIH 1 (Cys) and 3 – KIH 2; 
and non-reduced gel b) shows the presence of the Fc-containing multimer in lane 1, and variations in dimer size between 
the KIH 1 (Cys), lane 2, and KIH 2, lane 3, which were expected to be the same size. PAGE gel c) shows monomer size 
variations as expected of Fc-containing, Fc-containing (Cys), Fc-containing (Cys Longlink) and Fc-containing (Longlink) 
in lanes 1 – 4 respectively. Non-reduced gel d) shows a similar variation between multimer sizes where disulphide 
engineered variants Fc-containing (Cys), lane 2, and Fc-containing (Cys Longlink), lane 3 are smaller in size than their 
non-stabilised counterparts Fc-containing, lane 1, and Fc-containing (Longlink), lane 4, respectively. 
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Figure 3.10 and Table 3.3 show a summarising comparison of all BsAbs and conditions 
analysed through SEC HPLC with regards to stability of the tandem scFv versus all Fc-
containing and KIH formats. The tandem scFv remained as a stable monomer when stored 
in Dulbecco’s PBS (DPBS) at 4 °C for up to 12 weeks (Table 3.3.A) and as such a variant 
on the basic format was not created; however storage at -20 °C for as little as one week 
resulted in degradation and loss of the BsAb (Table 3.3.B). Homodimeric Fc-containing 
BsAb formats lacking stability engineering formed large aggregates post-purification which 
persisted for the 12 week analysis period when stored at 4 °C (Table 3.3.E), and exhibited 
similar product loss as the tandem scFv when stored in DPBS at -20 °C (Table 3.3.F). 
Adding L-Arginine to the tandem scFv (Table 3.3.C – D) and Fc-containing (Table 3.3.G – 
J) BsAb solution prevented BsAb loss when stored at -20 °C; and decreased the
aggregation rate of the latter format at 4 °C over time.181, 263, 264
Increasing the linker length 138 connecting the CH3 domain of the Fc to the anti-LPS, 
EDVTM-targeting scFv did not improve stability when stored at 4 °C in DPBS for up to 3 
months unless combined with the inclusion of additional disulphide bridges in the scFv 
domains (Table 3.3.K and N).141, 181 BsAbs that lack the longer linker at CH3 but contain 
disulphide bridges engineered into the scFvs remain stable (Table 3.3.L – M) indicating 
that in this case the longer linker does not influence overall product stability. The same 
was observed for the KIH formats with disulphide bridge scFv stability engineering, and 
without. Preliminary data suggests a concentration-based link to the observed aggregation 
for KIH 1 (Cys) (Table 3.3.P) when concentrated from 0.02 mg/ml to 0.2 mg/ml. In 
comparison, the same concentration increase for the Fc-containing (Cys) BsAb format 
resulted in a slight aggregation increase (Table 3.3.M). Dilution post-purification does not 
improve aggregation levels (data not shown). Although the variants showed evidence of 
improved stability, observations were made at low concentrations of 0.02 mg/ml at which 
level protein loss is possible due to adsorption and therefore not an adequate means of 
storage. 
SEC-MALS analysis was used to determine the true molar mass of the Fc-containing 
(Cys), Fc-containing (Cys Longlink), KIH 1 (Cys), in addition to the previously mentioned 
tandem scFv BsAb formats. These BsAb formats were analysed at CSL, Melbourne, and 
were selected due to their superior stability in comparison to the non-stability engineered 
formats, Fc-containing, Fc-containing (Longlink) and KIH 2. Due to the low protein 
concentrations of the 3 disulphide stability engineered BsAbs, the hydrodynamic radii (Rh) 
84 
of these sample could not be accurately determined. Dynamic light scattering (DLS) 
results indicated that “Peak 1” of all 3 disulphide engineered BsAbs were monodispersed 
(of a single sized product) of the expected dimeric products: Fc-containing (Cys), 159 kDa, 
Fc-containing (CysLonglink), 170 kDa and KIH 1 (Cys), 135 kDa (Figure 3.11). 
Table 3.3: SEC HPLC evaluation of BsAb stability under varying conditions. Original tandem scFv (A – D) and Fc-
containing (E – J) BsAb formats were stored at either 4 °C or -20 °C in 1x Dulbecco’s PBS or with added 100 mM L-
Arginine as an excipient. SEC graphs provided a means to compare percentage of stable BsAb versus aggregate in 
solution at various time points. The formulation study (Table 3.2) did not provide a solution for the aggregation of the Fc-
containing format which led to the design and evaluation of stability engineered formats stored at 4 °C in Dulbecco’s PBS 
over time (K – Q). Aggregate:BsAb ratio remained the same at 0.2 mg/ml for Fc-containing format. L – M) Samples at 
0.02 mg/ml were transfected in 300 ml volumes whereas 0.2 mg/ml batch was expressed in a 1 L total volume. O – P) All 
batches transfected in 300 ml volumes; 0.2 mg/ml sample was concentrated from an aliquot of the 0.02 mg/ml batch.
BsAb Storage conditions Stable Aggregate 
ID Buffer 
Time 
(weeks) 
Temperature 
(°C) 
Concentration 
(mg/ml) 
BsAb 
(%) 
(%) 
A 
Tandem scFv 
PBS 
1-12 4 0.50 >95 <5 
B 1-12 -20 0.10 unstable Unstable 
C PBS + 100 mM L-
Arginine 
6 4 0.50 >95 <5 
D 12 -20 0.50 >95 <5 
E 
Fc-containing 
PBS 
1-12 4 0.60 <10 >90
F 1-12 -20 0.10 unstable Unstable 
G 
PBS + 100 mM L-
Arginine 
6 4 0.60 ~60 ~40 
H 12 4 0.60 <20 >80
I 6 -20 0.60 ~60 ~40
J 12 -20 0.60 ~40 ~60
K 
Fc-containing 
(Longlink) 
PBS 1-12 4 0.20 <10 >90
L Fc-containing 
(Cys) 
PBS 
1-12 4 0.02 >80 <20 
M 1 4 0.20 ~60 ~40 
N 
Fc-containing 
(Cys Longlink) 
PBS 1-12 4 0.02 >80 <20 
O 
KIH 1 (Cys) PBS 
1-12 4 0.02 >85 <15 
P 1 4 0.20 ~65 ~35 
Q KIH 2 PBS 1-12 4 0.20 <10 >90
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Figure 3.11: Dynamic Light Scattering (DLS) of disulphide engineered BsAbs. a) Fc-containing (Cys) DLS trace 
showing a polydispersed peak 3 and monodispersed peak 1 and 2 where peak 1 is of the expected dimer, concentration 
was 20 µg/ml. b) Fc-containing (Cys Longlink) sample concentration was 70 µg/ml and all 3 peaks were monodispersed 
with peak 1 the expected dimer. c) KIH 1 (Cys) concentration was 20 µg/ml and both peaks monodispersed where peak 
1 is of the expected dimer. 
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3.3.2. Functional binding 
Binding to recombinant protein targets 
Binding activity has been maintained for both targets on all engineered BsAb formats 
(Figure 3.12. and Table 3.4). Surface plasmon resonance (SPR) analysis of recombinant 
EGFR binding using Biacore T-200 showed that BsAb association constants (ka) were 5 to 
10-fold lower than that of the published Vectibix-mAb (using purified native EGFR).46, 265 
Dissociation rate constants (kd) of the Vectibix-scFvs for the tandem scFv, Fc-containing 
and Fc-containing (Longlink) BsAbs have values similar to the published full mAb whereas 
all remaining EGFR-targeting formats have off-rates (kd) up to 10-fold slower. A non-
specific tandem scFv BsAb showed no specific binding to EGFR. Reformatting the 
Vectibix-scFv into an IgG1 mAb showed similar ka, kd and KD values as those reported for 
the published Vectibix IgG2 mAb. Binding affinities (KD) of the EGFR-targeting BsAbs were 
all in the nanomolar (nM) range with slight differences relating to different constructs.  
Figure 3.12: ABX-EGF (Panitumumab or Vectibix) and 1H10 representative binding curves. SPR sensorgrams 
illustrative of A) ABX-EGF tandem scFv (1 nM, 3 nM, 10 nM, 30 nM and 100 nM BsAb) and B) ABX-EGF-IgG1 mAb (1 
nM, 3 nM, 10 nM and 30 nM BsAb) binding to immobilised recombinant EGFR. C) Biolayer interferometry kinetic curve of 
ABX-EGF tandem scFv the 1H10-mAb and ABX-EGF IgG1 mAb at 100 nM binding to captured LPS. Copyright 2015 The 
Authors. Published with license by Taylor & Francis Group, LLC. 
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Table 3.4: Surface plasmon resonance binding affinities for recombinant EGFR-mFc collected from a Biacore T-
200. Surface Plasmon Resonance (Biacore) analysis of BsAb binding to EGFR – ka (association rate constant), kd
(dissociation rate constant), and KD (binding affinity).  High performance (Multi-cycle) Kinetic Assay (HPKA) data is
shown for all BsAb constructs as well as for a reassembled, complete IgG1 Vectibix-mAb.  Standard error values
corresponding to binding values of recombinant EGFR is shown as ± x × 106 for ka and ± y × 10-5 for kd. Copyright 2015
The Authors. Published with license by Taylor & Francis Group, LLC.
Antibody ID 
Binding to recombinant EGFR 
ka (1/Ms) (×106) (±SE) kd (1/s) (×10-5) (±SE) KD (nM) 
Vectibix IgG2 mAb (published)  1.97 11.3 0.05 
Vectibix IgG1 mAb 2.18 ± 0.0025 15.5 ± 0.047 0.07 
Non-specific Tandem scFv 0.0034 ± 0.0018 7830 ± 140 22820 
Tandem scFv 0.26 ± 0.0004 13.6 ± 0.021 0.52 
Fc-containing 0.36 ± 0.0023 9.42 ± 0.028 0.26 
Fc-containing (Longlink) 0.19 ± 0.0005 21.6 ± 0.084 1.13 
Fc-containing (Cys) 0.48 ± 0.0002 4.89 ± 0.019 0.10 
Fc-containing (Cys Longlink) 0.70 ± 0.0004 2.47 ± 0.025 0.04 
KIH 1 (Cys) 0.82 ± 0.0005 2.67 ± 0.026 0.03 
KIH 2 0.50 ± 0.0021 6.75 ± 0.021 0.13 
Although unconfirmed it is possible that the weaker affinity of the Fc-containing (Longlink) 
BsAb could be related to how the protein is folded. Possibly, the longer linker at the CH3-
1H10 interface provides higher flexibility in this domain, resulting in some interference or 
miss-folding generated from the anti-LPS scFv entering the Panitumumab-scFv’s region. 
The Fc-containing (Cys Longlink) BsAb does not show the same weakened affinity; in fact 
it is one of the best at 0.03 nM, almost 100 times stronger than Fc-containing (Longlink); 
possibly explained by the presence of the engineered scFv disulphide bridges which 
ensure that the anti-LPS scFv components associate more closely. A similar observation is 
reflected in the KIH formats’ KD values albeit a lower difference of approximately 10 times; 
this can be attributed to the lack of both the anti-LPS VH and VΚ chains being present on 
each CH3 domain therefore limiting the reach and ability of the anti-LPS components to 
interfere with the opposite end of the BsAb molecule. 
Binding of all BsAbs to LPS was firstly confirmed by ELISA (results not shown). As LPS is 
naturally adhesive and binds strongly to surfaces (e.g. glass, plastic), performing binding 
studies by SPR was not compatible with the microfluidics system of the Biacore. The 
kinetics of 1H10-scFv component of the BsAbs binding to LPS were therefore determined 
by the Octet system (ForteBio), which circumvents the problems of a fluidics based 
system. Binding data was obtained for the original, hybridoma-derived 1H10-mAb [KD = 
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0.2 nM, ka = 8.20E+05 (±1.25E+04), kd = 1.36E-04 (±1.72E-05)] and 1H10-scFv of the 
tandem scFv format [KD = 10.0 nM, ka = 2.20E+04 (±1.76E+03), kd = 5.64E-04 (±2.39E-
05)] (Figure 3.12. C). The 60-fold difference in KD between the two formats is indicative of 
differences in avidity. 
Binding to native EGFR 
Flow cytometry analyses showed that all EGFR-targeting antibody formats (mAb and 
BsAb) were able to bind to EGFR-overexpressing MDA-MB-468 cells, whilst non-specific 
formats showed no binding (Figure 3.13).  A decreased shift for the tandem scFv BsAb 
compared to the Fc-linked formats can be attributed to the higher avidity of the EGFR-
bivalent, Fc-linked BsAbs. The lower fluorescence intensity of the tandem scFv could also 
be due to the different secondary antibody used for detection.  
Co-localisation of recombinant EGFR and EDVTMnanocells 
It was of interest to investigate the ability of BsAbs to crosslink the two antigens LPS and 
EGFR. A co-localisation experiment, using fluorescently labelled recombinant-EGFR 
(DL650) and BsAb-targeted EDVTMnanocells (AF488) provided visual confirmation that 
BsAbs could simultaneously bind their two targets (Figure 3.14). Results show that non-
targeted and non-specifically targeted EDVTMnanocells do not co-localise in the presence 
of recombinant EGFR (green fluorescence only). We included all seven of the BsAb 
formats, and observed their effect on nanocell clumping both visually and as particle 
counts on a nanosight (Table 3.5). The EGFR-targeting tandem scFv, KIH 1 (Cys), Fc-
containing (Cys) and Fc-containing (Cys Longlink) BsAbs caused less EDVTMnanocell 
aggregation illustrated by a uniform distribution of co-localised EGFR and targeted 
EDVTMnanocells, whereas nanocells targeted with KIH 2, Fc-containing and Fc-containing 
(Longlink) BsAbs produced large, aggregated clumps of co-localised recombinant EGFR 
and EDVTMnanocells. This illustrates how different recombinant BsAbs affect the 
EDVTMnanocells during and post targeting, and the final product stability. These findings 
highlight how BsAb design and properties in solution may influence the performance of the 
BsAb-EDVTMnanocell formulated product. 
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Figure 3.13: In vitro binding of BsAbs and IgG1 mAbs at 1µg/ml to EGFR overexpressing MDA-MB-468 Breast 
cancer cells. All specific BsAbs include Vectibix-scFvs (anti-EGFR). Non-specific formats include Synagis-scFvs 
(anti-RSV). Mean fluorescence intensities correlate well with the observed Biacore binding affinities. A) A non-specific 
IgG1 mAb (blue) did not result in a binding shift occurring however incubation with a Vectibix-IgG1 mAb (red) resulted 
in a positive binding shift as expected. B) No binding shift was evident in the presence of a non-specific tandem scFv 
BsAb (blue) but a shift was present when using the Vectibix tandem scFv format (red). C) All Fc-containing BsAbs 
resulted in a positive binding shift compared with cells only samples. Copyright 2015 The Authors. Published with 
license by Taylor & Francis Group, LLC. 
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Table 3.5: Average EDV nanosight counts post BsAb binding. EDV’s were prepared and aliquoted into tubes 
to ensure that roughly equal amounts were present in solution for each sample to be analysed. Once binding of 
BsAbs to EDVs had been achieved and sample preparations washed; duplicate measurements were made on a 
nanosight to determine the number of targeted or non-targeted EDVs present. Data showed that stable* BsAbs (2-6) 
bound to EDVs resulted in the number of EDVs/ml remaining constant when compared with non-targeted EDVs (1) that 
had undergone the same process of incubation and washing. Binding unstable* BsAbs to EDVs (7-9) resulted in an 
apparent decrease of EDVs/ml attributable to the presence of BsAb-EDV clumps. *Stable or unstable states were 
determined previously through SEC HPLC. 
BsAb-EDV ID Average count (x10
10
EDVs/ml)
1 Non-targeted-EDV 4.62 
2 Non-specific targeted-EDV 5.65 
3 Tandem scFv-EDV 4.58 
4 KIH 1 (Cys)-EDV 4.76 
5 Fc-containing (Cys)-EDV 4.55 
6 Fc-containing (CysLonglink)-EDV 4.58 
7 Fc-containing-EDV 0.87 
8 Fc-containing (Longlink)-EDV 1.42 
9 KIH 2-EDV 1.01 
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3.4. Discussion and Conclusion 
A variety of BsAb formats were investigated for their ability to bind EDVTMnanocells and 
recombinant or native EGFR.  Initial proof of principle studies were performed using 
rigorously tested approved therapeutic antibodies, which have ideal properties such as 
high affinity and stability. The modular nature of BsAb constructs allows alternative 
antibody specificities to be substituted depending on the receptor target. In order to create 
a cancer cell-targeting domain we selected EGFR, as several marketed anti-cancer 
therapeutics target this molecule.12, 14, 16, 17  
Panitumumab (Vectibix or ABX-EGF) is a FDA approved commercial anti-EGFR mAb 
developed via transgenic humanised mouse technology by Abgenix Inc and Amgen.24, 67, 83 
The mAb has picomolar affinity for EGFR and is the first fully human mAb created through 
transgenic humanised mouse technology to be approved for therapeutic use. Its 
properties, including affinity, specificity and immunogenicity, have been extensively 
evaluated making Panitumumab an ideal candidate to be incorporated in the EnGeneIC 
drug delivery system.129 
The tandem scFv BsAb was designed to include a 5 amino acid glycine-serine linker (G4S) 
between the Vectibix- and 1H10-scFv. The shorter linker reduces flexibility and therefore 
prevents misfolding from occurring between the two scFv components. Administered in 
isolation, tandem scFv BsAbs exhibit low avidity, and due to their small size have a low 
serum half life.156, 193 However pharmacokinetic properties of tandem scFv BsAbs bound to 
the large EDVTMnanocell (400 nm in diameter), will be enhanced. Furthermore, coating of 
the EDVTMnanocell with tandem scFv BsAbs imparts multivalency and avidity to the NP, 
and provides multiple binding sites for the cancer-targeting domain.129 
To produce more complex BsAbs compared to the tandem scFv BsAb, manipulation of the 
standard IgG mAb format has produced a plethora of Fc-containing BsAbs, whereby 
designs generally rely on the principle that Fc-containing BsAbs will dimerise through the 
Fc, similar to native, whole mAbs.118, 154, 156, 169, 193 Features of these antibodies include 
engineering Fc components to improve or remove various related functions, forced 
heterodimerisation, removal of redundant domains and addition of other binding motifs to 
the IgG molecule.84, 154-156, 259 We used an IgG1 Fc-domain to link and separate the two 
scFvs spatially (Vectibix-scFv at the N-terminus of human IgG1 Fc domain, and an 1H10-
scFv at the C-terminus) to create the Vectibix-Fc-1H10 homodimeric Fc-containing BsAb, 
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similar to the scFv-Fc-scFv BsAb dimer described in Jendreyko et al. 2003 and the 
Emergent BiosolutionsTM product termed ADAPTIRTM Multi-Specific.151, 266  
A benefit of the Fc-containing BsAbs over the tandem scFv format is the presence of two 
scFvs to bind each target – promoting high avidity binding to both the EDVTMnanocell and 
the EGFR on the cancer cell surface; however a potential drawback could result if the Fc-
domain stimulates an unwanted immune response and complement cascade.144, 239 
Although it is well known that Fc-related immune responses can be avoided through 
various mutations 84 throughout the domain – our work thus far has focussed on the 
production of a stable drug delivery system rather than potential immunogenicity. 
EnGeneIC’s original BsAb format also retained fully functional Fc domains without 
significant immunogenicity being noted.103, 129, 239 
Presence of aggregation is undesirable in therapeutic products and therefore necessitated 
the need to attempt stability engineering of the Fc-containing format.136, 181, 267 Previous 
studies have found that inclusion of a number of design modifications, including variations 
in CH3-scFv linker length and type, and also scFv stability engineering via addition of 
disulfide bonds, improved construct stability.134, 138, 141, 181 However, the stability appears to 
be largely related to the nature of the scFv at the CH3 domain – an observation reiterated 
in our results (Table 3.3.K – N).136, 138 A concern with the Fc-linked dimeric design was 
whether the presence of two anti-LPS scFvs would result in EDVTMnanocell aggregation 
via binding of multiple nanocells rather than high avidity binding of a single nanocell.  
An alternative Fc-linked BsAb was engineered consisting of two EGFR targeting scFvs at 
the N-terminus (high avidity) and a single anti-LPS scFv at the C-terminus of the final 
product.  Heterodimeric BsAb formats were based on the common Knob-in-hole 
constructs138, 155 and partly on the TandAb BsAb designed by Affimed where variable linker 
lengths are used to determine chain association for functional BsAb formation.140, 190 The 
single anti-LPS site is formed through forced heterodimerisation of the CH3 domain via 
Knob-in-Hole (KIH) engineering, where the VH and VΚ domains of the scFv are expressed 
on separate polypeptides in a single cell. To ensure that the VH- and VΚ-chains associate 
with one another to form a functional 1H10-scFv, a longer linker between CH3 and the 
1H10-scFv component was designed to allow extra flexibility in the area for functional 
association of the nanocell-targeting scFv components.138 
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In summary we engineered several BsAb constructs and found differences in format 
design affected BsAb production and function. These are important findings as they can 
influence potential application of BsAbs as targeting reagents for NP drug delivery vehicles 
and also have implications for scale-up production thereof. Based on co-localisation 
images of the various BsAb formats binding to EDVTMnanocells and to EGFR, four of the 
BsAbs are of particular interest for further development: tandem scFv, Fc-containing (Cys), 
Fc-containing (Cys Longlink) and KIH (Cys).  The other formats resulted in clumping of the 
EDVTMnanocells.  All of these constructs can be routinely expressed in CHO-S and purified 
through simple purification protocols. 
Preliminary results suggest that although the disulphide engineered Fc-linked BsAbs are 
poorly expressed in CHO-S cultures it is possible to increase product yield through 
optimisation of the transfection protocol. The differences in anti-EGFR avidity between 
constructs would likely not impact the BsAb-EDVTMnanocell function significantly due to 
the presence of multiple BsAbs bound to the surface of the EDVTMnanocell. Where avidity 
binding will likely be of importance though is during the targeting process of BsAbs binding 
to EDVTMnanocells – multiple anti-LPS scFvs can provide a stronger interaction between 
BsAb and EDVTMnanocell resulting in more EDVTMnanocells retaining targeting 
capabilities. However as there are expected to be multiple binding sites present on the 
EDVTMnanocell surface, if a tandem scFv does dissociate from the EDV it will re-associate 
at a second LPS site. 
BsAb format stability plays an important role in the development of the EDVTMnanocell 
targeting system. The tandem scFv was shown to have superior stability over the Fc-
containing variants indicating that individual scFv components were not responsible for 
any observed stability issues, but that stability was influenced by the linker connecting 
them. Without the ability to routinely produce predictable amounts of stable BsAb, the 
quality of the BsAb targeted EDVTMnanocells cannot be maintained and would hinder 
production of a viable therapeutic drug delivery system. 
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4. Targeting EnGeneIC drug delivery vehicles (EDVTMnanocells) 
 
4.1. Chapter summary 
Engineered BsAbs are proteins designed to be capable of binding two distinct targets; 
whereas traditional mAbs or scFvs only bind a single target. One arm of a BsAb binding 
domain is engineered to bind a disease antigen while the second is used as a targeting 
moiety. The use of BsAbs as therapeutic products is on the increase – particularly in pre-
clinical cancer treatment studies. NPs are also being developed as therapeutic agents. 
Greater therapeutic efficacy is achieved through loading NPs with cytotoxic drugs, siRNA 
and proteins, and by actively targeting the NPs reduced systemic toxicity can be achieved. 
Our work describes how EGFR displaying cancers could potentially be treated by BsAbs 
that bind the disease target while carrying a therapeutic payload enclosed in a NP, the 
EnGeneIC delivery vehicle (EDVTMnanocell). We show that stable BsAbs can be bound to 
EDVTMnanocells to produce a uniform, non-chemically conjugated BsAb-EDVTMnanocell 
distribution with little product loss, thereby improving scalability. The BsAb-EDVTMnanocell 
products maintain functional binding in vitro as illustrated through flow cytometry against 
EGFR-overexpressing MDA-MB-468 breast cancer cells. The G4S-linked tandem scFv 
BsAb format was the optimal design with respect to EDV binding and expression yield. 
Doxorubicin-loaded EDVTMnanocells were actively targeted with tandem scFv BsAb in vivo 
to MDA-MB-468 derived tumours in mouse xenograft models, and showed enhanced 
tumour regression by 40% compared to passively targeted EDVTMnanocells. BsAbs 
therefore provide a functional means to deliver EDVTMnanocells to target cells. 
 
4.2. Introduction 
Recently a large number of engineered NPs have been developed.218, 226, 233, 234, 268, 269 The 
concept of NP-mediated drug delivery is attractive as it can lead to improvement in drug 
safety and efficacy. A myriad of engineered NPs for drug delivery have been developed, 
and include liposomes, polymeric-based NPs, silica, carbon, metal oxides and other 
materials.  Some are also derived from bacteria, viruses (e.g. virus-like particles) and 
eukaryotic cells (exosomes). 220, 223, 226, 227, 232-234, 270 Advantages of NP-mediated drug 
delivery include protection of payloads such as DNA and RNA from degradation, improved 
drug pharmacokinetics, being able to increase the dose concentration above what would 
be too toxic for systemic exposure and enabling effective drug dosing where drugs are 
insoluble.225, 226, 239, 252 Notwithstanding the large number of NPs that have been developed 
for therapeutic application, at present there are only six nanomedicines approved for 
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clinical use, including liposomal NPs Myocet, Doxil, Daunoxome and Depocyt, Abraxane 
(albumin-based NP) and Genexol-PM (micelle).235 All these nanomedicines operate 
through passive targeting, i.e. enhanced extravasation of NPs at the tumour site, facilitated 
by poorly differentiated tumour vasculature.  There are a number of nanomedicines 
presently in clinical trials, with several of these targeted by antibodies.218, 231   
Barriers to successful NP-mediated drug delivery - including the reticular endothelial 
system, efficient extravasation, crossing the anatomical and physical barriers between 
endothelial and tumour cells, penetrating the tumour structure, endocytosis uptake and 
intracellular release of therapeutic agents, can be improved upon through active targeting 
of NPs using targeting agents. NPs can carry drug payloads that include small molecule 
drugs, DNA or RNA.225, 226, 252 Targeted NPs are being developed to enable efficient 
delivery of therapeutic compounds directly to a disease target (active targeting), such as 
cancer cell surface markers, thereby localising the effects of the therapeutic agent.49, 271 
An emerging application of BsAbs is active targeting of drug-loaded NP to tumour sites by 
cross-linking the NP to tumour cells, leading to endocytosis, fusion with lysosomes and 
drug release intracellularly.103, 118, 129, 246 
Delivery of drugs sequestered within or attached to NPs opens the drug therapeutic 
window and addresses the low therapeutic index of free-drug administration; i.e. systemic 
drug delivery at required therapeutic doses results in acute toxicity and can elicit severe 
patient side effects. Furthermore multiple drug resistance (MDR) can be alleviated by 
packaging NPs with siRNA or shRNA capable of interfering with cellular mechanisms 
promoting MDR.103, 239 For active targeting of NPs to tumour cells with antibodies, anti-
tumour mAbs can be chemically conjugated to the NP, or alternatively be tethered to the 
NPs by using BsAbs which simultaneously bind the NP and the tumour target antigen.224,
236
BsAbs have gained popularity in recent years owing to their ability to target multiple 
antigens.118, 124, 188, 255 EnGeneIC’s EDVTMnanocell technology incorporates both the use of 
a novel drug delivery vehicle and a means to target cancer cells through BsAbs. 
EDVTMnanocells or minicells are bacterially derived, anucleate NPs capable of being 
loaded with high concentrations of various drug classes including chemotherapeutics and 
siRNA; and are successfully internalised on targeted cell surfaces despite their large size 
of 400nm.129 The only disadvantage of the EDVTMnanocells is the presence of LPS which 
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can illicit an immune response in patients; however it is possible that when the anti-LPS 
component of BsAbs bind the O-polysaccharides on the LPS-arms, these sites are 
shielded from the immune system (MacDiarmid personal communication).129 Coupling 
EDVTMnanocells to BsAbs with affinity for specific cancer cell surface antigens provides 
the potential of having high cytotoxic payloads or siRNA delivered directly to where 
required; thereby limiting the severe toxicity associated with non-targeted drug delivery.103,
129, 226, 239 Once delivered to the cancer cell surface, the BsAb and drug-loaded 
EDVTMnanocells are internalised by the cell; and on completion of intracellular degradation 
the cytotoxic payload is released.103, 129 Drug resistance can be circumvented using this 
technology through a two-step process of firstly delivering siRNA and then cytotoxic drugs 
to the target cells.103, 272  
EnGeneIC’s initial approach to producing a BsAb compatible with the EDVTMnanocell 
included two full mAbs - one directed towards the O-polysaccharides on the LPS-arms and 
another towards the target cell surface antigen (EGF-Receptors), linked through the Fc 
regions of the mAbs by means of purified recombinant protein A/G (Figure 4.1).  
Figure 4.1: Diagrammatic representation of a BsAb created through Protein A/G linkage. The diagram shows how 
a Protein A/G molecule with six potential binding sites for antibody Fc-domains can form a functional BsAb when bound 
to two different mAbs targeting different antigens. 
Using this protein A/G as a linker complicates manufacturing and produces variable 
construct sizes since the linker is capable of binding variable proportions of up to six 
different anti-LPS or anti-EGFR mAbs. Initial studies showed that these BsAb- 
EDVTMnanocells are effectively internalised by targeted cancer cells but to optimise the 
therapeutic benefits and manufacturing of the technology the BsAb design needs to be 
improved.129 Three stable BsAb formats, a G4S-linked tandem scFv format and cysteine 
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stabilised homodimeric Fc-containing and heterodimeric Knob-in-Hole (KIH) engineered 
BsAbs were evaluated as to their ability to simultaneously bind EDVTMnanocells (Figure 
4.2) and a cancer target – EGFR; both in vitro and in vivo. 
Figure 4.2: BsAb format binding to EnGeneICTMnanocells. Graphical representation of how different types of BsAb 
formats are expected to bind the EnGeneICTMnanocell with different levels of avidity for the LPS O-polysaccharide on the 
nanocell surface. A) Shows a Knob-in-Hole BsAb and B) a tandem scFv BsAb binding to a nanocell, both BsAbs bind 
with lower avidity than C) the homodimeric Fc-containing BsAb format. 
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4.3. Results 
4.3.1. Characterisation of stable BsAbs binding to EDVTMnanocells 
Conjugation of BsAbs to AF488 labelled EDVTMnanocells showed limited aggregation as 
illustrated in nanosight data (Table 4.1). EDVTMnanocells were resuspended to 
approximately 4 x 10
10 
EDVs/ml after completion of binding and wash steps. Actual mean 
counts indicate very little variation from this expected value indicating that little product 
loss occurred during the conjugation process. If aggregation is high due to the conjugation 
process then particle counts are significantly lower than pre-conjugation counts and the 
size distribution also wider than the observed “tight” peaks. Fluorescent images of BsAb-
EDVTMnanocells (AF488) samples taken with microscope showed presence of single 
green or aggregated (green clumps) BsAb-EDVTMnanocells (Figure 4.3). Particle sizes 
were also distributed within the expected range of at around 400 – 500 nm. 
4.3.2. In vitro binding of BsAb-EDVTMnanocells to MDA-MB-468 breast cancer cells 
The BsAbs which resulted in a uniform distribution in the co-localisation study described in 
chapter 3 were further investigated by binding to cells using flow cytometry (Figure 4.4) 
and confocal microscopy (Figure 4.5). For confocal microscopy MDA-MB-468 cells 
(labelled with AF647) were targeted with AF488-labelled BsAb-EDVTMnanocells. Non-
targeted EDVTMnanocells did not localise on MDA-MB-468 cell surfaces nor did non-
specific EDVTMnanocells. Confocal microscopy (Figure 4.5) and flow cytometry analyses 
(Figure 4.4) showed that while all BsAbs localised on the MDA-MB-468 cell surface, the 
tandem scFv and KIH 1 (Cys) BsAb formats, possessing only a single 1H10-scFv, 
displayed a lower distribution across the cell surface compared to the distributions of the 
Fc-containing (Cys) and Fc-containing (Cys Longlink) targeted EDVTMnanocells, with two 
1H10-scFvs. Variation in flow cytometry binding shifts therefore reflects effects that can be 
associated with the degree of binding avidity. The Fc-containing (Cys) and Fc-containing 
(Cys Longlink) targeted EDVTMnanocells presented as larger shifts compared to the 
tandem scFv and KIH 1 (Cys) targeted EDVTMnanocells. These results could also indicate 
that the tandem scFv and KIH 1 (Cys) formats don’t bind EDVTMnanocells as tightly as the 
other two formats, resulting in more BsAb loss with increased time from initial conjugation 
to EDVTMnanocells through to final cellular uptake. However significant numbers of 
nanocells still reach the target cell surface and preliminary observations at EnGeneIC 
indicate that high numbers of nanocells bound to target cell-surfaces could encumber 
cellular uptake (personal communication Ilya Sedliarou). 
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Table 4.1: Experimental sample breakdown. BsAb-EDV
TM
nanocells particle characterisation and counts post-
conjugation.  
Sample ID 
Mean EDV count 
(x10
10
EDVs/ml) 
Mean size 
distribution (nm) 
1 Non-targeted EDV
TM
nanocells 4.83 455 
2 Non-specific  tandem scFv- EDV
TM
nanocells 4.62 429 
3 Tandem scFv- EDV
TM
nanocells 4.56 483 
4 Fc-containing (Cys)- EDV
TM
nanocells 3.78 460 
5 
Fc-containing (Cys Longlink)- 
EDV
TM
nanocells
4.73 464 
6 KIH (Cys)- EDV
TM
nanocells 3.99 474 
Figure 4.3: Analysis of BsAb-EDVTMnanocell aggregation post-conjugation. Each individual green spot is illustrative 
of a single AF488-labelled BsAb-EDVTMnanocell. Where clumps are visible as in KIH 1 (Cys)-EDVs in the bottom right 
panel, particle aggregation has occurred. 
Figure 4.4: In vitro binding of BsAb-EDVTMnanocells to EGFR overexpressing MDA-MB-468 breast cancer cells. 
All specific BsAbs include ABX-EGF-scFvs (anti-EGFR), non-specific formats include a Synagis-scFv (anti-RSV) and all 
BsAbs include the 1H10 (anti-LPS) scFv. The diagram illustrates degrees of binding shifts associated with AlexaFluor 
488 labelled EDVTMnanocells (EDVs) binding to cells via various bound BsAbs. All non-aggregating BsAb formats were 
used to target EDVs to MDA-MB-468 cells. Positive binding shifts occurred for all formats targeted to EGFR with slightly 
larger shifts observed for BsAbs, Fc-containing (Cys) and Fc-containing (Cys Longlink), where higher avidity binding to 
EDVs is possible. Copyright 2015 The Authors. Published with license by Taylor & Francis Group, LLC.  
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4.3.3. EDVTMnanocell-mediated tumour regression in a mouse xenograft model 
The tandem scFv BsAb can be produced as uniform, predictable and stable amounts and 
therefore it was the only recombinant BsAb format tested in a mouse xenograft model for 
tumour regression. To evaluate the efficacy of EDVTMnanocells targeted using the ABX-
EGF tandem scFv (Tandem scFv EDV) compared to those targeted with EnGeneIC’s original, 
Protein A cross-linked anti-LPS / anti-EGFR BsAb (Protein A/G EDV),129 in vivo experiments 
were carried out utilising a MDA-MB-468 mouse xenograft model, with dosing 
commencing 14 days after subcutaneous injection of MDA-MB-468 cells (tumour volume 
approx. 80-100 mm3) (Figure 4.6). EDVTMnanocells targeted with the tandem scFv and 
loaded with Doxorubicin (Tandem scFv EDV Dox) effectively suppressed tumour growth over a 
38 day period post xenograft compared to controls. Active targeting with Tandem scFv EDV Dox
showed tumour regression was similar to that achieved with EDVTMnanocells targeted by 
protein A/G cross-linked BsAbs (Protein A/G EDV Dox). Importantly, active targeting of 
Doxorubicin-loaded EDVTMnanocells by the tandem scFv BsAb resulted in a 40% 
reduction in tumour volume compared to that of loaded passively targeted EDVTMnanocells 
(EDV Dox) 38 days post xenograft (i.e. 140 mm3 and 240 mm3, respectively). Targeted 
EDVTMnanocells not loaded with Doxorubicin (Tandem scFv EDV) had a minor tumour 
suppressing effect, whereas non-targeted, Doxorubicin-loaded EDVTMnanocells (EDV Dox) 
showed significant tumour regression compared to saline controls; the latter being most 
likely due to passive targeting through leaky tumour vasculature of tumour xenografts 
(pore sizes 0.2–1.2 µm).222, 231, 273 
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4.4. Discussion and Conclusion 
The Protein A/G linked BsAb format originally included as EnGeneIC’s active targeting 
moiety in the EDVTMnanocell system presented quality results as a proof of principle 
concept in the ability of BsAbs to act as facilitators of targeted drug delivery.103, 129, 239, 245 
However BsAb production proved to be cumbersome and non-uniform owing to the 
presence of six potential binding sites on the Protein A/G molecule, and limited control 
over the ratio of each mAb component incorporated into the BsAb.129 We initially evaluated 
various engineered BsAb formats with respect to their product yield, stability and target 
binding post-purification from mammalian cell culture. From these results we were able to 
select improved formats for use in the EDVTMnanocell system and further analyse their 
ability in respect to being suited to their end purpose, which is to facilitate active drug 
delivery to targeted cancer cells.  
The modular nature of the designed BsAbs means that clinically approved as well as new 
targeting scFv moieties can easily be substituted into the BsAb to target various disease 
phenotypes once the optimal BsAb-EDVTMnanocell system is fully evaluated. Our formats 
incorporated a scFv derived from a clinically approved mAb (Vectibix, Panitumumab or 
ABX-EGF)24, 67, 83 which targets EGFR on cancer cells, thereby circumventing the need for 
complete validation of the BsAbs specificity when bound to the cancer cell as this 
information is readily available in published results and patent information. 
Given that the biggest requirement for the BsAb-EDVTMnanocell system associated with 
our work is the facilitation of cytotoxic payload delivery to the intended target, BsAb mode 
of action as a therapeutic in isolation by itself and the resulting variation thereof between 
formats (and variation from the standard mAb format) wasn’t a priority factor in the initial 
product development. All proposed formats utilising the commercial model (Panitumumab) 
were expected to be effective in the system albeit that there would be higher avidity 
associated with the Fc-containing (Cys) and Fc-containing (Cys Longlink) formats due to 
the presence of two scFvs targeting each of EGFR (cancer) and LPS (EDVTMnanocell). 
The added avidity would improve NP binding but further research would be required to 
evaluate the higher binding avidity’s influence on tumour penetration compared with the 
tandem scFv format. Another possible difference might be in the immunogenicity 
associated with presence of an Fc linker between scFvs rather than a simple G4S linker. 
However, our work thus far has focussed on the production of a stable drug delivery 
system rather than potential immunogenicity. EnGeneIC’s original BsAb format also 
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retained fully functional Fc domains without significant immunogenicity being noted.103, 129,
239
Based on co-localisation images of the various BsAb formats binding to EDVTMnanocells 
and to EGFR, four of the BsAbs were of particular interest for further development: tandem 
scFv, Fc-containing (Cys), Fc-containing (Cys Longlink) and KIH 1 (Cys).  The other 
formats resulted in clumping of the EDVTMnanocells (Figure 3.14).  Confocal images 
(Figure 4.5) showed that there was a lower distribution of KIH 1 (Cys) BsAb-
EDVTMnanocells present on MDA-MB-468 cell surfaces. A possible explanation for this 
observation is that the association of the Vh and Vk domains of the anti-LPS scFv from 
different polypeptides in the KIH format might not be very stable, in addition to the lower 
avidity effects associated with the presence of only a single anti-LPS scFv on the 
construct. The sum of which results in less affinity of the BsAb to the EDVTMnanocells and 
consequently less reaching the MDA-MB-468 cell surfaces compared with the IgG-like 
(Cys) and IgG-like (CysLonglink) BsAb formats. Additional stability engineering in the anti-
LPS scFv components might benefit the construct to improve functional heterodimer 
formation. 
As the expression yields of the disulphide-engineered, Fc-linked BsAbs were 6-9 fold 
lower than the tandem scFv, the tandem scFv was chosen for further investigation. The 
tandem scFv BsAb was designed to include a 5 amino acid glycine-serine linker (G4S) 
between the ABX-EGF- and 1H10-scFv. The shorter linker reduces flexibility and therefore 
prevents misfolding from occurring between the two scFv components. Administered in 
isolation, tandem scFv BsAbs exhibit low avidity, and due to their small size have a low 
serum half life.156, 193 However pharmacokinetic properties of tandem scFv BsAbs bound to 
the large EDVTMnanocell (400 nm in diameter), will be enhanced. Furthermore, coating of 
the EDVTMnanocell with tandem scFv BsAbs imparts multivalency and avidity to the NP, 
and provides multiple binding sites for the cancer-targeting domain.129 
Tumour regression in MDA-MB-468 breast cancer cell xenografts showed that BsAb-
mediated targeting with anti-EGFR antibody is essential for optimal inhibition of tumour 
growth.  Although EDVTMnanocells have previously been successfully targeted by cross-
linking two IgG antibodies with protein A, utilising the tandem scFv, whereby one arm 
binds the EDVTMnanocell and the other targets the tumour, requires the production of one 
new molecular entity (NME). A biologic NME can be characterised for binding activity and 
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manufactured according to cGMP. Fc-containing BsAbs produced during this project have 
not as yet been produced as stable single NMEs at predictable yields and are therefore 
currently unsuitable for cGMP production. Although the 1H10-scFv is of murine origin the 
scFv is expected to be shielded between the nanocell and the BsAb, thereby limiting the 
possibility of a HAMA response.103, 129, 239 The coating of BsAb on the surface of the 
EDVTMnanocell also imparts other properties to the nanocell.  Depending on BsAb density 
on the nanocell surface, the imparted avidity would enhance apparent affinity of the 
EDVTMnanocell for its target, compared to that of the target scFv alone. Furthermore, 
coating with a BsAb, where the cancer targeting scFv is of human origin, alters the 
physicochemical properties of the EDVTMnanocell in vivo, and would impact parameters 
such as pharmacokinetics and immunogenicity.   
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5. Concluding remarks and future work
During this project we successfully engineered and expressed a stable BsAb format best 
suited to targeting drug-laden EnGeneICTMnanocells to cancer cells presenting the EGFR. 
In contrast to EnGeneIC’s original BsAb format, the selected tandem scFv BsAb can be 
produced as a uniform and reproducible product with consistent characteristics relating to 
physical structure (one binding arm per target), yield, stability, binding affinity and 
function.129, 240 EnGeneIC has subsequently initiated a number of clinical trials both in the 
U.S. and in Australia wherein they have incorporated the tandem scFv as their targeting 
moiety (personal communication Ilya Sedliarou). A stable cell line has been developed for 
this BsAb format and they have since also progressed to having the product manufactured 
at cGMP scale. BsAb stability and release specifications were also recently finalised on 
pre-IND with the FDA. 
A Phase 1 clinical trial was completed in Australia during June 2014 using the EGFR-
targeting EDVTMnanocells for the treatment of recurrent glioma. Results from these trials 
have informed EnGeneIC’s ability to progress to a Phase 2a clinical trial in the U.S. using 
the same nanocell technology loaded with doxorubicin, in the treatment of recurrent 
glioblastoma – an aggressive form of brain tumour. The results from a Phase 1 clinical trial 
in paclitaxel-loaded EDVTMnanocells showed limited toxicity associated with the treatment; 
a result then reiterated in a phase 1 trial of glioblastoma patients treated with doxorubicin-
loaded nanocells. Another Phase 1 clinical trial (collaboration between EnGeneIC and the 
Asbestos Disease Research Institute) seeks to evaluate the potential of the EGFR-
targeting nanocell technology when loaded with microRNA in the treatment of malignant 
pleural mesothelia (MPM) (www.prnewswire.com). 
The collaborative efforts between our group at the Australian Institute for Bioengineering 
and Nanotechnology (AIBN) and EnGeneIC in selecting the optimal BsAb targeting moiety 
has subsequently provided the opportunity for further research and development of the 
novel EDVTMnanocell platform, specifically in regards to new and novel targets. EnGeneIC 
have been evaluating the potential of targeting cancers relating to mesothelioma, non-
small cell lung cancer and melanoma. 
Currently AIBN researchers are working on identifying and producing tandem scFv BsAbs 
to be used as an alternative to the EGFR-targeting product. The modular nature of the 
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engineered tandem scFv BsAb makes this possible by using basic molecular techniques 
where newly identified targeting sequences can be inserted into the BsAb framework 
through restriction enzyme digestion and subsequent cloning to produce new vectors for 
mammalian protein expression. Currently the work involves incorporating a mesothelin 
targeting scFv derived from Amatuximab into the technology to target human 
mesothelioma and identifying novel binding moieties against canine c-kit (CD117) through 
phage display. EnGeneIC are currently performing in vivo studies on the mesothelin-
targeting BsAb-EDVTMnanocells (personal communication Mohamed Alfaleh). 
Furthermore, the mechanism that facilitates EDVTMnanocell uptake is currently unknown 
and the subject of a recently submitted ARC-Linkage grant application. 
 
In addition to the work being completed through collaboration between EnGeneIC and 
AIBN, our engineered tandem scFv BsAb has informed other researchers in the field of 
diagnostic and therapeutic NPs as to the potential of using BsAbs to facilitate targeted 
particle delivery. Current collaborative work includes the development of a BsAb targeting 
Polyethylene glycol (PEG) on a NP surface and EGFR simultaneously using the described 
tandem scFv BsAb format. This work is currently confidential pending the investigators 
pursuing the potential to patent the developed product. 
 
Although the tandem scFv format has shown great promise as a facilitator of 
EDVTMnanocell delivery to target cell surfaces, it is worth noting that this may not be the 
case for all applications. The tandem scFv does not possess high avidity binding due to 
the BsAb being monovalent for each of its two targets – if a different particle was used that 
had low levels of target cell surface density the targeting moiety may be lost if the binding 
affinity isn’t strong enough or the dissociation rate too high. In the case of the 
EDVTMnanocell however, LPS on the nanocell surface is readily available which endows 
the product with the potential of high avidity – the tandem scFv to reattach should it 
become dissociated from one LPS site. 
 
In conclusion, the work described in this thesis has been able to inform a wide audience 
spanning fields such as molecular, chemical and cell biology in the potential use and 
production of BsAbs. We have shown that although BsAbs are most commonly used as a 
therapeutic where the mode of action is to redirect an immune response, a large amount of 
potential is evident in using BsAbs as facilitators of targeted NP delivery.29, 118, 123, 124 The 
work brings together NP and antibody engineering fields to improve on the current 
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knowledge base to develop next generation novel therapeutics capable of improving the 
availability and quality of disease treatment options. Nanomedicine is poised to play an 
increasingly important role in cancer therapy in the future, with at present seven passively 
targeted nanomedicines approved for cancer therapy.218, 231  Actively targeting NPs to 
tumours with antibodies, as demonstrated in this study, can have significant advantages 
and improve efficacy compared to passive targeting alone.  Designing new BsAbs that are 
able to efficiently target NPs opens a new dimension in active NP targeting. 
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Nanocell targeting using engineered bispecific 
antibodies
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There are many design formats for bispecific antibodies (BsAbs), and the best design choice is highly dependent 
on the final application. Our aim was to engineer BsAbs to target a novel nanocell (EnGeneIC Delivery Vehicle or 
EDVTMnanocell) to the epidermal growth factor receptor (EGFR). EDVTMnanocells are coated with lipopolysaccharide 
(LPS), and BsAb designs incorporated single chain Fv (scFv) fragments derived from an anti-LPS antibody (1H10) and 
an anti-EGFR antibody, ABX-EGF. We engineered various BsAb formats with monovalent or bivalent binding arms and 
linked scFv fragments via either glycine-serine (G4S) or Fc-linkers. Binding analyses utilizing ELISA, surface plasmon 
resonance, bio-layer interferometry, flow cytometry and fluorescence microscopy showed that binding to LPS and to 
either soluble recombinant EGFR or MDA-MB-468 cells expressing EGFR, was conserved for all construct designs. 
However, the Fc-linked BsAbs led to nanocell clumping upon binding to EDVTMnanocells. Clumping was eliminated 
when additional disulfide bonds were incorporated into the scFv components of the BsAbs, but this resulted in lower 
BsAb expression. The G4S-linked tandem scFv BsAb format was the optimal design with respect to EDV binding and 
expression yield. Doxorubicin-loaded EDVTMnanocells actively targeted with tandem scFv BsAb in vivo to MDA-
MB-468-derived tumors in mouse xenograft models enhanced tumor regression by 40% compared to passively 
targeted EDVTMnanocells. BsAbs therefore provide a functional means to deliver EDVTMnanocells to target cells.
Introduction
Therapeutic monoclonal antibodies (mAbs) approved for
clin-ical use, such as bevacizumab (Avastin), adalimumab 
(Humira), trastuzumab (Herceptin), cetuximab (Erbitux) 
and panitumumab (Vectibix), comprise a significant portion 
of the global pharmaceutical market.1,2 Of the total mAb sales 
in 2010, half were attributed to cancer-related therapies.3 In 
2012, half of the antibody-based oncology products under
clinical evaluation were full-length IgG mAbs, while the
remaining candidates included drug-conjugated or radio-labeled
mAbs, protein- and glyco-engineered mAbs and fragment or 
domain antibodies.4–6 Also under evaluation are bispecific 
antibodies (BsAbs)7, which are subject to increasing interest in 
recent years owing to their ability to target multiple
antigens. 118-
BsAbs are able to crosslink antigenic determinants and so have
value beyond that of single antigen-specific mAbs (Fig.1).1,11-15
The most prominent therapeutic utility for BsAbs in cancer thera-
peutics is the cross-linking of cell-surface antigens or receptors, so
that immune cells can be tethered to cancer cells through a bispe-
cific antibody.9,11,12,16,17 Catumaxomab (Removab) was 
approved for therapeutic use in Europe in 2009, and remains the
only approved therapeutic BsAb, although the number of BsAb
formats entering clinical trials is increasing steadily.7, 13
Catumaxomab is a T-cell engager, with specificity for both CD3
on cytotoxic T cells and the EpCAM antigen on ovarian cancer
cells, for the treatment of malignant ascites.18-20 Another 
emerging application of BsAbs is active targeting of drug-loaded
nanoparticles (NP) to tumor sites by cross-linking the NP to
tumor cells, leading to endocytosis, fusion with lysosomes and
drug release intracellularly.1,11,21,22
The concept of NP-mediated drug delivery is attractive as it
can lead to improvement in drug safety and efficacy. A myriad
of engineered NPs for drug delivery have been developed, and
include liposomes, polymeric-based NPs, silica, carbon, metal
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oxides and other materials. Some are also derived from bacteria,
viruses (e.g., virus-like particles) and eukaryotic cells (exosomes).
23-30 Advantages of NP-mediated drug delivery include protec-
tion of payloads such as DNA and RNA from degradation,
improved drug pharmacokinetics and the enabling of effective
drug dosing where drugs are insoluble.2, 31 Notwithstanding the
large number of NPs that have been developed for therapeutic
application, at present there are only 7 nanomedicines approved
for cancer therapy. All these nanomedicines operate through pas-
sive targeting, i.e., enhanced extravasation of NPs at the tumor
site, facilitated by poorly differentiated tumor vasculature. There
are a number of nanomedicines presently in clinical trials, with
several of these targeted by antibodies.32, 33
NPs can carry drug payloads that include small molecule drugs,
DNA or RNA.2,30,34 Accumulation of the NPs at the tumor site
by passive targeting decreases biodistribution, ideally localizing the
therapeutic effects of the drug payload at the tumor site(s).35, 36
Delivery of drugs sequestered within or attached to NPs opens the
drug therapeutic window and addresses the low therapeutic index
of free-drug administration, i.e., systemic drug delivery at required
therapeutic doses results in acute toxicity and can elicit severe
patient side effects. Furthermore, multiple drug resistance (MDR)
can be alleviated by packaging NPs with siRNA or shRNA capable
of interfering with cellular mechanisms promoting MDR.22, 31
For active targeting of NPs to tumor cells with antibodies,
anti-tumor mAbs can be chemically conjugated to the NP, or
alternatively be tethered to the NPs by using BsAbs that simulta-
neously bind the NP and the tumor target antigen.37, 38 BsAbs
can be produced by chemical conjugation of 2 mAbs or frag-
ments with different specificities (e.g., via bis-maleimide cross-
linking through Thiomab technology)39 or alternatively via an
affinity ligand such as Protein A or Protein G.21 However, these
methods can be associated with antibody inactivation, low yields
and product heterogeneity; for example, yields of 10 - 40%
dimeric BsAb from hetero-bifunctional reagents and 65 - 75%
from homo-bifunctional reagents.39 These methods rely on het-
erodimeric association of 2 mAbs. However homodimers can
also be produced, limiting the yield of functional product.40, 41
Another method to construct BsAbs is to combine binding
moieties such as scFvs or single domain antibodies into a single
recombinant polypeptide chain using linkers such as the flexible
9,10,17glycine-serine (G4S) motif or Fc (Hinge-CH2-CH3)
domain. Improved scFv stability can be achieved through engi-
neering additional cysteine residues within framework regions.41
The modular design of recombinant BsAbs has resulted in the
creation of a variety of novel BsAbs.14 Formats range from non-
IgG like varieties containing chemical or protein linkers, through
to recombinant Fc-containing, Dock-and-lock and knobs-into-
holes (KIH) BsAbs.42 Some of the more well-known formats
include Triomabs, dual affinity retargeting (DART) molecules,
bispecific T-cell engagers (BiTEs), and the F-star mAb2TM
BsAbs.9,20,43-45 Design features may endow the BsAb with spe-
cific properties, such as enhanced serum half-life or complement
activation, by fusion with PEG, BSA or Fc domains.46, 47
In this study, we designed several BsAbs based on 3 basic
design formats for active targeting of the EnGeneIC delivery
vehicle (EDVTMnanocell) to the epidermal growth factor recep-
tor (EGFR), to replace the currently used protein A/G linked
mAbs.48-50 The EDVTMnanocell (a 400 nm particle of bacterial
origin capable of carrying a drug payload) was originally targeted
using a BsAb moiety produced by incubating 2 different mAbs
with protein A/G (Pierce, USA).21 Although functional BsAbs
capable of delivering the EDVTMnanocell were prepared, it was
noted that multimer formation and the inability to control the
ratio of mAbs bound to the protein A/G, which has 6 potential
Fc-binding sites, rendered the targeting entity unsuitable for
commercial manufacture and downstream clinical trials.21, 32
Recombinant BsAbs offer an advantage of producing one anti-
body with dual target binding capability.
The EDVTMnanocell is coated with lipopolysaccharide (LPS),21
and thus BsAb designs incorporated scFvs derived from an anti-LPS
antibody (1H10) with the anti-EGFR antibody ABX-EGF.51-53
ABX-EGF (panitumumab) was developed via transgenic humanized
mouse technology by Abgenix Inc.,51-53 and is approved for clinical
use in the treatment of colorectal cancer. ABX-EGF has picomolar
affinity for EGFR, and its properties, including affinity, specificity
and immunogenicity, have been extensively evaluated and is an ideal
model antibody to incorporate into the design and testing of bispe-
cific formats.21 Three BsAb formats were evaluated for EDVTMna-
nocell targeting; a G4S-linked tandem scFv format, homodimeric
Fc-containing BsAbs and KIH-engineered formats to promote
forced heterodimerisation of the EDV-targeting variable fragments.
Figure 1. Applications of bispecific antibodies. Therapeutic modalities
include: (A) crosslinking separate antigens on the cell surface; (B) T cell
engagement by cross-linking CD3 on cytotoxic T cells to tumor cells; (C)
targeting drugs or radiolabels to cell surface; (D) targeted delivery of
drug-loaded nanoparticles to tumor cells (image not to scale).
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Additionally, modifications of the latter 2 formats were investigated,
incorporating additional disulfide bridges in the scFv domains and
longer linkers between the Fc-CH3 and anti-LPS scFv interface
(Table 1). We evaluated these different formats with regard to
expression yields, their ability to bind respective targets and their
effect on EDVTMnanocell clumping. The tandem scFv design was
further evaluated to show its ability to target the EDVTMnanocell to
MDA-MB-468 breast cancer cells overexpressing EGFR in vitro,
and to target the drug-loaded EDVTMnanocell to mouse xenografts
in vivo, resulting in tumor regression.
Results
Production and yield
Various BsAbs of different designs were expressed in Chinese
hamster ovary (CHO)-S transient cell culture and purified from
culture supernatant. We observed that BsAb yields from transient
CHO-S cultures were lower compared to that of full length,
ABX-EGF-IgG1 mAb (52.6 mg/L); tandem scFv BsAb expres-
sion routinely yielded around 5 mg/L in transient cell culture
supernatant, whereas yields of Fc-containing and KIH BsAbs
increased 2-3 fold compared to that of the tandem scFv BsAb.
Engineering disulfide bridges into Fc-containing and KIH vari-
ant scFvs dramatically decreased BsAb yields 6-9 fold compared
to those of non-stabilised formats. A qualitative Western blot
confirmed that BsAbs were efficiently secreted and that the lower
product yields were not due to retention in the endoplasmic
reticulum via cellular mechanisms such as the unfolded protein
response (results not shown). 54-57
Targeted binding
Binding activity was maintained for both EGFR and LPS tar-
gets for all engineered BsAb formats (Table 2; Fig. 2). Surface
plasmon resonance (SPR) analysis of recombinant EGFR binding
using Biacore T-200 (GE) showed that BsAb association con-
stants (ka) were 5 to 10-fold lower than that of the published
ABX-EGF (using purified native EGFR).58, 59 Dissociation con-
stants (kd) of the ABX-EGF-scFvs incorporated within the tan-
dem scFv, Fc-containing and Fc-containing (Longlink) BsAbs
have values similar to the published kd for ABX-EGF-IgG2 mAb,
whereas all remaining EGFR-targeting formats have kd values up
to 10-fold slower. A control, non-specific tandem scFv BsAb tar-
geting RSV and LPS, showed no binding to EGFR.
Table 1. BsAb format and sequence design parameters. (A) Tandem scFv, (B) Fc-containing and (C) Knobs-into-Holes (KIH) BsAbs. (A) The tandem scFv,
incorporated a G4S linker as well as N-terminal His and C-terminal myc tags. Homodimeric Fc-containing variants (B) incorporated an IgG1-Fc linker; variants
of (B) included either G4S or a longer (Longlink) linker to connect 1H10 scFvs to the CH3 domain. Variants also included or excluded engineered cysteine
residues in scFvs for enhanced stability. KIH constructs (C) are heterodimers with 1H10 heavy and light variable regions on separate chains. Format design
included a longer (Longlink) linker connecting CH3 to 1H10 variable fragments and again either included or excluded engineered cysteine residues in scFvs
BsAb ID Sequence information
Additional
disulfide bridges
CH3-aEDV Linker
Structural
IllustrationG4S Longlink
A Tandem scFv His-(ABX-EGF scFv)-G4S-(1H10 scFv)-myc NA NA
B Fc-containing (ABX-EGF scFv)-G4S-Fc-G4S-(1H10 scFv)
Fc-containing
(Longlink)
(ABX-EGF scFv)-G4S-Fc-Longlink-(1H10
scFv)
Fc-containing
(Cys)
(ABX-EGF scFv) (cys)-G4S-Fc-G4S-(1H10
scFv) (cys)
Fc-containing
(Cys Longlink)
(ABX-EGF scFv) (cys)-G4S-Fc-Longlink-(1H10
scFv) (cys)
C KIH 1 (Cys) (ABX-EGF scFv) (cys)-G4S-Fc(Knob)-
Longlink-VH(1H10)(cys)
C
(ABX-EGF scFv) (cys)-G4S-Fc(Hole)-Longlink-
KIH 2
VL(1H10)(cys)
(ABX-EGF scFv)-G4S-Fc(Knob)-Longlink-VH
(1H10)
C
(ABX-EGF scFv)-G4S-Fc(Hole)-Longlink-VL
(1H10)
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Reformatting the ABX-EGF-scFv to an IgG1 mAb resulted in
similar ka, kd and binding affinity (KD) values as those reported
for the published ABX-EGF IgG2 mAb (Fig. 2). KD for the
EGFR-targeting BsAbs were all in the nanomolar (nM) range.
The Fc-containing (Longlink) BsAb showed a 4 to 5-fold
decrease in KD compared to that of the Fc-containing BsAb.
Flexibility imparted by the long linker may have a destabilizing
effect on the scFvs within the BsAb. Interestingly, cysteine stabili-
zation restores the high affinity of Fc-containing (Longlink) BsAb
for EGFR (0.04 nM). Similarly, cysteine-stabilised KIH 1 (Cys)
BsAb showed greater binding affinity than that of the KIH 2
BsAb. Although the reasons for the effect of cysteine stabilization
of scFvs within a specific BsAb format were not investigated, it is
hypothesized that the additional disulfide bonds offer a further
degree of stabilization and rigidity within the scFv binding enti-
ties, which enhances binding affinity.
Binding of all BsAbs to LPS was confirmed by ELISA (results
not shown). As LPS is naturally adhesive and binds strongly to
surfaces (e.g., glass, plastic), performing binding studies by SPR
was not compatible with the microfluidics system of the Biacore.
The kinetics of 1H10-scFv component of
the BsAbs binding to LPS were therefore
determined by the Octet system (Forte-
Bio), which circumvents the problems of a
fluidics-based system, and provided bind-
ing data for the original, hybridoma-
derived 1H10-mAb [KD D 0.2 nM, ka D
8.20EC05 (§1 .25EC04), kdD 1.36E-04
(§1 .72E-05)] and 1H10-scFv of the tan-
dem scFv format [KD D 10.0 nM, ka D
2.20EC04 (§1 .76EC03), kdD 5.64E-04
(§2.39E-05)] (Fig. 2C). The 60-fold dif-
ference in KD between the 2 formats is
indicative of differences in avidity.
Flow cytometry analyses showed that
all EGFR-targeting formats (mAb and
BsAb) were able to bind to EGFR-over-
expressing MDA-MB-468 cells, while
non-specific formats showed no binding
(Fig. 3A-C). A decreased shift for the
tandem scFv BsAb compared to the Fc-
linked formats can be attributed to the
higher avidity of the EGFR-bivalent, Fc-
linked BsAbs. The lower fluorescence
intensity of the tandem scFv could also
be due to the different secondary anti-
body used for detection.
Table 2. Surface plasmon resonance binding affinities for recombinant EGFR-mFc collected from a Biacore T-200. Surface Plasmon Resonance (Biacore) anal-
ysis of BsAb binding to EGFR – ka (association constant), kd (dissociation constant), and KD (binding affinity). High performance (Multi-cycle) Kinetic Assay
(HPKA) data is shown for all BsAb constructs as well as for a reassembled, complete IgG1 ABX-EGF mAb. Standard error values corresponding to binding val-
ues of recombinant EGFR is shown as § x £ 106 for ka and § y £ 10¡5 for kd
Binding to recombinant EGFR
Antibody ID ka (1/Ms) (£106) (§SE ) kd (1/s) (£10–5) (§SE ) KD (nM)
1.97 11.3 0.05
2.18 § 0.0025 15.5 § 0.047 0.07
No binding No binding No binding
0.26 § 0.0004 13.6 § 0.021 0.52
0.36 § 0.0023 9.42 § 0.028 0.26
0.19 § 0.0005 21.6 § 0.084 1.13
0.48 § 0.0002 4.89 § 0.019 0.10
0.70 § 0.0004 2.47 § 0.025 0.04
0.82 § 0.0005 2.67 § 0.026 0.03
ABX-EGF IgG2 mAb (published)
ABX-EGF IgG1 mAb (reformatted)
Non-specific Tandem scFv
Tandem scFv
Fc-containing
Fc-containing (Longlink)
Fc-containing (Cys)
Fc-containing (Cys Longlink)
KIH 1 (Cys)
KIH 2 0.50 § 0.0021 6.75 § 0.021 0.13
Figure 2. ABX-EGF and 1H10 representative binding curves. SPR sensorgrams illustrative of (A) ABX-
EGF tandem scFv (1 nM, 3 nM, 10 nM, 30 nM and 100 nM BsAb) and (B) ABX-EGF-IgG1 mAb (1 nM, 3
nM, 10 nM and 30 nM BsAb) binding to immobilised recombinant EGFR. (C) Biolayer interferometry
kinetic curve of ABX-EGF tandem scFv the 1H10-mAb and ABX-EGF IgG1 mAb at 100 nM binding to
captured LPS.
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It was of interest to investigate the ability of BsAbs to crosslink
the 2 antigens LPS and EGFR. A co-localization experiment
using fluorescently labeled recombinant-EGFR (DL650) and
BsAb-targeted EDVTMnanocells (AF488) provided visual confir-
mation that BsAbs could simultaneously bind their 2 targets
(Fig. 4). Results show that non-targeted and non-specifically tar-
geted EDVTMnanocells do not co-localize in the presence of
recombinant EGFR (green fluorescence only). We included all 7
of the BsAb formats, and observed their effect on nanocell
clumping. The ABX-EGF tandem scFv, KIH 1 (Cys), Fc-con-
taining (Cys) and Fc-containing (CysLonglink) BsAbs caused
less EDVTMnanocell aggregation, as illustrated by a uniform dis-
tribution of co-localized EGFR and targeted EDVTMnanocells,
whereas nanocells targeted with KIH 2, Fc-containing and Fc-
containing (Longlink) BsAbs produced large, aggregated clumps
of co-localized recombinant EGFR and EDVTMnanocells. This
illustrates how different recombinant BsAbs affect the EDVTM-
nanocells during and post targeting, and the final product stabil-
ity. These findings highlight how BsAb design and properties in
solution may influence the performance of the BsAb-EDVTMna-
nocell formulated product.
The BsAbs that resulted in a uniform distribution in the co-
localization study were further investigated by binding to cells
using flow cytometry (Fig. 3D) and confocal microscopy
(Fig. 5). For confocal microscopy, MDA-MB-468 cells (labeled
with AF647) were targeted with AF488-labeled BsAb-EDVs.
Non-targeted EDVTMnanocells did not localize on MDA-MB-
468 cell surfaces nor did non-specific EDVTMnanocells. Confo-
cal microscopy (Fig. 5) and flow cytometry analyses (Fig. 3D)
showed that while all BsAbs localized on the MDA-MB-468 cell
surface, the tandem scFv and KIH 1 (Cys) BsAb formats, possess-
ing only one 1H10-scFv, displayed a lower distribution across the
cell surface compared to the distributions of the Fc-containing
(Cys) and Fc-containing (CysLonglink) targeted EDVTMnano-
cells, with 2 1H10-scFvs.
Stability
Various buffer formulations were tested to improve the stor-
age stability of the BsAbs. Formulations tested thus far have not
shown significantly improved stability of Fc-containing and KIH
variants, and there is evidence of concentration-dependent aggre-
gation above 0.1 mg/ml (results not shown). Size exclusion chro-
matography (SEC) HPLC analyses over a 1 month period
indicated that tandem scFv stability, when stored at a concentra-
tion of 0.12 mg/ml, is affected by buffer formulation. Product
storage in a formulation of PBS/trehalose resulted in slightly
increased aggregation levels when stored at -20C compared with
4C. However, stability was maintained at both 4C and -20C
in a HEPES/Trehalose buffer formulation (Fig. 6A). Dynamic
light scattering (DLS) data confirmed the tandem scFv to be a
monomer of 55 kDa in size, with a hydrodynamic radius of
2.5 nm (results not shown). Thermostability determined by
Figure 3. In vitro binding of IgG1 mAbs, BsAbs and BsAb-EDVs to EGFR overexpressing MDA-MB-468 breast cancer cells. All specific BsAbs include ABX-
EGF-scFvs (anti-EGFR), non-specific formats include a palivizumab-scFv (anti-RSV) and all BsAbs include the 1H10 (anti-LPS) scFv. (A) Whole mAbs, non-
specific (anti-RSV) and ABX-EGF-IgG1 (anti-EGFR) binding to cells detected by APC-conjugated anti-human IgG; (B) Tandem scFv BsAbs (anti-RSV and
anti-EGFR) binding to cells detected by FITC-conjugated anti-c-myc; (C) Various Fc-containing BsAbs binding to cells detected by APC-conjugated anti-
human IgG; and (D) AlexaFluor 488 labeled EDVTMnanocells (EDVs) binding to cells via various bound BsAbs.
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differential scanning calorimetry (DSC) indicated that the tan-
dem scFv has a melting temperature (Tm) of 57C (Fig. 6B).
Additionally, co-incubating the tandem scFv with human serum
(HS) over a 48-hour period showed no protease-mediated degra-
dation of the BsAb (results not shown).
EDVTMnanocell-mediated tumor regression in a mouse
xenograft model
Due to the superior properties of the tandem scFv BsAb, it
was the only recombinant BsAb format tested in a mouse xeno-
graft model for tumor regression. To evaluate the efficacy
of EDVTMnanocells targeted using the ABX-EGF tandem scFv
(Tandem scFv EDV) compared to those targeted with EnGeneIC’s
original, Protein A cross-linked anti-LPS / anti-EGFR BsAb
(Protein A/G EDV),21 in vivo experiments were carried out utilizing
a MDA-MB-468 mouse xenograft model, with dosing com-
mencing 14 d after subcutaneous injection of MDA-MB-468
cells (tumor volume approx. 80–100 mm3) (Fig. 7). EDVTMna-
nocells targeted with the tandem scFv and loaded with doxorubi-
cin (Tandem scFv EDV Dox) effectively suppressed tumor growth
over a 38 day period post xenograft compared to controls. Active
targeting with Tandem scFv EDV Dox showed tumor regression was
similar to that achieved with EDVTMnanocells targeted by
protein A/G cross-linked BsAbs (Protein A/G EDV Dox). Impor-
tantly, active targeting of doxorubicin-loaded EDVTMnanocells
by the tandem scFv BsAb resulted in a 40% reduction in tumor
volume compared to that of loaded passively targeted EDVTMna-
nocells (EDV Dox) 38 d post xenograft (i.e., 140 mm
3 and
240 mm3, respectively). Targeted EDVTMnanocells not loaded
with doxorubicin (Tandem scFv EDV) had a minor tumor suppress-
ing effect, whereas non-targeted, doxorubicin-loaded EDVTMna-
nocells (EDV Dox) showed significant tumor regression
compared to saline controls; the latter being most likely due to
passive targeting through leaky tumor vasculature of tumor xeno-
grafts (pore sizes 0.2–1.2 mm).32,60,61
Discussion
A variety of BsAb formats were investigated for their ability to
bind EDVTMnanocells and recombinant or native EGFR. This
initial proof-of-principle study was performed using BsAbs con-
taining the scFv binding sequence derived from ABX-EGF (pani-
tumumab), a rigorously tested, approved therapeutic antibody,
which has ideal properties such as high affinity and stability.
ABX-EGF targets EGFR, which is commonly over-expressed on
Figure 4. Co-localization imaging by confocal microscopy of recombinant EGFR-His (DL650) and EDVTMnanocells (AF488) with or without specific BsAb.
Recombinant EGFR was co-incubated with EnGeneIC Delivery Vehicles (EDVTMnanocells or EDVs) pre-targeted with various BsAbs prior to microscopy.
EDVTMnanocells are represented in green (AF488) while DyLight650-labeled EGFR-His is represented in purple (color substitution from red has been
applied to improve co-localization imaging). Overlap of the 2 fluorophores (co-localization) results in near-white imaging. Panels represent the filter
showing EGFR (DL650) alone, EDV (AF488) alone and the merged overlay image of the 2.
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a variety of cancer cells and the target for several marketed anti-
cancer therapeutics.3,7,50,62 The modular nature of BsAb con-
structs allows alternative antibody specificities to be substituted
depending on the receptor target.
The tandem scFv BsAb was designed to include a 5 amino
acid glycine-serine linker (G4S) between the ABX-EGF- and
1H10-scFv. The shorter linker reduces flexibility and therefore
prevents misfolding from occurring between the 2 scFv compo-
nents. Administered in isolation, tandem scFv BsAbs exhibit low
avidity and, due to their small size, a low serum half-life;46, 47
however, pharmacokinetic properties of tandem scFv BsAbs
bound to the large EDVTMnanocell (400 nm in diameter) will
be enhanced. Furthermore, coating of the EDVTMnanocell with
tandem scFv BsAbs imparts multivalency and avidity to the NP,
and provides multiple binding sites for the cancer-targeting
domain.21
To produce more complex BsAbs compared to the tandem
scFv BsAb, manipulation of the standard IgG mAb format has
produced a plethora of Fc-containing BsAbs, whereby designs
generally rely on the principle that Fc-containing BsAbs will
dimerize through the Fc, similar to native, whole
mAbs.11,46,47,63,64 Features of these antibodies include engineer-
ing Fc components to improve or remove various related func-
tions, forced heterodimerisation, removal of redundant domains
and addition of other binding motifs to the IgG mole-
cule.47,63,65-67 We used an IgG1 Fc-domain to link and separate
the 2 scFvs spatially (ABX-EGF scFv at the N-terminus of
human IgG1 Fc domain, and an 1H10 scFv at the C-terminus)
to create the ABX-EGF-Fc-1H10 homodimeric Fc-containing
BsAb, similar to the scFv-Fc-scFv BsAb dimer described in Jen-
dreyko et al. and the Emergent BiosolutionsTM product termed
ADAPTIRTM Multi-Specific.68, 69 A benefit of the Fc-containing
Figure 5. Confocal in vitro imaging of stable BsAb-EDVTMnanocells binding to the surface of MDA-MB-468 breast cancer cells. MDA-MB-468 cells were
labeled with anti-EGFR-AF647 (red) to visualize the cell surface while BsAb-EDVs were labeled with AF488 (green). After 3 hours of incubating labeled
BsAb-EDVs with EGFR overexpressing MDA-MB-468 cells, the samples were washed, fixed and labeled with the AF647. Cover slips were mounted and
cells visualised on a Confocal LSM Zeiss 710 using a Plan-Apochromat 63x/1.40 Oil DIC M27 objective. Analyses were performed using ZEN 2008 software.
Scale bars in white indicate a length of 10 mm.
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BsAbs over the tandem scFv format is the presence of 2 scFvs to
bind each target – promoting high avidity binding to both the
EDVTMnanocell and the EGFR on the cancer cell surface;
whereas a potential drawback could result if the Fc-domain stim-
ulates an unwanted immune response and complement cas-
cade.20,31 Although it is well known that Fc-related immune
responses can be avoided through various mutations 67 through-
out the domain, our work thus far has focused on the production
of a stable drug delivery system rather than on potential immu-
nogenicity. EnGeneIC’s original BsAb format also retained fully
functional Fc domains without significant immunogenicity being
noted.21,22,31
Previous studies have found that inclusion of a number of
design modifications, including variations in CH3-scFv linker
length and type, and also scFv stability engineering via addition
of disulfide bonds, improved construct stability. 70-75 A concern
with the Fc-linked dimeric design was whether the presence of 2
anti-LPS scFvs would result in EDVTMnanocell aggregation via
binding of multiple nanocells rather than high avidity binding of
a single nanocell. An alternative Fc-linked BsAb was engineered
consisting of 2 EGFR targeting scFvs at the N-terminus (high
avidity) and a single anti-LPS scFv at the C-terminus of the final
product. Heterodimeric BsAb formats were based on the com-
mon KIH constructs65, 75 and partly on the TandAb BsAb
designed by Affimed where variable linker lengths are used to
determine chain association for functional BsAb formation.76, 77
The single anti-LPS site is formed through forced heterodimer-
isation of the CH3 domain via KIH engineering, where the VH
and VK domains of the scFv are expressed on separate polypepti-
des in a single cell. To ensure that the VH- and VK-chains associ-
ate with one another to form a functional 1H10-scFv, a longer
linker between CH3 and the 1H10-scFv component was
designed to allow extra flexibility in the area for functional associ-
ation of the nanocell-targeting scFv components.75
Based on co-localization images of the various BsAb formats
binding to EDVTMnanocells and to EGFR, 4 of the BsAbs are of
particular interest for further development: tandem scFv, Fc-con-
taining (Cys), Fc-containing (Cys Longlink) and KIH (Cys).
The other formats resulted in clumping of the EDVs. However,
as the expression yields of the disulfide-engineered, Fc-linked
BsAbs were 6-9 fold lower than the tandem scFv, the tandem
scFv was chosen for further investigation.
Tumor regression in MDA-MB-468 breast cancer cell xeno-
grafts showed that BsAb-mediated targeting with anti-EGFR
antibody is essential for optimal inhibition of tumor growth.
Although EDVTMnanocells have previously been successfully tar-
geted by cross-linking 2 IgG antibodies with protein A, utilizing
the tandem scFv, whereby one arm binds the EDVTMnanocell
and the other targets the tumor, requires the production of a new
molecular entity (NME). A biologic NME can be characterized
for binding activity and manufactured according to cGMP. The
coating of BsAb on the surface of the EDVTMnanocell also
imparts other properties to the nanocell. Depending on BsAb
density on the nanocell surface, the imparted avidity would
enhance apparent affinity of the EDVTMnanocell for its target,
compared to that of the target scFv alone. Furthermore, coating
Figure 6. Tandem scFv stability data. (A) Tandem scFv samples were
stored in various buffers at different temperatures to evaluate stability
during storage over a 3 month period. The representative trace is indica-
tive of stable product stored in Hepes/trehalose buffer for 3 months. (B)
Thermostability of tandem scFv BsAb in PBS was determined by differen-
tial scanning calorimetry and indicates unfolding and subsequent aggre-
gation of the tandem scFv BsAb at 57C.
Figure 7. Mouse MDA-MB-468 xenograft results following EDVTMnano-
cell (EDV) treatment. Tandem scFv refers to the EGFR targeting ABX-EGF
BsAb format in the BsAb-EDVTMnanocell configuration whereas protein
A/G refers to EnGeneIC’s original BsAb format composed of anti-EGFR
and 1H10 mAbs connected through a protein A/G molecule. Dox refers
to the chemotherapeutic agent doxorubicin. At various time points, indi-
cated with a blue triangle, mice were treated with 1£109 EDVs.
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with a BsAb, where the targeting scFvs are of human origin, alters
the physicochemical properties of the EDVTMnanocell in vivo,
and would affect parameters such as pharmacokinetics and
immunogenicity.
Nanomedicine is poised to play an increasingly important role
in cancer therapy in the future, with at present 7 passively tar-
geted nanomedicines approved for cancer therapy.32, 33 Actively
targeting nanoparticles to tumors with antibodies, as demon-
strated in this study, can have significant advantages and improve
efficacy compared to passive targeting alone. Designing new
BsAbs that are able to efficiently target nanoparticles opens a new
dimension in active nanoparticle targeting.
Materials and Methods
Sequence design
The DNA sequence of the extracellular domain (amino acid
residues 25 - 645) of wild type human EGFR (Swiss-Prot
P00533) was synthesized by Geneart, incorporating a mamma-
lian leader sequence from IgK and a C-terminal His tag, with
codon optimisation for expression in CHO cells. Further con-
structs consisting of amino acid residues 25 - 525 followed by
either human or mouse Fc tags were created, similar to that
described by Adams, 2009.78 The heavy and light chain variable
region sequences of the anti-LPS monoclonal antibody were
determined by isolating and sequencing cDNA isolated from the
hybridoma 1H10, using established protocols.79 The sequence
information for the heavy and light chain variable regions for
panitumumab (ABX-EGF) was obtained from US Patent 6 235
883. The sequence for an unrelated control antibody (anti-RSV)
palivizumab (Synagis), was obtained from the RCSB Protein
Data Bank file, 2 HWZ.
The DNA templates for all BsAb formats were synthesized
by Geneart with codon optimisation for CHO expression,
then cloned into the mammalian expression vector pcDNA3.1
(Invitrogen). Cysteine stabilization substitutions were made at
Kabat position VH44 and VL100 of the scFvs.72, 73 Variants
included either a short (G4S) linker or a longer linker
(SSDKTHTSPPSPGGGGSGGGGSGGGGSGGGG), as des-
cribed in Moore et al., connecting the CH3 domain to the
1H10-scFv.75 A “knob” was produced by amino acid substitu-
tion for a longer side chain (T366’W), whereas a "hole" was pro-
duced by amino acid substitutions for shorter side chains
(T366’S:L368’A:Y407’V); the sequence positions are as indicated
by Kabat et al.80 The tandem scFv included 6xHis and c-myc
tags for purification and detection, while the other constructs uti-
lised the Fc domain for purification and detection. For the KIH
constructs, 2 DNA templates were required, one containing the
1H10 Vh region and one containing the 1H10 Vk region. Whole
mAbs for panitumumab (ABX-EGF) and palivizumab were cre-
ated by reformatting the BsAb sequences using a previously
described method.81
Mammalian expression and purification
Transient expression of all BsAbs was performed using PEI-
mediated transfection of suspension adapted CHO cells as previ-
ously described.82 KIH chains were co-transfected at a 1:1 DNA
ratio (1H10-Vh : 1H10-Vk). Culture supernatants were har-
vested 7 - 10 d post-transfection by centrifugation, then filtered
and stored frozen at -80C until purification could be completed.
For the tandem scFv purification, 2 sequential IMAC chroma-
tography steps were utilised, first with HisTrap Excel (GE
Healthcare), which tolerates nickel-chelating agents present in
mammalian cell culture media, followed by HisTrap FF (GE
Healthcare), which further removes impurities. Manufacturer-
recommended buffers were used for equilibration and loading,
with 500 mM Imidazole added for elution. The eluted product
was buffer exchanged into PBS using a HiPrep desalting column
after each IMAC step. Tandem scFv BsAb monomer was isolated
using a GE gel filtration column (HiPrep 26/60 Sephacryl S-200
HR) and the monomer subsequently used for kinetic experiments
and long-term stability studies.
For constructs containing an Fc domain, purification was per-
formed in one step using a MabSelect Sure Protein A HP col-
umn. Following purification the BsAbs were desalted using the
HiPrep desalting column into Dulbecco’s PBS buffer for storage
at 4C unless specified otherwise.
Dynamic Light Scattering
Analysis was completed by CSL, Melbourne, Australia. Molar
mass and hydrodynamic radius (Rh) was determined using SEC-
MALS. A Wyatt WTC-030-N5 4.6 column was used with buffer
composed of 100 mM phosphate/200 mM sodium chloride, pH
6.8. The column was equilibrated in the buffer and flow rate set
to 0.2 ml/min with 100 ml sample injections. A DAWN Heleos
MALS detector was normalized using BSA and used in series
with an Agilent 1200 series UV diode array detector and an Opti-
lab T-rEx RI detector. Wyatt’s Astra VI software was used to cal-
culate the weight-averaged molar mass and hydrodynamic radius.
Analysis of tandem scFv by differential scanning calorimetry
The tandem scFv BsAb was concentrated to 1 mg/ml in PBS
using membrane based centrifugal concentrators with nominal
molecular weight cutoff of 10 Kda (Millipore). 500 ml of 1 mg/
ml tandem scFv was vacuum degassed and loaded into the sample
chamber of the VP differential scanning calorimeter (VP-DSC,
Microcal). The same volume of PBS was loaded into the refer-
ence chamber. The sample and reference chambers were scanned
once from 25C to 90C for 1 h to determine the melting profile
of the tandem scFv. The data was analyzed using Origin 7.0
software and graphed as time (min) (x axis) versus heat capacity
(Cp) (y axis).
Size exclusion chromatography HPLC
A mobile phase of 0.1 M sodium phosphate buffer, 0.2 M
sodium chloride, pH 6.8 was prepared and filtered using a
0.22 mm filter. A gel filtration standard was included on each
run of the HPLC to calculate molecular weights by their reten-
tion times. Samples were not concentrated prior to performing
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SEC so as to avoid the potential that concentration-based aggre-
gation may occur. The guard column and SEC-HPLC column
were connected to the HPLC system, flushed and equilibrated in
mobile phase. 100 ml sample injections were used in all cases
with a flow rate of 0.8 ml/min. Columns were stored in 20% eth-
anol pre- and post-run completion.
Tandem scFv stability in buffer formulations of PBS/trehalose
and HEPES/trehalose was completed by The Australian Protein
Analysis Facility. SEC was performed using a Zorbax BioSeries
GF-250 column (Agilent). Flow rate was set to 0.5 ml/min and a
mobile phase of 100 mM sodium phosphate, pH 7, 250 mM
NaCl used as a buffer. Sample injections were set to 25 ml.
Surface plasmon resonance
To evaluate binding affinities of the EGFR-targeting ABX-
EGF-scFvs on all constructs, kinetic data was collected from
either Single Cycle Kinetic (SCK) Assays or High Performance
(Multi-cycle) Kinetic Assays (HPKA) performed on a Biacore T-
200. A CM5 chip was coated with an anti-mouse IgG antibody
on flow cells 1 and 2 as described in the Mouse Antibody Cap-
ture Kit guidelines (GE Healthcare). Recombinant EGFR-mFc
was captured on flow cell 2 at 10 mg/ml for 8 - 15 seconds and
variable concentrations of BsAb (1 – 100 nM) flowed over both
flow cells 1 and 2. Recommended flow rates (30 mL/min) and
regeneration conditions (10 mM glycine pH 1.7; 10 mL/min for
180 s) were used. The dissociation phase was 1800 s. Reference
subtractions of flow cells 2 - 1 were incorporated in the analysis
as were blank and buffer only sample runs. Kinetic analyses were
performed using a 1:1 fit of binding curves using BiaEvaluation
software (GE Healthcare).
Biolayer interferometry kinetic characterization of LPS
binding
The binding of mAbs and BsAbs to LPS molecules was tested
utilizing Biolayer Interferometry and the ForteBio Octet mod-
ule. Aminopropylsilane (APS) biosensors (ForteBio) were briefly
hydrated in PBS and coated with 1 mg/ml LPS (Salmonella enter-
ica, serotype typhimurium - Sigma L7261) diluted in PBS. A
concentration range of the 1H10-mAb (anti-LPS) or tandem
scFv BsAb was set up using 2-fold dilutions starting at 100 nM
and subsequently tested for binding to immobilised LPS. PBS
was added to LPS coated sensors as a reference.
Flow cytometry of BsAb and mAb samples against MDA-
MB-468 cells
All BsAb and mAb samples had been stored at 4C prior to
commencement of the experiment. The Indirect Flow Cytometry
(FACS) Protocol described by Abcam was used (available online
at http:\\www.abcam.com). All components were added to a cell
suspension of 2 £ 105 MDA-MB-468 cells in 100 ml of 10%
FCS/DPBS and kept at 4C to prevent receptor-mediated endo-
cytosis from occurring. Primary BsAb and mAb stock dilutions
to 10 mg/ml were made in ice cold 5% BSA C Dulbecco’s PBS
buffer as were secondary antibody dilutions. Final BsAb and
mAb concentrations were at 1 mg/ml in the final cell suspension
volume. Mouse anti-c-myc:FITC (AbD Serotec; Bio-Rad) was
used as the secondary antibody for detecting binding shifts when 
the ABX-EGF tandem scFv and non-specific tandem scFv were 
incubated with MDA-MB-468 breast cancer cells; whereas APC-
conjugated F(ab)’2 fragment goat anti-human IgG (Jackson 
ImmunoResearch) was used for detection of all mAb, Fc-contain-
ing and KIH constructs. Fluorescence shift was then analyzed on 
the Accuri C6 flow cytometer. Cells were gated using forward 
and side scatter, and the cell sample incubated with secondary 
antibody only was used to determine the cut-off fluorescence for 
non-specific binding. Events were limited to 100 ml or 100,000 
events.
Preparation of labeled BsAb-EDVTMnanocells
One £ 1012 Non-targeted EDVTMnanocells were incubated 
with 1 mg of Invitrogen’s NH2-reactive AlexaFluor488 (internal 
protocol) and excess dye was removed by 4 spin wash cycles in 
sterile PBS. The fluorescently labeled EDVTMnanocells were 
counted using a NanoSight and found to be 5 £ 1010 EDVs/ml 
at EnGeneIC Pty Ltd. Doses were prepared as 2.5 £ 1010 EDV 
(AF488) particles in 0.5 ml. 2.5 £ 1010 EDV (AF488) particles 
were incubated with 6 mg of various BsAb constructs at room 
temperature for 30 min while shaking at 300 rpm. Samples then 
underwent 3 PBS spin wash cycles at 9,000 g for 8 min each to 
remove any excess BsAb. BsAb-EDVTMnanocells were resus-
pended to concentrations as required for specific experiments.
Flow cytometry analysis of EDVTMnanocell binding to 
MDA-MB-468 cells
One £ 105 MDA-MB-468 cells grown on coverslips in 
400 ml RPMI C 5% FCS C 1% PC-SM were treated with 1 £ 
109 pre-targeted and AF488-labeled EDVTMnanocells and 
returned to 37C for 3 h. This was repeated for the non-targeted 
EDVTMnanocell and each of the 5 BsAb-EDVTMnanocells –
non-specific and ABX-EGF tandem-scFv, KIH 1 (Cys), Fc-con-
taining (Cys) and Fc-containing (CysLonglink), with only the 
control remaining untreated. On completion of the 3 h incuba-
tion period, coverslips were washed 3 times with sterile DPBS 
and cells scraped for flow analyses on a Beckman FC500 flow 
cytometer. Flow rate was set to high and cells were again gated 
using forward and side scatter. The “cells only” sample was used 
to determine the cut-off fluorescence for non-specific binding. 
Events were detected over a 250 sec period. Final analyses were 
completed using CXP and VenturiOne software.
Co-localization
AF488-Labeled, non-targeted and targeted EDVTMnanocells 
were prepared as previously mentioned and observations made 
regarding clumping of the BsAb-EDVTMnanocells during each 
resuspension. BsAb-EDVTMnanocells were resuspended to an 
approximate concentration of 4 £ 1010 EDVs/ml in 500 ml. 
Counts and aggregation analysis were again performed using 
established techniques on the nanosight. EGFR-His (1 mg) label-
ing was completed using a DyLight650 amine-reactive labeling kit 
(Thermo Scientific) as per the manufacturer’s instructions after 
having been concentrated to 1.6 mg/ml using a 10 kDa spin 
column.
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To set up samples for co-localization imaging, 2 mg EGFR-
His (DyLight650) was added to 5 £ 109 particles of each of the
conjugated BsAb-EDVTMnanocells. The resulting suspension
was then incubated at RT for 30 min on a shaker at 300 rpm to
allow sufficient time for recombinant EGFR binding to occur.
Samples underwent 3 spin wash cycles as before to remove excess
unbound labeled EGFR-His and checked for evidence of clump-
ing resulting from BsAb-nanocell interaction with recombinant
EGFR. EGFR-BsAb-nanocell suspensions were resuspended to a
concentration of 0.4 £ 1010 EDVs/ml. For analysis on an Olym-
pus IX81 confocal microscope using Xcellence RT software,
slides were prepared by pipetting 10 ml sample onto a clean slide
that is then spread out by addition of a coverslip.
Confocal microscopy of in vitro binding of BsAb-
EDVTMnanocells to MDA-MB-468 cells
MDA-MB-468 cells were incubated on coverslips in the pres-
ence or absence of targeted [non-specific and ABX-EGF tandem
scFv, KIH 1 (Cys), Fc-containing (Cys) and Fc-containing
(CysLonglink)] and non-targeted EDVTMnanocells – 7 slides
total. EDVTMnanocells (labeled with AF488) were added to each
of 6 samples at a ratio of 10,000 EDVs per cell and the seventh
was left as a "cells only" control. Plates were returned to 37C for
3 hours which was followed by 3 washes in sterile DPBS.
Fixative volume of 500 ml, or enough to cover each coverslip,
of 4% PFA was added to each of the 7 samples and left for 10
minutes for cells to become fixed. This was again followed by 3
DPBS washes. After the final wash, 500 ml DPBS was added to
each well to cover the coverslips completely. An anti-EGFR
mAb, 528 mAb, was labeled with AF647 to be used as a cell
membrane stain; 4 mg was added directly to each sample. Wells
were mixed gently and left for 10 min to allow cells to stain suffi-
ciently. All coverslips were again washed 3 times with DPBS fol-
lowed by a final wash in Milli-Q water.
Coverslips were removed from the water and placed on tissue
paper cell side up to allow complete drying to occur, at which
point they were mounted on clean slides using Fluka Eukitt
(Sigma-Aldrich) quick-hardening mounting medium. Dry slides
were stored at 4C until confocal microscopy could be com-
pleted. Microscopy was completed on a LSM Zeiss 710 confocal
using a plan-apochromat 63£/1.40 Oil DIC M27 objective and
ZEN 2008 software for image formatting.
Effect of ABX-EGF tandem scFv-EDVTMnanocell on tumor
regression
The experiment was performed in compliance with the Aus-
tralian National Health and Medical Research Council guidelines
for the care and use of laboratory animals and with the approval
of the EnGeneIC Animal Ethics Committee. Five-to-6 week old
female Balb/C athymic nude mice were obtained from the Labo-
ratory Animal Services at the University of Adelaide, South Aus-
tralia. The animals were housed at the EnGeneIC Animal
Facility under specific pathogen-free conditions.
MDA-MB-468 cells were obtained from ATCC and grown in
RPMI with 10% fetal calf serum and penicillin/streptomycin.
Each mouse was injected subcutaneously on the left flank with 1
£ 107 cells in 100 ml of media together with 100 ml of growth
factor reduced matrigel (BD Biosciences). Tumor volume was
determined by measuring length (l) and width (w) and calculat-
ing volume (V D l £ w2 £ 0.5). Once the tumors reached 80 –
100 mm3 the mice were randomized into treatment groups
which included 7 mice per group. The treatment groups were as
follows:
 Group 1 – Saline
 Group 2 – Tandem scFv EDV (ABX-EGF tandem scFv BsAb tar-
geted EDVTMnanocell not loaded with Doxorubicin)
 Group 3 – EDV Dox (Non-targeted EDVTMnanocell loaded
with Doxorubicin)
 Group 4 – Protein A/G EDV Dox (Protein A/G linked BsAb tar-
geted EDVTMnanocell loaded with Doxorubicin)21,22
 Group 5 – Tandem scFv EDV Dox (ABX-EGF tandem scFv BsAb
targeted EDVTMnanocell loaded with Doxorubicin)
The amount of Doxorubicin was measured by HPLC for all
loaded EDVTMnanocells and determined to be 1 § 0.1 mg per 1
£ 109 EDVTMnanocells (one intravenous dose); method com-
pleted as previously described.21,22 All treatments were injected
intravenously via the tail vein and administered 3 times a week
for 3 weeks. Tumors were measured using a caliper 3 times a
week. The mice were weighed twice a week for 3 weeks.
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